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ABSTRACT
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The overall objectives of this research project were i) to develop and evaluate methods of
characterizing nasal spray products using realistic nasal airway models as more clinically relevant
in vitro tools and ii) to develop and evaluate a novel high-efficiency antibiotic nanoparticle dry
powder formulation and delivery device. Two physically realistic nasal airway models were used
to assess the effects of patient-use experimental conditions, nasal airway geometry and formulation
/ device properties on the delivery efficiency of nasal spray products. There was a large variability
in drug delivery to the middle passages ranging from 17 – 57 % and 47 – 77 % with respect to
patient use conditions for the two nasal airway geometries. The patient use variables of nasal spray
position, head angle and nasal inhalation timing with respect to spray actuation were found to be
significant in determining nasal valve penetration and middle passage deposition of Nasonex ®.

XXX

The developed test methods were able to reproducibly generate similar nasal deposition profiles
for nasal spray products with similar plume and droplet characteristics. Differences in spray plume
geometry (smaller plume diameter resulted in higher middle passage drug delivery) were observed
to have more influence on regional nasal drug deposition than changes to droplet size for
mometasone furoate formulations in the realistic airway models.
Ciprofloxacin nanoparticles with a mean (SD) volume diameter of 120 (10) nm suitable
for penetration through mucus and biofilm layers were prepared using sonocrystallization
technique. These ciprofloxacin nanoparticles were then spray dried in a PVP K30 matrix to form
nanocomposite particles with a mean (SD) volume diameter of 5.6 (0.1) µm. High efficiency
targeted delivery of the nanocomposite nasal powder formulation was achieved using a modified
low flow VCU DPI in combination with a novel breathing maneuver; delivering 73 % of the
delivered dose to the middle passages. A modified version of the nasal airway model
accommodating Transwell® inserts and a Calu-3 monolayer was developed to allow realistic
deposition and evaluation of the nasal powder. The nanocomposite formulation was observed to
demonstrate improved dissolution and transepithelial transport (flux = 725 ng/h/cm2) compared to
unprocessed ciprofloxacin powder (flux = 321 ng/h/cm2).
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1

CHAPTER 1

BACKGROUND AND INTRODUCTION
1.1 Anatomy and physiology of the nose
The nose has a number of major functions including i) heating, humidification of
inspired air and gas exchange, ii) olfaction and iii) particulate filtration [1-3].
The nasal cavity is divided into two separate left and right chambers by the nasal septum
with a total volume of approximately 15 mL and surface area (SA) of around 150 cm2 for each side
[4]. Each chamber can be segmented in three parts of i) the nasal vestibule which covers the area
inside the nostril, ii) the olfactory region which is located in the roof of the nasal cavity with an
approximate SA of 15 cm2 on each side and iii) the respiratory region [1]. The nasal vestibule is
covered with a keratinized, non-ciliated squamous epithelium which is not suitable for drug
absorption. The nasal valve area, located posterior to the nostril (approximately 2 cm away), has a
very small surface area of 0.3 cm2 and is at a 90º angle toward the nasal floor. The nasal valve area
is the primary flow-limiting segment of the upper respiratory airway and it introduces up to 75 %
of the total resistance against the inspired air flow. It also causes change in the flow rate and
direction of airflow during inhalation [4, 5]. The nasal valve area connects the anterior nose region
to the respiratory region containing the nasal turbinates which are attached to the sidewall of the
nasal cavity. The turbinates are three projections (Figure 1.1) referred to as the inferior, middle
and superior turbinates. Turbinates have bony structures with a ciliated respiratory epithelium
lining (these include pseudostratified columnar epithelium, ciliated and non-ciliated columnar cell
with microvilli and cilia) and serve the purpose of heating and humidifying of inspired air with
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their increased mucosal surface area and blood flow. There is laminar airflow in the nasal valve
during normal nasal breathing at flow rate of 15 Lmin-1 which corresponds to an air velocity of 18
m/s. In turbinate regions, a reduced air velocity of 2-3 m/s facilitates warming and humidification
of the inhaled air to about 34ºC and 100% relative humidity in the nasopharynx region [2].

Figure 1. 1. Schematic view of the nasal cavity (A) sagittal cross section and (B) coronal cross
section [6]

The area underneath each turbinate is called the meatus. The middle meatus is where the
paranasal sinuses such as frontal, maxillary and ethmoidal sinuses drain into the nasal cavity. The
paranasal sinuses are air-filled cavities and they function to lighten the skull and increase the
resonance of sound [3].
Nasal mucociliary clearance (MCC) is one of the most important defense mechanisms to
protect against potentially harmful airborne contaminants. MCC can also acts as an obstacle for
nasal drug delivery since it may clear drug formulations prior to their absorption. MCC consists
of two major components, the mucus blanket and the ciliated epithelium. The secretion product of
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goblet cells, submucosal glands and fluid transported across the epithelium in the respiratory
region forms a 2-phase mucus layer with a total thickness of about 10 - 15 μm. The mucus sol
(watery) layer covers the epithelium and the gel layer is exposed to air covering the entire nasal
cavity regions to efficiently filter inhaled particles in the range of 3 - 10 µm [2, 5]. The gel-like
mucus properties are due to the content of mucins (high molecular weight glycoproteins)
composed of 80 - 90% carbohydrate, 20% protein containing 1 - 2% sulfate bound to
oligosaccharide side chains. The matrix format of mucus is formed by water molecules binding to
these oligosaccharide side chains which also lubricates and protects the mucosal surfaces. Except
in the inferior turbinate region where the mucus transport is directed toward the anterior region, in
the remaining respiratory area, with the aid of cilia (5 µm shafts) beating at an average of 6
mm/min, and the mucus blanket, particles entrapped are propelled posteriorly toward the
nasopharynx, throat and then the gastrointestinal tract [5]. The cilia beat also moves mucus
secretions into the paranasal sinuses such as frontal, maxillary and ethmoidal sinuses through their
narrow openings called ostia, located in the middle meatus (in the area under the middle turbinate).

1.2 Intranasal drug delivery
Drugs are administered intranasally for the local treatment of disorders including nasal
allergy, congestion, sinusitis and infections. Sinusitis is a prevalent disease in the United States,
which is characterized by persistence (up to 4 weeks) of sinonasal mucosal inflammation due to
allergies, viral or bacterial infection and inhaled irritants. It can progress to chronic rhinosinusitis
(CRS) characterized by the accumulation of highly viscoelastic mucus and loss of cilia, obstruction
of the nasal airways and sinuses which may stimulate further inflammation, creation of nasal
polyps, olfactory dysfunction, headache, and breathing problems. CRS is one of the major chronic
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diseases which affect 15% of the US population. These disorders can be treated using nasal
delivery systems delivering antihistamines, mast-cell inhibitors, anticholinergics, corticosteroids
or by treatment with systemic antibiotics [7].
Nasal delivery can also be used as a non-invasive means of systemic delivery of
medications with poor oral absorption, low bioavailability, and slow onset of action [4]. By
avoiding first pass metabolism and due to rapid absorption, peptides, vaccines and pain relief
medications have been administered via the nose for systemic purposes. There are number of
emergency medications that can be delivered intranasally for controlling pain or seizures, inducing
sedation and for treating opioid overdose [8]. In addition, nose to brain delivery of small molecules
and macromolecules deposited in the olfactory region through olfactory nerve and branches of the
trigeminal nerve have been considered for “nose-to-brain” transport. Generally, drugs need to
reach to the mucosal surface of the respiratory region to exert their pharmacological actions in the
treatment of local and systemic diseases via the nasal route [7].
1.2.1 Factors influencing nasal drug delivery
The physicochemical properties of the drug and formulation together with the nasal
anatomy and physiology play an important role in delivering drugs to their site of action and their
absorption following nasal administration. Small lipophilic drugs can cross the nasal epithelium
via transcellular and paracellular (diffusion or receptor mediated) routes. It has been reported that
nasal administration of lipophilic drugs such as propranolol, progesterone, pentazocine and
fentanyl demonstrated rapid and complete absorption [9, 10]. For more polar compounds,
incomplete absorption from the nasal mucosa results in low bioavailability, with values as low as
10% for small molecular weight drugs and less than 1% for peptides such as insulin, calcitonin
and leuprolide [9]. The poor absorption can be explained by a combination of low membrane
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permeability, efficient drug clearance from the nasal cavity due to MCC and finally for peptides
and proteins some degree of enzymatic degradation. One strategy that has been employed to
improve absorption has involved formulation with excipients such as absorption enhancers or
mucoadhesive agents to increase residence time in the nasal cavity. The intranasal delivery of
morphine utilizing chitosan as a mucoadhesive agent, and also its ability to temporarily open tight
junctions, enhanced the drug’s bioavailability by 6 times compared to the initial formulation.
Further improvements in the formulation resulted in an 80 % bioavailability and rapid decline in
breakthrough pain during a Phase II clinical trial in cancer patients [9, 11].
For efficient nasal delivery for treatment of local disease within the nose, medication needs
to reach the middle passages where the middle meatus, and the superior and middle turbinates are
located with minimal delivery to the lower respiratory tract and the lungs. The anatomical barriers
for efficient delivery include the presence of the nasal valve with its small surface area and right
angle bend. For sinus drug delivery, this is even more challenging, as drug must penetrate through
the small sinus ostia which are in the range of 3 - 5 mm in diameter. These ostia are often blocked
in sinusitis, and the sinuses remain a poorly ventilated region that makes them difficult to reach.
Moreover, the presence of mucociliary clearance results in translocation of drug to the posterior
region of the nasal cavity and nasopharynx within 10 - 30 min. This requires that poorly soluble
drugs such as corticosteroids must be dissolved within this short time window [2, 7, 8]. In addition
to the complex geometry of the nasal cavity, there is significant inter and intra-subject variability
with respect to race, sex and age, along with the variability associated with nasal septal deviation
or the presence of the nasal cycle which can result in increased variability in delivered dose [1214].
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The primary site of drug deposition is also highly dependent upon the delivery system,
formulation (liquid, gel or powder) and patient administration technique. The drug concentration
and volume (in case of liquid formulations) must be optimized to maximize respiratory epithelial
coverage and reduce removal of the formulation by dripping from the nose or mucociliary
clearance. The presence of local irritaion or disease in the nose also needs to be considered; for
example in nasal atrophy and severe vasomotor rhinitis the capacity for nasal drug absorption is
reduced which results in drug dripping out of the nose or down the back of the throat for liquid
formulations, thus reducing bioavailability [8]. Changes in airflow pattern within the nasal cavity
depending upon device insertion location within the nostril have been reported to result in varying
drug distribution in the nasal cavity which makes the release point of medication one of the
important factors that needs to be considered [15].
1.2.2 Assessment of the regional nasal drug deposition
Ideally, to assess drug deposition, distribution and clearance of nasal delivery systems in
vivo, two-dimensional imaging such as scintigraphy (gamma camera imaging), three-dimensional
imaging using CT, single-photon emission computed tomography (SPECT) or endoscopic
visualization with an aerosolized dye are the gold standards [7, 16-18]. However, these methods
are expensive, time consuming, mostly qualitative or at best, semi-quantitative, and there can be
risks due to radiation. Probably most importantly, for use from a regulatory perspective, they
require the incorporation of a radiolabel agent which may not distribute homogeneously in
suspension formulations and represents an altered form of the proposed commercial formulation
[2]. It is considered important that deposition studies to establish local delivery are performed on
the unmodified proposed commercial formulation for regulatory purposes. As an alternative,
employing a realistic nasal in vitro geometric model to assess the deposition pattern of nasal spray
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products would be an inexpensive and efficient alternative to these studies during product
development and evaluation and would allow testing with the unmodified proposed commercial
formulation. The assessment of both new and generic nasal spray products would benefit from the
use of clinically meaningful in vitro methods to assess the delivery efficiency of nasal drug
products.
1.2.3 Use of realistic airway geometries
Nasal airway models have historically been used for assessing the deposition efficiency of
submicron and micron size particles in nasal airways to evaluate environmental exposure to
airborne materials or for simulation of nasal airflow dynamics [19] and heat and humidity transport
in the nasal cavity [20-26]. Advanced imaging techniques including magnetic resonance imaging
(MRI) [27] and computed tomography (CT) enable improved accuracy in the measurement of
nasal airway dimensions of human subjects compared to measurements derived from casts
obtained post-mortem from human cadavers resulting in more accurate models [25, 28]. Rigid or
soft airway models can now be produced with realistic nasal geometries and dimensions using
stereolithography [29].
It should be noted, however, that these models have some limitations including the absence
of a nasal mucociliary clearance process and the models may not reflect the in vivo physiology of
different nasal disease states. Also, these models lack the dynamic capacity for altering the size
and tonicity for the nasal valve region during nasal breathing and nasal cycling (dynamic and
irregular change in nasal passages caliber and alternating congestion and decongestion) [25]. In
addition, for rigid models, small sized nostrils may restrict the positioning of the nasal spray within
the nostril. Lastly, application of organic solvents on the surface of the nasal model for extraction
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of administered poorly soluble steroid drug formulations may results in extraction and dissolution
of plastic resin and change in the nasal airway dimensions over time.
Attempts to validate nasal models have used methods to measure the pressure drop across
the model and compare the total deposition efficiency in the model with in vivo deposition data
[20, 23, 30, 31]. Table 1.1 summarizes the nasal airway geometries that have been used for
assessing the delivery efficiency of nasal sprays and the developed standardized and average nasal
models.
Table1.1 Human nasal models: Model origin and regions of interest
Nasal Model type

Data Source

Nasal Region
Segments

Ref

Idealized model

Derived from CT scans of 10 infants
aged 3–18 months

One part model

[32]

Average model

Derived from CT scans of 30 healthy
adults aged 17-78, Does not consider
the shape deviation in the nasal cavity

3 sections: anterior nose,
middle passage and
nasopharynx regions

[6]

Derived from CT scans of 26 healthy
adults aged 17-70, Considers the
variations in nasal passages

3 sections: anterior nose,
middle passage and
nasopharynx regions

[33]

Derived from CT scans of 3 healthy
adults aged 31-53, Considers the
variations in nasal passages

3 sections: anterior,
middle and posterior
cavity

[14]

Bespak

Derived from CT scan of healthy
female

5 sections: anterior nose,
anterior turbinates,
posterior turbinates,
olfactory and nasopharynx
regions

[34]

Boehringer Ingelheim

Derived from CT scan of 40-year-old
healthy Caucasian male

5 sections: anterior nose,
inferior, middle and
superior turbinates, and
nasopharynx regions

[35]

Individual “typical”
model
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Koken

Cast derived from human cadaver

2 sections: divided into
left and right nasal cavity
One part model with
access to maxillary
sinuses

[19, 3638]

NC1

Cast model derived from a human
cadaver

One part model

[39]

NC2

Replica constructed from CT scan of
NC1

One part: nose-throat
model

[40]

Saint

Derived from CT scan of 9-monthold Caucasian female

3 sections: anterior nose,
middle passage and
nasopharynx regions

[41]

VCU model 1
(also, used by Lovelace
and CIIT Center for
Health Research)

Derived from MRI scan of
nonsmoking, 53-year old Caucasian
male with no pathophysiological
Conditions

2 sections: anterior nose,
middle passage and
nasopharynx regions

[21, 31,
42, 43]

VCU model 2

Derived from CT scan of healthy 20year old female

2 sections: anterior nose,
middle passage and
nasopharynx regions

[44]

The use of a physically realistic model, compared to the current FDA in vitro methodology,
may offer insights into the predicted deposition pattern of nasal spray products within the nose.
However, it is important to consider a number of issues as we look to harmonization and
standardization of the methodology. From a regulatory method perspective, one important issue is
the identification of single or multiple model airway geometries that can be made available to the
scientific community. To date, however, several different models have been described and are
summarized in Table 1. Options available include, the development of an idealized nasal airway
geometry, similar to the infant nasal airway described by Javaheri et al. [32], the use of composite
“average” human nasal airways [6, 33] or the use of an individual “typical” human nasal airway
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based on average airway geometries [21, 31, 34-36, 39, 41]. The infant idealized nasal and throat
models were able to mimic average deposition in multiple anatomical models by including
simplified features of the anatomical airways, and an average value of representative characteristic
dimensions that captures the variability among multiple anatomical models [32, 45]. A new
developed average model was obtained by the use of a deformable template method for aligning
and averaging the nasal airway geometry from computed tomography (CT) scans of 26 individuals
where there were good agreement between the landmark locations between input CT scan of
individual and the average model [33]. At Virginia Commonwealth University (VCU), our two
nasal airway models are constructed from an MRI scan and a CT scan of non-smoking 53-year old
man and a 20-year old female, respectively. For VCU nasal model 1, the dataset was originally
reported by Guilmette et al. [46] and been used in a number of nasal particle deposition
experiments [29, 43] and simulations [47]. For VCU nasal model 2 the CT scan data was obtained
from VCU Medical Center. In order to measure regional drug deposition in the model, the nasal
cast was divided into the anterior/nostril, middle passage and nasopharynx regions [48]. The VCU
nasal model 1 was also complimented by the development of three additional nasal models that
seek to address the issue of disease state and population variability during testing. The ’Average’,
‘Constricted1’, and ‘Constricted 2’ models were developed from 12 CT scans of adults ranging
from 19 to 60 years at VCU to form a set of nasal anatomies that span the expected range of surface
area to volume ratios found in the adult population [44]. In addition to defining the airway
geometric model, it is also important to define the regions of interest, if regional deposition is to
be investigated. Table 1.1 shows the nasal regional segments employed by a series of nasal airway
geometries, with the most significant difference being the divisions made to the middle passages.
The Lovelace [31] and Boehringer Ingelheim [35] models segment the middle passage horizontally
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into the inferior, middle and superior turbinates, while the Bespak model [34] is segmented
vertically into the anterior and posterior regions. The VCU in vitro model considers the total
middle passage deposition [21], but has been segmented in previous CFD studies in multiple ways.
The nasal airway models are manufactured from a variety of polymer resins with the VCU model
being made from Accura ClearVue resin (3D Systems, Inc., Rock Hill, SC); solvent resistant resins
from which deposited drug can be completely recovered are essential.
These models have been used to study the effects of device and formulation characteristics,
nasal airway variability and nasal spray administration methods on the nasal deposition pattern
[42]. However, the conclusions reached about the importance of these variables are often
inconsistent. Guo et al., [36] found no significant effect when assessing the presence and absence
of constant inhalation airflow on regional deposition of nasal spray formulation, whereas Trows et
al., [35] observed greater deposition in nasal vestibule, middle and upper turbinates when
administering a nasal spray during inhalation. These observations may be due to the differing
experimental protocols used to perform the studies or the different in vitro nasal models with
different geometries. In addition, there is a lack of standardization for segmentation of the middle
passages and the region of interest in middle passages such as turbinate area is often segmented
differently. In this research, using in vitro nasal airway models, the effect of formulation and device
variables, administration technique and inter-subject variability in the geometry of the nasal cavity
can be assessed for developing new and generic nasal spray products. However, in vivo validation
may be needed to establish in vitro – in vivo correlations.
1.2.4 Intranasal delivery devices
Intranasal delivery of aqueous solution and suspension formulations can be achieved using
a rhinyle catheter, dropper, unit dose pipette, mechanical spray pump such as a squeeze bottle, unit
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dose or multiple dose metered dose spray pump, pMDI and nebulizer. Powder formulations can
be delivered via a nasal powder inhaler and nasal insufflator. However, among all devices
mentioned above, the metered dose nasal spray is the most popular option [2, 7].
1.2.4.1 Metered dose nasal sprays
Nasal drug delivery using solution and suspension metered dose nasal spray products has
been employed widely for both local (e.g. corticosteroids for CRS) and systemic therapeutic effects
(e.g. sumatriptan for migraine). The metered dose pump typically delivers 100 μL (25 – 200 μL)
per spray as single or multiple dose delivery systems. The therapeutic ingredient can be dissolved
or suspended in a formulation along with excipients such as buffering agents, osmolality modifiers,
wetting agents, bio-adhesive polymers or viscosity enhancers, and preservatives [49]. New designs
of nasal sprays use a collapsible bag, a movable piston or compressed gas to compensate for the
delivered liquid, reducing the need for incorporating preservative in the formulations. Other
approaches use filters for reducing contaminations in the incoming air to the spray pump, or utilize
the oligodynamic activity of a silver wire in the tip of the actuator or a silver coated spring and
ball (antiseptic properties of silver ion released in the formulation) [50].
The droplet size and plume properties exiting from most nasal sprays depends on the pump
design and the actuator orifice, formulation properties and applied actuation force, together with
the swirl effect and break-up length. On nasal spray actuation, by applying force and creating
pressure, the liquid formulation is transferred from the dip tube and exits from the spray orifice
under the action of both radial and axial forces [51]. A swirling thin sheet of liquid exiting from
the nozzle breaks up after a few millimeters into “ligaments” before forming the droplets (breakup length). This forms a hollow spray cone with droplets mainly at the periphery. The spray angle
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diameters (Dmax and Dmin) are typically 2 to 3 cm measured at 1.0 to 2.5 cm from the spray
nozzle. For a spray pump, inserted at a depth of 10 - 15 mm into the nostril, only a small portion
of the plume can penetrate deep into the nasal cavity [52]. In addition, it has been suggested that
there are 90% of particles or droplets larger than 10 μm and nearly 80 % of particles larger than 5
μm that will impact within the nasal cavity [53]. Most nasal sprays produce droplets larger than
40 μm and usually in the size range of 30 to 120 μm [54, 55]. Therefore, due to the presence of the
nasal valve with its small surface area compared to the spray plume geometry and the high initial
velocity of the emitted plume from the nasal spray, the majority of drug impacts on the anterior
nose with only a small fraction penetrating into the middle passages. Moreover, it has been shown
that within 15 to 30 minutes, more than 50% of the formulation delivered by a nasal spray will be
cleared from the nose by mucociliary clearance which further reduces the formulation efficacy [4].
1.2.5 Development of generic nasal sprays
FDA received the first generic nasal spray application or abbreviated new drug application
(ANDA) in 1978 and by the end of 2013, 85 nasal spray drug product ANDAs had been submitted
to the FDA. Based on FDA reports, the average number of nasal spray ANDA submissions in the
past 10 years (2003-2013) is six applications per year. FDA has established guidance for
pharmaceutical manufacturers to assist in the development of generic nasal spray solution products
and to establish equivalence between test and reference products. This guidance includes
demonstration of equivalent in vitro performance shown by in vitro tests including determination
of droplet size distributions using laser diffraction, determination of the % of drug < 10 µm using
cascade impaction and characterization of the spray plume angle and spray pattern [56]. In
addition, manufacturers must show formulation sameness and device comparability between the
test and reference products to ensure similarity. However, in case of nasal spray suspension
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products the FDA indicated that equivalence should be established based on a ‘weight of evidence’
approach through equivalent in vitro test performance, equivalent systemic exposure demonstrated
with a pharmacokinetic (PK) study and equivalent local delivery based on a pharmacodynamic
(PD) or clinical endpoint study. In addition, device similarity and formulation sameness should be
demonstrated. These additional steps for the suspension formulations are required due to the
complexity of suspension formulations and potential differences in the suspending drug particle
characteristics (e.g. size, crystallinity) altering the rate and extent of drug availability locally at the
nasal sites of action and in the systemic circulation following absorption. Nasal suspension
formulations can contain more than one suspended component and current particle sizing
technologies are limited in their ability to adequately characterize the particle size distribution
(PSD) of the active ingredient in the presence of other suspended excipients.
Despite the established use of a number of in vitro characterization methods, Suman et al.
[52] recognized that these in vitro tests were capable of discriminating between different nasal
spray products, the differences did not necessarily translate to differences in vivo nasal deposition
and absorption. While it appears that these tests are useful as quality control tests for assessing
nasal spray performance, in practice, the confined anatomy of the nose makes it extremely unlikely
that an emitted spray formulation develops into the fully developed plume, and therefore, the
clinical relevance of such in vitro methodologies is doubtful [17].
1.2.5.1

Comparison of device nasal drug delivery efficiency
Nasal drops and vapors are the oldest and simplest nasal delivery systems. Nasal drops can

be administered via a pipette. The main limitations of these delivery devices is the lack of precision
in the administered dose and required complex administration maneuvers. Penetration of the
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formulation through the nasal valve region is superior for drops compared to the nasal spray pump.
However, administration of drops requires a head – down body position which results in poor
patient compliance [57]. Nasal liquid formulations can also be delivered using a fine catheter by a
trained person to the desired site. A hydrofluoroalkane (HFA) based pressurized metered doseinhaler (pMDI) delivery system for beclomethasone dipropionate (QNasal, Teva Respiratory,
LLC) has recently been developed in the USA [58]. Similar to nasal spray products, the pMDI
produces localized deposition on the anterior non-ciliated nose as the emitted plume has an even
larger velocity than the nasal spray plume [18]. However, the amount of drug loss due to dripping
from the anterior nose and the deposition fraction in the throat are reduced and less variable with
an overall higher drug retention and slower clearance compared to Nasonex® and Flonase® nasal
spray products when administered to patients with allergic rhinitis [18].
Small volumes administered by nasal sprays (20 - 200 µL) are suitable for potent drugs
(such as corticosteroids) and can be formulated as suspensions or solutions. Previously, for
treatment of local infection in the nose, nebulizers have been used. Nebulizer delivery of antibiotics
provided an increased drug penetration through the nasal valve region due to their small droplet
size (often 3µm) [59, 60]. With respect to drug clearance, no differences in MCC rate for drugs
administered by nebulizer or by nasal sprays was observed. However, nebulizers can deliver drugs
to the olfactory region and upper portion of the nasal cavity where the MCC is slower. The
limitation of using nebulizers is the large potential of lung drug delivery [17]. However, sonic jet
nebulizers have shown improved results for sinus delivery of antibiotics [60].
Powder formulations can offer longer retention in the nasal cavity by the addition of
mucoadhesive excipients to the formulation. In addition, they absorb moisture from the nasal lining
fluid and may adsorb to the surfaces. Nasal powders have been administered via powder spray
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devices similar to liquid sprays, or by breath-actuated inhalers (using patient inspiratory effort to
aerosolize powder and delivery dose to the nasal cavity) and nasal insufflators devices with
connected mouth and nose pieces [61].
1.2.6 Use of antibiotics in chronic rhinosinusitis
Chronic rhinosinusitis (CRS) is a common chronic disease of the nasal airways and
paranasal sinuses affecting approximately 10 - 15% of the US population [62, 63]. The etiology of
CRS is not completely clear, but it is believed that one or more factors, such as anatomical
obstruction due to high mucus secretion, accumulation of bacterial or fungal infection in the
sinuses, or allergies result in a chronic inflammation of the nasal airways. The most widely
employed classification of CRS divides the disease into two classes, CRS with nasal polyposis
(CRSwNP) and CRS without nasal polyposis (CRSsNP), on the basis of the presence or absence
of bilateral nasal polyps as confirmed with nasal endoscopy. The main organisms in CRS
include Staphylococcus aureus, Enterobacteriaceae spp., and Pseudomonas spp., and less
commonly Streptococcus pneumoniae, Haemophilus influenza, and beta hemolytic streptococci
[64-66]. In patients who had previous sinus surgery, Pseudomonas aeruginosa is a frequent cause
of sinusitis. In addition, in cystic fibrosis (CF) patients the most dominant organism isolated from
sinuses is Pseudomonas aeruginosa [67]. There is a high rate of endoscopic sinus surgery (ESS)
in North America due to ineffective drug treatment options [62].
The main therapies for CRS include topical nasal irrigation, nasal steroids and oral
antibiotics [68]. The first-line agent for treatment of acute sinusitis is extended use of antibiotics
such as amoxicillin/clavulanic acid. However, a double-blind study including 251 CRS patients
with major infection of S. pneumonia, S. aureus and Haemophilus influenza compared the
effectiveness of ciprofloxacin and amoxicillin/clavulanic acid (500mg BID (two times a day) for
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9 day for each treatment) and the results showed that ciprofloxacin was as effective as
amoxicillin/clavulanic acid. There was a similar clinical cure rate of 58.6 % and 51.2% and
bacterial eradication of 88.9 % vs 90.5%, respectively, for ciprofloxacin vs. amoxicillin/clavulanic
acid [69]. A clinical study also assessed the effect of oral administration of ciprofloxacin in 56
patients with CRS (30 patients were diagnosed with bacterial infection, mostly with S. pneumonia,
S. aureus and Haemophilus influenza). These patients were given 500 mg of ciprofloxacin orally,
BID, for 9 months. The bacterial infection was eradicated in 90% of the cases with the bacterial
infection and cure rate greater for these patients compared to patients with no evidence of infection
(83 % and 71 %, respectively) [70].
Despite the main use of antibiotics for treatment of CRS being administered systemically,
there are studies which have examined the use of local delivery of antibiotics. Vaughan et. al [71]
assessed the effect of nebulized ciprofloxacin for a duration of three weeks in patients with CRS
with previous sinus surgery who were positive for bacterial infection by S. aureus and
Pseudomonas aeruginosa. The dose of ciprofloxacin was 90 mg twice a day. The results showed
that patients treated with nebulized ciprofloxacin had 11-16 infection free weeks compared to the
standard therapy (average of 6 weeks). A clinical trial was conducted using nebulized levofloxacin
(125 mg-twice a day) for 14 days to assess its efficacy in treatment of CRS for patients with a
history of bilateral endoscopic sinus surgery [72]. The device used was the NasoNeb nebulizer
(MedInvent, LLC, Medina, OH), which is a pulsating nebulizer. The device produces an aerosol
with a droplet size of 23.3 microns and no particles smaller than 15 microns. It is designed to
deliver between 0.2 to 15 mL of liquid formulation [73]. The manufacturers website indicated that
“NasoNeb-delivered levofloxacin demonstrate a reduction in total bacterial abundance in a
randomized, controlled trial of chronic sinusitis patients”.
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However, using nebulizer delivery systems, the drawbacks are lower formulation stability
and long nebulization time, the need for rigorous cleaning after each use to reduce the risk for
contamination, and they are relatively bulky to carry around. Improved physicochemical and
microbial stability can be accomplished by formulation of nasal powders. Also, for nasal sprays,
inadequate distribution of the particles produced by nasal spray pumps limit the therapeutic effects
for topical and systemic applications. Nasal powder formulation is a viable system for less potent
drugs (needing higher doses) and for delivery of therapeutics such as antibiotics with greater
distribution in posterior nasal cavity.
It has been suggested that inhaled micro-antibiotic formulation would be entrapped in the
biofilm produced by Pseudomonas aeruginosa in CF patients [74-76]. The biofilm produced by
bacteria was shown to be a complicated 3D heterogeneous mesh with holes ranging from 100 nm
to 500 nm, therefore drug formulation should be small enough to travel through the mesh [77, 78].
The mucus secretion in CRS patients (CRSM) are also highly viscous due to excess mucin
secretion and release of DNA and actin from degenerating neutrophils. Based on the mobility of
different sized PEGylated particles, the average pore size of fresh CRSM has been reported to be
at least 150 ± 50 nm [76]. Therefore, one approach for successful powder antibiotic delivery to the
nasal cavity may involve formation of a matrix of nanoparticles which releases the primary
nanoparticles upon deposition in nasal fluid. This possibility has been investigated in this
dissertation.
1.2.6.1 Ciprofloxacin
Ciprofloxacin, a fluoroquinolone, is a broad-spectrum antibiotic first introduced in 1980
and was effective against a wide variety of Gram-negative and Gram-positive bacteria. It is a
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zwitterion and exhibits poor solubility at physiologic pH = 7.4 [79, 80]. The solubility curve for
ciprofloxacin is shown in Figure 1.2 as a function of pH [79]. The change in solubility with respect
to pH can be explained by formation of different species at respective pH (Figure 1.3). Based on
Figure 1.2, the lowest solubility values are observed in the pH region around 7.4. Higher solubility
is observed at pH values < 5.9 and > 8.9. The dominant species at pH values lower than 5.9, are
the soluble ciprofloxacin+ species (ciprofloxacin ion with + charge) and at pH higher than 8.9 are
the soluble ciprofloxacin- (ciprofloxacin ion with - charge) species. The pH range from 5.9 (pKa1)
to 8.9 (pKa2) contains three different species producing the lowest solubility in water at pH 7.4
due to the dominant presence of the ciprofloxacin zwitterion species which is neutral (Figure 1.3)
[80]. Therefore, ciprofloxacin is more soluble when present as either its cation or anion forms.
The bactericidal action of ciprofloxacin results from interfering with replication,
transcription repair and recombination of bacterial DNA by inhibition of the enzymes
topoisomerase II (DNA gyrase) and topoisomerase IV followed by formation of complexes of
quinolone-enzyme-DNA leading to the production of cellular poisons and cell death. The drug’s
carboxyl group and ketone moiety have been suggested to be involved in its binding to the bacterial
DNA/DNA-gyrase complex and to facilitate its penetration into the cells (Figure 1.3) [81, 82]. The
MIC for 90% of the P.aeruginosa strains (MIC90) for ciprofloxacin was shown in several studies
to be around 0.25 mgL-1. A previous study of ciprofloxacin pharmacokinetics for normal subjects
demonstrated that the drug was rapidly absorbed after oral administration and that levels in plasma
were well above the MICs for Enterobacteriaceae, Haemophilus influenzae, P. aeruginosa, and
Staphylococcus aureus. Maximum serum concentrations (Cmax) were attained 1 to 2 hours after
oral dosing. Cmax after 12 hours dosing with 250, 500, or 750 mg are 0.1, 0.2, and 0.4 µg/mL,
respectively. The serum elimination half-life (t1/2) in subjects with normal renal function was
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approximately 4 hours. Serum concentration - dose proportionality was observed up to a dose of
1000 mg [83, 84]. After oral administration of ciprofloxacin 750 mg twice a day, drug
concentration measured in the nasal and saliva secretion on days 4 to 6 of therapy were reported
as 1.84 ± 0.91 µg/mL and 1.29 ± 0.91µg/mL with peak and trough serum concentration of 2.56 ±
1.80 µg/mL and 0.97 ± 0.81 µg/mL [85]. In another study the concentration of ciprofloxacin in the
nasal secretion of healthy subjects was measured after 750 mg BID administration for 2 days.
Specimens were collected 2, 5 and 8 hr after the last dose. The mean concentration in nasal
secretion after two and eight hours were 0.27 ± 0.4 µg/mL and 0.04 ± 0.03 µg/mL, respectively
[86].

Figure 1.2. Ciprofloxacin solubility profile as a function of pH at 25ºC [79]
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Figure 1.3. Ionization of ciprofloxacin (shown as CPX on diagram) as a function of pH [80]
Intratracheal administration of a micronized suspension (50% < 3µm and 90% < 7µm) of
ciprofloxacin betaine showed prolonged half-life (t1/2) of 13.5 hr in the lungs vs <1hr and 1.96 hr
compared with ciprofloxacin hydrochloride and ciprofloxacin suspension. Differences in half-life
were perhaps due to differences in the dissolution rate of the betaine and hydrochloride forms,
together with particle size [87]. Also in development is a powder formulation of ciprofloxacin for
inhalation in a dry powder inhaler (PulmoSpheresTM Technology by Novartis with particle size of
≤5 µm). This formulation uses ciprofloxacin betaine and is currently in Phase III clinical trials for
the treatment of bronchiectasis in non-CF patients [88]. For this formulation, the mean deposition
of ciprofloxacin in the trachea/bronchi and alveolar space was 22.3 % and 17.2 % of the total dose,
respectively, with moderate inter-subject variability being observed [89]. This antibiotic
formulation exhibits markedly reduced systemic absorption, thus enhancing its local action and
potentially minimizing side effects. The dual formulation of liposomal ciprofloxacin, Pulmaquin,
finished Phase 3 clinical trial study [90]. This product is a mixture of extended-release
ciprofloxacin mixed with a small amount of ciprofloxacin dissolved in an aqueous medium
developed for the management of chronic lung infections with Pseudomonas aeruginosa in
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subjects with non-cystic fibrosis bronchiectasis and cystic fibrosis patients. The minimum
inhibitory concentration (MIC) for ciprofloxacin against gram positive and negative bacteria is
reported to be in the range of 0.008 to 1.0 µg/mL and minimal bactericidal concentration (MBC)
does not generally exceed this range by a factor of more than 2 [83, 84]. Fluoroquinolones
including ciprofloxacin generally exhibit concentration-dependent antimicrobial effectiveness and
drug concentration above the MIC or Peak/MIC of >10 and concentration–time curve (AUC/MIC)
ratios of >125 have been identified as possible pharmacodynamic predictors of clinical and
microbiological outcome as well as the development of bacterial resistance. However, there are
contradictory results for the role of time dependency of ciprofloxacin [91].
A nanocomposite powder formulation of ciprofloxacin which releases the ciprofloxacin
nanoparticles upon deposition on the nasal fluid may be useful in the enhanced local treatment of
the infections in the nose such as CRS as nanoparticles may show faster penetration in the high
viscoelastic mucus mesh and biofilms produced by bacteria in the CRS patients.

1.3 Dry powder and nanoparticle nasal delivery strategies
1.3.1

Next generation dry powder delivery devices

The Breath–Powered Bi DirectionalTM device is a new nasal technology for delivery of nasal
powders in which patients exhaling through the device mouthpiece deliver powder particles into
an airstream through a delivery tube to one nostril in which the tube is sealed. Powders will be
swept entirely around the nasal septum, and any un-deposited powder will escape from the other
nostril. Lung delivery is prevented by simultaneous oral exhalation into the device that creates a
positive pressure in the oropharynx so the soft palate will close therefore separating the nasal and
oral cavities. Clinical studies showed that the device delivered more drug to the upper and middle
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posterior passages compared to a conventional nasal spray pump (54% vs 16%, respectively) [61].
Sumatriptan, zolmitriptan, oxytocin and butorphanol are in the pipeline for systemic delivery and
fluticasone for topical delivery using this device [92]. Compared to conventional nasal sprays, a
similar bi-directional breath actuation technique for nasal powders produced superior distribution
in upper and middle posterior part of the nasal cavity. In general, dry powders have the advantage
of longer stability compared to liquid formulation with no need for addition of preservatives
(which are often locally irritant); they are also more portable and suffer from less risk of microbial
contamination. A phase III clinical trial for nasal administration of 16 mg sumatriptan (Onzetra®
Xsail®, OptiNose) for pain relief in migraine was completed using the bi-directional approach,
demonstrating the feasibility of using powder delivery to administer milligram quantities of drug
to the nose.
1.3.2

Nanoparticle formation strategies
For drugs to be pharmacologically active they first need to dissolve at the absorption site

(for local and systemic effects) and then be taken up into local cells or transferred to the systemic
circulation [93]. However, many new pharmacologically active compounds exhibit low solubility
and permeability [94-96]. Classical approaches to increase drug dissolution rate include the use of
co-solvents, complex or salt formation, addition of surfactant, and pH adjustment [97]. Particle
size reduction is another technique that can be used to enhance dissolution rate which is achieved
by increasing the surface area according to the Noyes-Whitney equation:
𝑑𝑄
𝑑𝑡

=

𝐷
ℎ

𝑆(𝐶𝑠 – 𝐶)

Equation 1.1
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where the dissolution rate,

𝑑𝑄
𝑑𝑡

, is directly proportional to the diffusion coefficient of the drug, 𝐷 ,

the available surface area, 𝑆, and the difference between saturation solubility of the drug in the
boundary layer , 𝐶𝑠 , and concentration of drug in the bulk fluid, 𝐶 . As particle size decreases,
surface area increases which leads to improved dissolution rates. To achieve this increased
dissolution, one approach is by the production of nanoparticles for pharmaceutical formulation.
These particles have a size below 1 μm, typically a few hundred nanometers [98].
Particles in nano- scale can be made by top-down methods, starting with larger particles
and breaking them down into smaller particles. This approach uses methods such as ball milling,
jet milling, wet milling and high pressure homogenization. The alternative is a bottom-up
approach, starting from atomic level with further assembly process and formation of
nanostructures. The later approach uses methods such as crystallization, precipitation and solvent
evaporation techniques including spray drying and freeze drying or a combination of these
technologies. Finally, a combination of a bottom-up technology such as freeze drying with a topdown method such as high pressure homogenization can be also employed [97, 99-101].
Common top-down processes are wet ball milling and high pressure homogenization in
which the larger drug particles are broken down to very small drug nanocrystals. Drug is suspended
into an aqueous or organic dispersion medium containing surfactants or polymeric stabilizers and
particle size reduction happens through attrition using media milling or a high-pressure
homogenizer which repeatedly forces the drug suspension through a very thin gap (typically about
25 μm) at extremely high velocity. Depending on the physicochemical properties of the drug and
the processing parameters, different milling time and homogenization cycles can be applied. In
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contrast to the bottom-up technologies, almost any poorly soluble drug can be processed using
these methods [101, 102].
The bottom-up methods have the advantage of producing smaller particle sizes (below 100
nm) usually by controlled precipitation, while top-down methods often require larger energy input
and are more time consuming. In addition, controlling the particle size, morphology and surface
characteristics seems to be more feasible by a bottom-up approach such as crystallization, even
though any un-desirable solvent residue must be removed [99]. However, it is noted that the topdown processes such as high pressure homogenization and wet ball milling are most commonly
used in pharmaceutical industry [97].
1.3.2.1 Liquid anti-solvent precipitation
Liquid anti-solvent precipitation has been used widely for preparation of nanometer and
micrometer sized drugs. This technique involves introducing a homogenous drug solution into an
anti-solvent. As the solutions mix, a meta-stable supersaturated solution is produced followed by
drug nucleation and crystal growth. The crystal growth occurs by condensation, coagulation and
agglomeration of particles.
In classical nucleation theory a multicomponent system initially exists as a single phase
[103, 104]. However, by changing the boundary conditions such as temperature, pressure or
mixing with a secondary component the free energy changes and is favorable to phase separation.
The particles, at atomic, ionic or molecular level, of one component coalesce and form nuclei of
the separating solid phase in the liquid or gaseous media. The free energy of a spherical nucleus
with radius r can be described as in Equation 1.2.
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4

Δ𝐺 = Δ𝐺𝑆 + Δ𝐺𝑉 = 4𝜋𝑟 2 𝛾 + 𝜋𝑟 3 Δ𝐺𝑣

Equation 1.2

3

Where the Δ𝐺𝑠 is the excess free energy between the surface of particle and the bulk of particle
and Δ𝐺𝑣 is the excess free energy between a very large particle and the solute in the solution. 𝛾 is
the interfacial tension at solid-liquid interface and Δ𝐺𝑣 is the difference in free energy per unit
volume between the two phases. These two terms of Δ𝐺𝑆 and Δ𝐺𝑉 (as shown in Figure 1.4) have
opposite signs, so as r increases Δ𝐺 passes the maximum. The maximum value or Δ𝐺𝑐𝑟 critical
free energy corresponds to nucleus with radius r* defining the minimum size of stable nucleus.
Particle smaller than this size dissolve in a liquid media to reduce the free energy and particles
larger than r* continue to grow.
r* = −2 𝛾/ Δ𝐺𝑣

Equation 1.3

From equations 1.2 and 1.3

Δ𝐺𝑐𝑟 =

16 𝜋 𝛾3

Equation 1.4

3 (Δ𝐺𝑣 )2

The rate of nucleation (the number of nuclei formed per unit time per volume, J, is then can be
defined as

J = A exp (−

ΔGcr
kT

)

Equation 1.5

k is the Boltzmann’s constant, T is the absolute temperature.
From equations 1.4 and 1.5

J = (𝐴 𝑒𝑥𝑝

16 𝜋𝜐2 𝛾3
3 (𝑘𝑇)3 (ln(1+𝑆))2

)

Equation 1.6
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A is the pre-exponential factor (1032 to 1036) and depends on the crystal growth mechanism at the
particle surface.

Figure 1.4. Energy diagram of Gibbs free energy [103]
The supersaturation or S is defined as
𝐶

S = 𝐶∗

Equation 1.7

In which 𝐶 is the particle concentration in the solution and 𝐶 ∗ is the equilibrium solubility in the
mixture of solvent /anti-solvent. Therefore, higher nucleation rate is governed by lower Gibbs free
energy. Based on the equation 1.6, nucleation rate mostly depends on degree of supersaturation
(S) and interfacial energy (𝛾).
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The time from mixing of the drug solution with the anti-solvent solution to the appearance
of crystals is called the induction time and is described as

t 𝑖𝑛𝑑 = 𝑘𝑐1−𝑝

Equation 1.8

where 𝑐 is the initial concentration of a supersaturated solution, 𝑘 is a constant and 𝑝 is
the number of molecules in a critical nucleus. Induction time can range from microsecond to days
depending on the degree of supersaturation. The mixing event which is followed by generation of
supersaturation is critical in the crystallization process.
After nuclei formation, nuclei will grow by addition of particles on the crystal face. Three
physical phenomena occur for crystal growth: i) transport of materials to be crystalized from the
bulk solution to the crystal surface boundary layer, ii) transfer of materials from the solution
boundary layer to the crystal surface, and iii) diffusion of the growth unit from the impingement
site to the growth site and incorporation into the crystal unit. Crystal growth rate depends on
temperature and supersaturation. The crystal habit formed can have different shapes and size
depend upon the crystallization conditions [104, 105].
1.3.2.2

Sonocrystallization
One approach to modify the rate of nucleation and crystal growth during liquid anti-solvent

precipitation involves utilizing power ultrasound. Sonocrystallization is the application of power
ultrasound (frequency of 10 – 100 kHz) during the crystallization process. Previous researchers
have shown its benefits of providing faster and more uniform nucleation at lower supersaturation
ratios, reducing agglomeration and producing more uniform size crystals [105]. By applying
ultrasound, alternative cycles of compression and rarefaction within the media, creates tiny water-
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vapor bubbles [106, 107]. The sudden release of energy as a result of bubble explosion causes
extremely rapid and localized temperature reductions that generate rapid nucleation in the solution
[106]. Also, the collapse of the bubbles produces intense shock waves which are propagated
through the liquid at velocities higher than the speed of sound (in air) leading to uniform micromixing of the drug solution and anti-solvent. The sonocrystallization process can be influenced by
ultrasound variables such as frequency, intensity, power and duty cycle, as well as by physical
variables such as temperature, pressure, time, volume of the vessel and probe diameter [107]. Park
et al. [108] investigated the induction time for roxithromycin crystals in the absence and presence
of ultrasound in an anti-solvent crystallization process. In the absence of ultrasound, the induction
time of roxithromycin crystallization decreased with increasing supersaturation. When ultrasound
was employed, the induction time decreased significantly for all levels of supersaturation that were
investigated. The authors concluded that it was an acceleration in diffusion in the presence of
ultrasound that caused the reduction in induction times. Micronized albuterol powder for
pulmonary administration with volume mean diameter of 1.8 µm was produced by optimizing
sonocrystallization conditions such as increasing sonication amplitude, lowering temperature and
increasing drug concentration in solution [109]. For griseofulvin crystallization, application of
ultrasound at 25 W during crystallization significantly reduced the mean particle size of the
crystals to 4.87 µm compared to 23.49 µm when no ultrasound was applied during crystallization.
However, it was observed that further increasing the ultrasound energy only slightly further
reduced the crystal particle size. Also, it has been reported that the probe diameter in relation to
the crystallization vessel size was important. Increasing probe diameter was observed to result in
production of a smaller crystals by providing more efficient mixing [110]. However, it has also
been reported that the flow pattern or mixing of the liquids depends on probe immersion depth,
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therefore any change in the flow pattern due to probe immersion may affect the crystallization rate
[106].
In a recent technique of spray sonocrystallization, the drug solution was passed into a flowthrough ultrasonic probe which was immersed into the anti-solvent with continuous flow. Drug
formulation was sprayed into the flow of anti- solvent as fine droplets of solution. The diameter of
the spray sonocrystallized particles were 75 -175 nm [111].
In this research, the feasibility of using sonocrystallization technique for producing
ciprofloxacin nanocrystals with mean volume diameter of 100 - 200 nm suitable for penetration
through mucus and biofilm layers produced by bacteria was assessed.
1.3.2.3

Spray drying
Spray drying is a popular bottom-up approach in the pharmaceutical industry for the

production of micrometer and sub-micrometer sized particles [112]. The spray drying technique
involves i) atomization of a liquid from feed solution, emulsion, or suspension (in aqueous or
organic media) through a nozzle to produce micron-sized liquid droplets; ii) drying of the liquid
droplets into powder form using a hot dry gas (usually > 50 °C), and; iii) collection of the particles
from the moist gas or air. Particle collection is done using deposition in a cyclone or by electrostatic
precipitation. Spray drying of the biological materials is also feasible while maintaining their
biological activity as the drying process is very short (in the order of 11ms) and there is reduced
temperature in the vicinity of the protein due to evaporative cooling [113, 114]. Control of the
drying conditions can be achieved by changing the gas feed rate, solution feed rate and the inlet
temperature. The particle size and distribution of the atomized droplets can be controlled by choice
of the atomizer, which includes rotary, ultrasonic, twin fluid nozzle designs. The air to liquid ratio
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in the atomizer and the feedstock solids concentration define the particle size distribution of the
final particle [115, 116]. It is possible to generate nanoparticles in the size range 200 - 400 nm
using the spray drying technique. This method usually requires the use of an organic solvent and
low solids concentration in the feed stock [117].
Spray drying can be also used for the conversion of nanocrystals (pure drug) or
nanosuspensions to a larger sized dry powder formulations suitable for nasal or inhalation drug
delivery. Van Eerdenbrug et. al [118] used spray drying to convert nano-suspensions of nine model
drugs with no added excipients. Nanoparticle agglomeration was observed visually for all dried
powder formulations but change in nanoparticle dry powder formulation dissolution was observed
to be specific to the drug compound characteristics (higher log P values was associated with more
aggregation). Kumar et al., [119] investigated the effect of low and high molecular weight sugar
excipients on indomethacin nano-crystalline suspension powders prepared by spray drying. Small
molecular weight sugars such as lactose, mannitol sucrose, maltose and trehalose were able to
protect nanosuspension formulations against particle aggregation using a drug:sugar ratio as low
as 1:2.5 % w/w, compared to those containing polysaccharides perhaps due to their interaction
with the surfactant coated nanoparticles. Additionally, higher powder yields were observed with
formulations containing sugars with higher glass transition temperatures during spray drying
[119]. In another study, Sham et al. [120] reported a conversion of gelatin and poly isobutyl
cyanoacrylate (PIBCA) nanoparticles micro-particles and using lactose as excipient with mass
median aerodynamic diameter (MMAD) of as 3.0 ± 0.2 µm. However, the nanoparticle size
increased approximately 30% after the spray-drying was statistically different only in case of
gelatin nanoparticles.
This project also focuses on the feasibility of using a spray drying technique to convert the
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ciprofloxacin nanocrystals into a nanocomposite powder in the size range of 5 - 10 µm suitable for
nasal drug delivery. The goal was to produce a powder formulation suitable for use in a nasal dry
powder inhaler containing dispersed nanoparticles in a matrix of water soluble excipients.
Therefore, after delivery to the nose, the excipients would rapidly dissolve leaving the
nanoparticles on the airway surface which would then penetrate through the mucus layer and exert
their antimicrobial effects.
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CHAPTER 2

HYPOTHESES AND SPECIFIC AIMS
The overall objectives of this research project were i) to develop and evaluate
methods of characterizing nasal spray products using realistic nasal airway models as more
clinically relevant in vitro tools and ii) to develop and evaluate a novel high-efficiency antibiotic
nanoparticle dry powder formulation and delivery device for the treatment of the local infections
in the nose.
To accomplish these objectives the following hypotheses and specific aims were defined:
Hypothesis 1. Simulated patient-use experimental conditions can influence the in vitro
regional drug deposition of nasal spray products in realistic nasal models.
Specific Aim 1-1: To develop a realistic in vitro testing method for assessing regional nasal
drug deposition of a nasal spray product.
Specific Aim 1-2: To assess the effects of patient-use variables on regional nasal deposition
of a nasal spray product (Nasonex®) in a realistic geometry of the nasal cavity.
Hypothesis 2. The in vitro regional drug deposition of nasal spray products in realistic
nasal models is determined by differences in the airway geometry of the nasal model and the
formulation / spray device properties.
Specific Aim 2-1: To compare the regional nasal deposition of a nasal spray product
(Nasonex®) in a 2nd realistic nasal model with varying geometric features (inter-subject
variability).
Specific Aim 2-2: To investigate regional nasal drug deposition of innovator and generic
nasal spray products using the developed realistic in vitro testing methods.
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Specific Aim 2-3: To characterize the regional nasal drug deposition of nasal spray products
with varying in vitro spray properties.
Hypothesis 3. Enhanced middle passage drug delivery can be accomplished using a
novel nanocomposite formulation and nasal powder delivery system.
Specific Aim 3-1: Prepare ciprofloxacin nanoparticles and nanocomposite nasal powder
formulations.
Specific Aim 3-2: Develop and evaluate a novel nasal delivery system to target delivery of
a nasal nanocomposite dry powder formulation to the nasal middle passages.
Specific Aim 3-3: Characterize the regional nasal drug deposition of the novel
nanocomposite formulation and nasal powder delivery system using the developed realistic in vitro
testing methods.
Specific Aim 3-4: Develop a technique to assess post nasal deposition events such as
transepithelial transport of drugs after realistic deposition on human epithelial cell monolayers in
a realistic airway geometry.
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CHAPTER 3

DEVELOPMENT OF A REALISTIC IN VITRO TESTING METHOD
TO ASSESS REGIONAL NASAL DRUG DEPOSITION OF NASAL SPRAY
PRODUCTS USING SIMULATED PATIENT-USE EXPERIMENTAL
CONDITIONS

3.1 Introduction
A large number of in vitro studies have employed realistic hollow nasal models to identify
the influence of nasal formulation properties, spray pump design and patient variables on regional
nasal drug deposition of spray products. These studies have investigated and optimized various
parameters including formulation characteristics such as viscosity or surface tension,
administration technique including positioning of the nasal spray product and nasal model to
optimize nasal drug delivery [19, 38]. Other studies have focused on the effects of simulated
patient use experimental conditions such as use of inhalation air flow profiles, nasal wall coating,
nasal spray actuation conditions, in attempts to reduce the variability observed during in vitro
testing and to simulate realistic patient use [34-37, 42]. The conclusions reached regarding the
importance of these formulation and spray variables to influence nasal deposition are sometimes
contradictory which may be due to the differing experimental conditions used to perform the
studies. However, it has been clearly demonstrated that the use of an automated nasal actuator is
of critical importance to control parameters such as actuation force and velocity, stroke length, rise
time, hold time and to ensure reproducible performance of the nasal spray product during in vitro
testing. It is also recognized that for meaningful in vitro testing of nasal spray products, these
actuation conditions should be derived from human performance data (adults and pediatrics, as
appropriate). Doughty et al. [121] described the use of hand force actuation monitors to determine

35

in use actuation conditions in appropriate patient populations that can be translated to in vitro test
conditions. Similarly, it is recognized that coating of the internal walls of the nasal model,
especially if powder delivery devices are investigated, should be considered. A number of different
materials including mixtures of detergent and acetone, PEGs (400/6000 mixture), propylene glycol
- isopropanol and glycerol - Brij-35 have been used to change the surface properties and mimic
the mucus lining in the nasal model [34-36, 122]. The selection of coating material is often
dependent upon the test drug and extraction solvent, together with compatibility with the drug
assay method.
In order to evaluate the importance of other patient related in vitro testing variables and
move towards a standardization of realistic in vitro testing methods for assessing regional nasal
drug deposition of nasal spray products, a marketed nasal spray product, Nasonex® nasal spray
product, was identified for testing. The instructions described in the Nasonex® patient information
leaflet have been incorporated into an in vitro test method designed to mimic the recommended
patient administration technique and examine the effect of varying these parameters. In the patient
information leaflet, the patient is advised to use nasal spray with the following steps: hold the nasal
spray in the upright position, insert the nasal spray in one nostril and block the other nostril, tilt
head forward, actuate the nasal spray, breathe gently in through one nostril and breathe out through
mouth. Therefore, the patient administration related variables that were defined for investigation
during the realistic in vitro testing were the nasal spray position within the nostril of the nasal
airway model, the head angle of the nasal airway model, the actuation force used to deliver the
nasal spray formulation to the nasal airway model, the presence or absence of an inhalation airflow
during nasal spray administration to the nasal airway model. The effects of each of these patient
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administration related variables on the regional drug deposition of Nasonex ® nasal spray product
was investigated.
This chapter describes the analytical method developed to selectively extract and quantify
the administered drug (mometasone furoate) from the in vitro nasal airway model, together with
preliminary studies that were performed to identify patient use factors that influence the regional
nasal deposition of the Nasonex® nasal spray product. Finally, a full factorial design of experiment
was constructed to determine the significant main factors or interactions between the patient use
study variables on the regional drug deposition of the nasal spray product.

3.2 Material and Methods
3.2.1 In vitro experimental setup to assess the regional drug deposition of Nasonex® nasal
spray product
Nasonex® nasal spray (Merck & Co. Inc., Whitehouse Station, NJ) delivering 50 mcg
mometasone furoate (anhydrous) per dose as mometasone furoate monohydrate was selected to be
tested. The experimental setup shown in Figure 3.1 was constructed to allow an in vitro simulation
of the realistic use of Nasonex®. The test components consisted of the eNSP automated actuation
station (MightyRunt, InnovaSystems, Moorestown, NJ), the realistic physical model of the nasal
cavity (VCU nasal model 1) and a programmable breathing simulator (ASL 5000-XL, IngMar
Medical, Pittsburgh, PA). The nasal spray was placed in nasal spray actuator in the vertical
position. A low resistance respiratory filter (PulmoGuard II, Quest Diagnostics, Brockton, MA)
was attached at the end of throat to capture drug that passed through the nasal airways. For these
studies, the nasal spray was administered to the left nostril and the right nostril blocked. A threeway solenoid valve was positioned between the respiratory filter and the breath simulator such that
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the patient exhalation was directed to the atmosphere and not through the nasal model simulating
an oral exhalation. The insertion depth of the nasal spray in the model was kept constant at 1 cm.
A glass fiber filter (81 mm, New Star Environmental, Inc, Rosewell, GA) with a central hole for
the nasal spray nozzle was placed around the nasal spray applicator and positioned at the exit of
the nostril to collect the formulation dripping from the nose as shown in Figure 3.2.
Before each experiment, the nasal spray was shaken by hand for 15 sec. Based on
instructions provided in the prescribing information the nasal spray was primed as follows: the
first ten sprays were fired to waste prior to initial use or if the nasal spray was not used for one
week [123]. One or two doses were administered in the left nostril of the model. The weight of
nasal spray was recorded before and after each experiment to determine the shot weight.

Figure 3.1. Experimental setup for realistic testing of regional nasal deposition of the Nasonex®
nasal spray product. The setup consists of an automated nasal spray actuator, realistic nasal
airway model, a respiratory filter at the end of throat and a breathing simulator
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Glass fiber filter

Figure 3.2. A glass fiber filter placed around the nasal spray applicator to collect formulation
dripped from the nostril when using the Nasonex® nasal spray product

3.2.2 Nasal mouth throat geometry – VCU nasal model 1
The realistic airway model consisted of the nasal passages and nasopharynx. The dataset
used for this model was first introduced by Guilmette [124] and was derived from magnetic
resonance imaging (MRI) of a 53-year-old adult male. This model has been used in a number of
in vitro and in silico studies [29, 43, 125-127]. The MRI multi-slice images were segmented in
MIMICS (Materialize, Ann Arbor, MI) according to the tissue-air contrast and were converted into
a set of coronal polylines that defined the nasal airway. Based on these contours, an internal nasal
surface geometry was constructed in Gambit 2.3 (ANSYS Inc., Canonsburg, PA). The nasal data
set was smoothed to produce a physiologically realistic 3D structure. The hollow model was built
using rapid prototyping, with a Viper SLA machine (3D Systems, Valencia, CA). The nasal airway
model was constructed using Accura ClearVue resin (3D Systems, Valencia, CA). The model is
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segmented in two parts of i) the anterior nasal vestibule ii) combined middle passages and
nasopharynx. As shown in Figure 3.3, the model was connected to the mouth-throat geometry that
was previously developed by Xi and Longest which was derived from a CT scan dataset of an
adult male [128].

Middle passage

Anterior nose

Nasopharynx

Throat

Figure 3.3. Nasal airway geometry (VCU nasal model 1)

3.2.3 Development of methods to extract and assay mometasone furoate following
deposition in the nasal airway model using the Nasonex® nasal spray product
The aim of this task was to develop extraction procedures and assay methods suitable for
the quantitative analysis of mometasone furoate (anhydrous) following deposition of drug in the
realistic nasal model during the in vitro deposition studies. The High-Performance Liquid
Chromatography (HPLC) method employed a Waters 2690 separation module, a 2996 PDA
detector using the wavelength of 230 nm and mobile phase of acetonitrile and water (60:40 % v/v)
at flow rate of 1.3 mL/min modified based on the European Pharmacopoeia monograph for
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mometasone furoate [129]. The volume of injection was 100 µL. The Hypersil Gold column (150
mm x 4.6 mm, 5 µm) temperature was kept as ambient temperature (21-23°C).
Different ratios of potential wash solutions containing acetonitrile - water, methanol –
water and dimethyl sulfoxide – water with capability of dissolving mometasone furoate were
assessed for their compatibility with the realistic physical model plastic resin, both from an
interfering extractable perspective and the long-term effects on the integrity of the airway model.
This was achieved by separately applying the wash solution and drug spiked wash solutions
containing mometasone furoate into VCU nasal model 1 and performing HPLC analysis on the
solution following recovery from the model. Wash solutions that did not produce interfering
extractables and altered the physical integrity of the airway model were advanced to the next stage
of testing.
If appropriate, the next step for the wash solution was to extract and recover mometasone
furoate from the nasal model following delivery of the Nasonex® nasal spray suspension
formulation. For this study, two actuations of the nasal spray were administered to the left nostril
of the nasal model which was then washed with 100 mL of the wash solution. Studies were
performed using both an uncoated realistic nasal model and with the model coated with artificial
mucus (pH 5.7) containing of 8 %w/v mucin type II [130]. The model parts soaked in the wash
solution were sonicated for 30 minutes. The expected concentration of mometasone furoate in the
wash solution was 1 µg/mL, assuming 100 µg dose dissolved in 100 mL of wash solution. For
HPLC method validation and system suitability assessment, mometasone furoate standard
solutions were prepared in the final selected wash solution.
Parallel to this task, it was determined that the wash solution following drug extraction
would require a filtration step to remove undissolved suspended excipients prior to HPLC injection
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of the samples for drug content quantitation. A series of filters were assessed to examine the
removal of suspended excipients without adsorption / absorption losses of mometasone furoate on
the filter. The filters evaluated were a nylon filter (Fisherbrand, pore size 0.2 µm, diam. 25 mm,
Fisher Scientific, Hampton, NH), a PVDF (polyvinylidene fluoride) membrane filter (Whatman
GD/X syringe filters, pore size 0.2 µm, diam. 25 mm, Sigma-Aldrich, St. Louis, MO), and an
Anotop® filter (Whatman, 0.2 µm, 25mm, Sigma-Aldrich, St. Louis, MO). The assessment was
performed by comparing the measured concentration following filtration of mometasone furoate
standard solutions with the concentration of the unfiltered solution by quantified using the
previously described HPLC methods. Standard solutions were prepared in wash solution in the
range of 0.04 – 10.2 µg/mL for passage through the test filters. The first milliliter of the filtrate
solution was discarded.
3.2.4 Determination of shot weight, single drug actuation content and formulation content
uniformity of Nasonex® nasal spray
To assess shot weight and single actuation content, after priming the Nasonex® nasal spray
product, one dose of the product was sprayed into a 50 mL Erlenmeyer flask. The nasal spray
weight was recorded before and after actuation. Actuation was performed manually by operator or
using the MightyRunt automated actuator at two actuation forces of 5.8 and 4.5 kg. The actuation
profile was defined as force rise time of 0.1 sec, hold time of 0.3 sec and force fall time of 0.1 sec
[131]. Following the actuation, drug was recovered from the flask using a known volume of wash
solution to produce a target drug concentration of 1 µg/mL. The nasal spray nozzle was washed
with 30 mL of wash solution to recover drug remaining on the device. The wash solutions were
sonicated for 30 min followed by filtration using the previously developed method.
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Formulation content uniformity was also assessed. The pump assembly of the Nasonex®
nasal spray was opened and 100 µL aliquots of the suspension formulation were sampled using a
volumetric pipette. Samples dissolved in wash solution to produce a target concentration of 1
µg/mL. 10 samples were taken to calculate the formulation drug content uniformity from a single
batch of the drug nasal spray product.
3.2.5 Preliminary assessment of the effect of patient use variables on in vitro regional nasal
deposition of Nasonex® nasal spray
Preliminary experiments were performed to evaluate the importance of a series of patient
use variables (described below) on the in vitro regional nasal deposition of Nasonex® nasal spray.
The following general method was employed after deposition of the nasal spray in the nasal model.
Following each experiment, the nasal model was dissembled into its constituent parts of
the anterior nose, combined middle passage and nasopharynx and throat sections. Know volumes
of wash solution (methanol – water 50:50 %v/v) were used to extract drug deposited on i) the nasal
spray device, ii) from the filter positioned to collect formulation dripping from the nose, iii)
individually from the nasal model parts (anterior nose, combined middle passage and nasopharynx
and throat sections) and iv) the respiratory filter at the end of throat. Wash solutions together with
the nasal model parts were sonicated for 30 min followed by filtration using Anotop® filter.
Samples were analyzed by HPLC to quantify mometasone furoate. The total drug mass recovered
was calculated based on the label claim dose. For each of the study variables described below,
mean data for regional nasal drug deposition were expressed as the percent of the recovered dose
together with the calculated standard deviation (SD).
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One-way analysis of variance (one-way ANOVA) followed by post hoc Tukey HSD using
JMP Pro 12 software (SAS Institute Inc., Cary, NC) was employed to identify the statistically
significant differences in anterior + drip deposition and the extent of drug delivery to the combined
middle passage and nasopharynx. The significance level was 0.05. The ANOVA assumptions of
the normality of data and residuals were assessed by normal quantile plot and residual versus
predicted response plot, respectively.
3.2.5.1 Effect of number of administered actuations on regional drug deposition of
Nasonex® nasal spray
Based on the information provided by manufacturer for dosage and use, Nasonex ® can be
administered as one or two sprays per nostril. To assess the effect of number of actuations on
regional drug deposition of Nasonex® one or two sprays were actuated into a single nostril. The
model head angle for testing was defined as 30° forward from horizontal. The studies were
performed using two actuation forces of 4.5 and 5.8 kg. The actuation profiles were defined with
a force rise time of 0.1 sec, hold time of 0.3 sec and force fall time of 0.1 sec. The nasal spray
positioning was defined with an insertion depth of 1 cm and the distance between the leading edge
of the spray and the front of the nostril was 9 mm while maintaining a constant distance from the
medial and lateral walls of the nostril (Figure 3.5). Two doses were administered to the left nostril
of VCU nasal model 1 in the absence of any inhalation flow.
3.2.5.2 Effect of head angle on the regional drug deposition of Nasonex® nasal spray
For assessing the effect of head tilt angle, the regional drug deposition of the Nasonex ®
was quantified when model head angle was varied from 30° forward from horizontal to 40° and
50° as demonstrated in Figure 3.4. The nasal spray positioning was defined as an insertion depth
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of 1 cm and the distance between the leading edge of the spray and the front of the nostril was 9
mm while maintaining a constant distance from the medial and lateral walls of the nostril. An
actuation force of 4.5 kg was used to actuate the product. The actuation profile was defined by a
force rise time of 0.1 sec, hold time of 0.3 sec and force fall time of 0.1 sec. Two doses were
administered to the left nostril of VCU nasal model 1 in the absence of any inhalation flow.

(a)

(b)

(c)

Figure 3.4. Nasal model head angles of (a) 30° (b) 40° and (c) 50° forward from horizontal used
to assess regional drug deposition of Nasonex® in VCU nasal model 1

3.2.5.3 Effect of actuation force on the regional drug deposition of Nasonex® nasal spray
To assess the effect of actuation force, Nasonex® was administered using three actuation
forces of 4.5, 5.8 and 7.5 kg. The other actuation profile parameters were kept constant with a
force rise time of 0.1 sec, hold time of 0.3 sec and force fall time of 0.1 sec. The head angle was
30° forward from horizontal. The nasal spray positioning was defined as insertion depth of 1 cm
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and the distance between the leading edge of the spray and the front of the nostril was 9 mm while
maintaining a constant distance from the medial and lateral walls of the nostril. Doses were
administered to the left nostril of VCU nasal model 1 in the absence of any inhalation flow.
3.2.5.4 Effect of nasal spray position in the nostril on the regional drug deposition of
Nasonex® nasal spray
Three different positions were investigated with the distance between the leading edge of
the spray and the front of the nostril being varied from 5, 9 and 11 mm, while maintaining a
constant distance from the medial and lateral walls of the nostril to provide a series of potential
positions that may be employed by the patient (Figure 3.5). Then, the nasal model head angle tilted
30° forward from horizontal. The nasal spray insertion depth was held constant at 1 cm. The
actuation parameters for the force-controlled actuator defined as actuation force of 4.5 kg, force
rise and fall time of 0.1 sec and force hold time of 0.3 sec. Two doses were administered to the left
nostril of VCU nasal model 1 in the absence of any inhalation flow.

(a)

(b)

(c)

Figure 3.5. Three nasal spray positions of (a) 11mm (b) 9mm and (c) 5mm distance between the
leading edge of the spray and the front of the nostril while maintaining a constant distance from
the medial and lateral walls of the nostril used to assess regional drug deposition of Nasonex® in
VCU nasal model 1

46

3.2.5.5 Effect of inhalation airflow on regional drug deposition of Nasonex® nasal spray
For assessing the effect of presence of inhalation airflow and its rate, regional nasal
deposition of the Nasonex® was assessed in the absence of inhalation airflow (NI) and in the
presence of slow (SI) and fast inhalation (FI) airflow. Realistic nasal breathing profiles were
adapted from Guo et al., [36] in which nasal breathing parameters for nine healthy adults recorded
while they were asked to breathe gently or vigorously from one nostril while the other nostril was
closed. The slow breathing profile was defined as peak inspiratory flow rate (PIFR) of 20.2 Lmin-1,
time to reach the peak of 0.4 sec, for total duration of 1.9 sec and tidal volume of 560 mL whereas
the fast breathing profile had a PIFR of 35.8 Lmin-1, time to reach the peak of 0.3 sec, for total
duration of 1.2 sec and tidal volume of 619 mL. The breathing profiles were simulated using breath
simulator ASL XL-5000 (Ingmar Medical LLC, Pittsburg, PA). The ASL breath simulator allows
coordination of the inhalation with the nasal spray actuation by connecting with the MightyRunt
nasal spray actuator. At the beginning of inhalation, a 5mV pulse from the breath simulator triggers
the nasal spray actuator via a solid-state relay (Crouzet 84134750, Newark Electronics, Chicago,
IL) which results in the actuation of the nasal spray. Following the start of inhalation, there is a 1
sec delay prior to actuation of the nasal spray to ensure that delivery occurs during the nasal
inhalation. The nasal spray positioning was defined as insertion depth of 1 cm and the distance
between the leading edge of the spray and the front of the nostril was 9 mm while maintaining a
constant distance from the medial and lateral walls of the nostril. The model head angle tilted 30°
forward from horizontal and actuated using an actuation force of 4.5 kg. The actuation parameters
for the force-controlled actuator defined as force rise and fall time of 0.1 sec and force hold time
of 0.3 sec. Two doses were administered into the left nostril of VCU nasal model 1.
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3.2.5.6 Effect of surface coating on the regional drug deposition of Nasonex® nasal spray
To assess the effect of a simulated nasal mucus lining on regional nasal drug deposition,
prior to the deposition experiment, the inner surface of the model was coated with an artificial
nasal mucus fluid, drained, and allowed to air-dry. The simulated mucus lining was prepared by
dispersing 8% w/v mucin (porcine stomach, type II, Sigma-Aldrich, St. Louis, MO) and 7.45
mg/mL NaCl, 1.29 mg/mL KCl and 0.32 mg/mL CaCl2. 2H2O in water adjusted to pH 5.7 [130].
The regional deposition was assessed in the presence of the fast inhalation profile. The nasal spray
positioning was defined as insertion depth of 1 cm and the distance between the leading edge of
the spray and the front of the nostril was 9 mm while maintaining a constant distance from the
medial and lateral walls of the nostril. The model head angle tilted 30° forward from horizontal
and actuated using an actuation force of 4.5 kg. The actuation parameters for the force-controlled
actuator defined as force rise and fall time of 0.1 sec and force hold time of 0.3 sec. Two doses
were administered into the left nostril of VCU nasal model 1.
3.2.6 CFD simulation for prediction of regional nasal drug deposition of Nasonex® nasal
spray product
The computational fluid dynamic (CFD) simulations was performed by Dr. Longest and
Dr. Rygg at VCU Department of Mechanical and Nuclear Engineering. Simulation of aerosol
particle transport in a gas-phase jet was used to assess the spray characteristics at the nasal spray
tip. The effects of aerosol momentum on the gas phase was determined by using a separate air jet
velocity at the nozzle orifice to account for momentum exchange between the aerosol and gas
phases. The air velocity induced by droplets exiting the spray pump at distance of 1cm downstream
of the nozzle tip was considered as 15 m/s. The initial aerosol injection velocity of 7 m/s was
specified for the nasal spray with a plume angle of 52º. The nasal spray regional deposition was
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predicted i) in the absence of the air flow, ii) with slow inhalation (20.2 Lmin-1), and iii) with fast
inhalation (35.8 Lmin-1). Simulations were run using ANSYS Fluent 15 (ANSYS Inc.,
Canonsburg, PA) [132].
3.2.7 Full factorial design of experiment (DOE) to assess the effect of patient use variables
on the regional drug deposition of Nasonex® nasal spray.
The preliminary studies described above were designed to identify the major factors that
affect the regional nasal deposition pattern of Nasonex® nasal spray product. The experimental
design was based on changing one variable at a time and did not consider interactions between
variables. A full factorial DOE for 4 factors with 2 experimental levels was conducted with a total
of 64 experiments to further explore the factors influencing the regional nasal deposition as well
as interaction among the factors. Based on the preliminary studies, four factors each with 2 levels
were identified as follows: (1) position of nasal spray in the nostril (9 and 5 mm, as the distance
between the leading edge of the spray and the front of the nostril while maintaining a constant
distance from the medial and lateral walls of the nostril), (2) nasal model head angle (30° and 50°
forward from horizontal), (3) actuation force (4.5 and 7.5 kg), and (4) inhalation – actuation
timing (nasal spray actuation during nasal inhalation (D) and nasal inhalation started at the end of
nasal spray actuation (E)). The fast nasal breathing profile with the PIFR of 35.8 Lmin-1, time to
reach the peak of 0.3 sec, for total duration of 1.2 sec was used. As previously described the nasal
spray actuator was triggered by the breath simulator during inhalation (Section 3.2.5.5). A
schematic view of the profiles and timings are shown in Figure 3.6. The nasal spray positioning
was defined as insertion depth of 1 cm. The actuation parameters for the force-controlled actuator
defined as force rise and fall time of 0.1 sec and force hold time of 0.3 sec. Two doses were
administered into the left nostril of VCU nasal model 1. Drug deposited on the device, nasal model
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parts and on the filter, was extracted and quantified similarly as performed and described in
Sections 3.2.3 and 3.2.5.

Figure 3.6. Inhalation timing with respect to nasal spray actuation, (a) nasal spray actuation
during nasal inhalation (D), (b) nasal spray actuation followed by nasal inhalation (E). The
breathing profile (shown by blue line) has a peak inspiratory flow rate of 35.8 Lmin-1 and time to
reach the peak of 0.3 sec, for total duration of 1.2 sec and tidal volume of 619 mL.
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3.2.8 Statistical analysis for full factorial design of experiment (DOE)
The response for the DOE analysis was assessed based on the drug deposited in the
combined middle passage and nasopharynx region as the site of action for Nasonex ®. The %
deposition (deposition fraction) in this region was calculated and expressed as percent of the total
recovered dose. The assessment of ANOVA assumption of normality of data was assessed using
a probability plot (normal quantile plot). The model assumptions of normality for residuals and
homogeneity of variances for the ANOVA test were tested using residual plot. Brown-Forsythe
test was used to check the equality of variances where a p-value greater than 0.05 demonstrated
equality of variances among groups.
Variables of inhalation-actuation timing and nasal spray position were defined as
categorical variables whereas actuation force and head angle were defined as continuous. The
influence of each factor and two factor interactions on the response were analyzed using full
factorial ANOVA and significant effects were recognized by p-value < 0.05. A linear regression
equation describes the model as follow:
Y=b0+b1x1+b2x2+b3x3+b4x4+b5x1x2+b6x1x3+b7x1x4+b8x2x3+b9x2x4+b10x3x4
Equation 3.1
where, b0 is intercept, and Y is the measured response associated with the factors (x1, x2, x3, and
x4) and the interaction terms (x1x2, x1x3, x1x4, x2x3, x2x4, x3x4). The p-values related to the
regression coefficients indicate the significance of the factors on the response. All the analysis
performed using JMP Pro 12 software (SAS Institute Inc., Cary, NC).
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3.3 Results and Discussion
3.3.1 Development of methods to extract and assay mometasone furoate following
deposition in the nasal airway model using the Nasonex® nasal spray product
There were a number of challenges to be addressed when developing assay methods
including dissolution of a low aqueous solubility steroid, extraction or dissolution of excipients in
the formulation and the compatibility of organic solvents with the plastic resin used to fabricate
the realistic physical model. The chemical structure of mometasone furoate is presented in Figure
3.7. It is highly lipophilic with a log P value of 3.5, poorly soluble in water (0.02 mg/mL), and
slightly soluble (4 - 8 mg/mL) in methanol [133, 134].

Figure 3.7. Mometasone furoate chemical structure [135]

Ideally, the drug would be dissolved and extracted using an organic solvent, and then
filtered to remove insoluble excipients. As an example, for a potential wash solution that was
evaluated, Figure 3.8 shows a HPLC chromatogram for a 3 µg/mL mometasone furoate standard
solution in the acetonitrile – water (30:70 %v/v) potential wash solution with a drug retention time
of 3.4 min. Figure 3.9 shows a HPLC chromatogram of the same standard solution following
washing on the realistic nasal model. As demonstrated in Figure 3.9, the drug retention was 3.4
mins, however, significant interfering extractable peaks were observed to co-elute with the
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mometasone furoate peak following washing on the airway model using this potential wash
solution.
Following extensive studies, methanol – water (50:50 %v/v) was identified as a suitable
wash solution, capable of dissolving mometasone furoate when used in combination with
sonication for 30 minutes. This solvent mixture was shown to be capable of extracting mometasone
furoate deposited on the uncoated realistic nasal model and on the model surface when coated with
an artificial mucus. Figure 3.10 demonstrates the absence of co-eluting peaks with the mometasone
furoate peak. The mean (SD) peak area for the mometasone furoate (3 µg/mL) peak before and
after washing in the nasal airway model was 370143 (358) and 369370 (968), respectively and was
not significantly different. HPLC analysis of wash solutions applied to the un-coated and artificial
mucus (pH 5.7) coated nasal model revealed peaks that were below the mometasone furoate
detection limit confirming the absence of any interfering peak. The ability of the selected wash
solvent was validated by determination of the drug content from two sprays of the Nasonex ®
formulation deposited into the nasal model and subsequently extracted using the wash solution.
The mean (SD) drug recovery (% of nominal dose) from the uncoated and artificial mucus coated
nasal model was 100.6 (3.2) % and 101.2 (2.8), respectively. Therefore, future studies would
employ appropriate volumes of the 50:50 % (v/v) of methanol – water wash solution to recover
drug during the in vitro deposition experiments.
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For assay method validation, standard solutions in the range of 0.04 – 10.57 µg/mL were
prepared in methanol – water (50:50 %v/v) and used to test the linearity of the HPLC assay method
(Figure 3.11). The precision of the method was assessed by calculation of % relative standard
deviation (RSD) of the mometasone furoate peak area following 6 replicate injections of 0.04
µg/mL mometasone furoate standard solution. The same solution was used to assess the accuracy
using 6 replicate injections and calculation of the concentration of mometasone furoate relative to
the nominal concentration. The limit of detection (LOD) and quantitation (LOQ) were calculated
based on the following equations of 3.2 and 3.3. The method validation results are summarized in
Table 3.1.
LOD =

3.3 × 𝑆𝐷 𝑜𝑓𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑖𝑜𝑛 𝑐𝑢𝑟𝑣𝑒 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝

LOQ =

10 × 𝑆𝐷 𝑜𝑓𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑖𝑜𝑛 𝑐𝑢𝑟𝑣𝑒 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝

Equation 3.2

𝑆𝑙𝑜𝑝𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑖𝑜𝑛 𝑐𝑢𝑟𝑣𝑒

Equation 3.3

𝑆𝑙𝑜𝑝𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑖𝑜𝑛 𝑐𝑢𝑟𝑣𝑒

Table 3.1. System suitability parameters for the mometasone furoate HPLC method
System suitability parameter
Linearity range tested
Precision
Accuracy
LOD
LOQ

Value
0.040 – 10.570 µg/mL, (r2>0.9999)
0.8 %
99.7 %
0.01 µg/mL
0.03 µg/mL
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Area

2.E+06

1.E+06

Y = 3.83 e5 X + 1.15 e2
R² = 0.99997

0.E+00
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00
Concentration (µg/mL)

Figure 3.11. Plot of response (area) versus concentration for mometasone furoate in the range of
0.040 -10.570 (µg/mL) measured at 230 nm. The R2 fitted by linear least square calculated as
0.99997.

Preliminary studies identified the need for sample filtration prior to HPLC of Nasonex ®
formulation derived samples. Filtration was necessary to remove undissolved suspended
excipients prior to HPLC injection of the samples for drug content quantitation. Table 3.2
summarizes the mean (SD) mometasone furoate concentration in the filtered standard solutions in
methanol – water (50:50 %v/v) following passage through the test filters (expressed as a
percentage of the unfiltered solution concentration). For the nylon and PVDF filter, with the low
concentration standard solution only, there were significant losses of drug following filtration.
There was no significant change in drug concentration relative to the starting concentration for the
standard solutions filtered through the Anotop® filters.
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Table 3.2. Mean (SD) mometasone furoate concentration in the filtered standard solutions in
methanol – water (50:50 %v/v) following passage through the test filters (expressed as a
percentage of the unfiltered solution concentration) (n=3)
Mometasone furoate
conc. (µg/mL)
0.04
0.25
0.6
10.2

Nylon Filter
(%)
84.8 (3.2)
78.1 (2.8)
84.8 (0.4)
82.1 (0.8)

PVDF Filter
(%)
93.2 (1.0)
98.6 (0.8)
97.9 (1.4)
98.6 (1.6)

Anotop® Filter
(%)
100.2 (2.4)
103.3 (0.9)
100.7 (1.7)
99.8 (2.1)

Based on these results, the Anotop® filters used in combination with a wash solution
methanol – water (50:50 %v/v) appeared to meet all requirements, with complete dissolution of
drug, removal of suspended excipients without altering the concentration of mometasone furoate
and the absence of interfering peaks when used to extract drug from the uncoated or artificial
mucus (pH 5.7) coated realistic nasal model.
3.3.2 Determination of shot weight, single actuation drug content and formulation content
uniformity of Nasonex® nasal spray product
Table 3.3 represent the corresponding results for the mean (SD) shot weight, single
actuation drug content and formulation content uniformity. When using the automated nasal spray
actuator to generate two different actuation forces of 4.5 and 5.8 kg and following manual
actuation, there was no significant difference in the total amount of drug recovered with respect to
the actuation technique or applied force in the tested range. Similarly, there was no difference in
the measured shot weight, which ranged from 98.8 to 100.4 mg. The corresponding drug content
for a single actuation ranged from 98.8 % to 103.0 % of the label claim. The content uniformity of
the formulation was also assessed for a single nasal spray product. The mean (SD) formulation
drug content for a single nasal spray device was 100.8 (2.1) % of the label claim concentration.
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Table 3.3. Mean (SD) single actuation dose content and shot weight of Nasonex® nasal
spray product
Experiment

Single actuation content –
actuation force of 4.5 kg
Single actuation content –
actuation force of 5.8 kg
Single actuation content –
hand actuation

Spray nozzle
deposition
(% label claim)
0.6 (0.1)

Drug recovery
(% label claim)

Shot weight
(mg)

98.8 (1.3)

98.8 (2.2)

0.3 (0.1)

100.5 (2.5)

99.3 (0.8)

0.7 (0.5)

103.0 (1.0)

100.4 (2.8)

3.3.3 Preliminary assessment of the effect of patient use variables on in vitro regional nasal
deposition of Nasonex® nasal spray
The results for the preliminary assessment of the effect of patient use variables on in vitro
regional nasal deposition of Nasonex® nasal spray are summarized in Table 3.4. The mean total
drug recovery in deposition studies performed, ranged from 87.7 % to 101.8 % of the labeled dose.
For all the deposition studies performed, nasal spray device deposition was low, with less than 2.5
% of the drug deposited on the device. Based on the data presented in Table 3.4, the majority of
drug was deposited on the anterior nose region (89.9 % – 70.2 %) with little drug penetration to
the combined middle passage and nasopharynx region (7.8 % – 32.1%). The amount of drug
recovered from the respiratory filter at the end of the throat for most cases was below 1.0 % and
indicated that very low amounts of drug was able to reach the respiratory filter. These results were
similar deposition patterns observed for nasal sprays in previous in vivo, in vitro and CFD studies
[16, 17, 31, 136, 137]. These studies also observed that the majority of drug deposited in the
anterior nose and there was no drug penetration to the lungs.
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3.3.3.1 Effect of number of actuation administered on regional drug deposition of Nasonex®
nasal spray
Based on the information provided by manufacturer for dosage and use [123], for the
treatment of nasal polyps, congestion and allergic rhinitis, adults and adolescents (above 12 years
of age) are recommended to use 2 sprays (100 microgram dose) in each nostril once daily. For
children 2-11 years of age the recommendation is one spray (50 microgram dose) in each nostril
daily. The effect of number of actuations on the regional nasal drug deposition was assessed using
the two actuation forces of 4.5 and 5.8 kg. As demonstrated in Figure 3.12 and Table 3.4 (Exp.
1,2,3 and 8) there was no differences in regional drug deposition for Nasonex® tested in the VCU
nasal model 1 when 1 or 2 sprays were administered in a single nostril which was corresponded to
administration of 100 µL or 200 µL of the formulation. This indicated that the administration of
the second dose did not change the initial regional deposition of the drug formulation within the
nasal cavity. Subsequent deposition studies were performed by administering two doses of the
Nasonex® to aid analytical quantification.
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Figure 3.12. Effect of number of actuations administered for Nasonex® nasal spray product on
the regional drug deposition in VCU nasal model 1. NSP: nasal spray device, AD: Anterior +
drip, MP: Combined middle passage and nasopharynx region, F: Filter. Recovery is presented as
% of label claim. Deposition is presented as % of recovered dose (n=4)
3.3.3.2 Effect of head angle on the regional drug deposition of Nasonex® nasal spray
Reviewing packaging insert for Nasonex®, patients are advised to tilt their head forward
slightly but there is no quantitative data about the degree of the tilt to be used by the patient. During
clinical use, it is likely that various head angles are used. In this study, the nasal model angle was
varied by tilting the model 30°, 40°, or 50° forward from horizontal while the distance between
the leading edge of the spray and the front of the nostril was 9 mm while maintaining a constant
distance from the medial and lateral walls of the nostril (Figure 3.4). The experimental conditions
and results for these studies are summarized in Table 3.4 by comparing Exp. 2, 4 and 5. The results
from the in vitro studies were compared with CFD simulations. Figure 3.13 compares the in vitro
and CFD deposition results for the effect of head angle. Both in vitro (mean (SD)) and CFD
simulations showed the highest anterior nose deposition of 89.9 (2.5) % and 89.7 %, respectively,
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and lowest combined middle passage and nasopharynx deposition of 8.8 (1.2) % and 8.9 %,
respectively, for the head angle of 30°. It appears that there may be a trend of increasing middle
passage deposition if the head angle is increased from 30° to 50° forward from horizontal which
was shown in both CFD simulations and in vitro deposition results. However, due to experimental
variability, statistical analysis indicated there was no significant differences in the mean (SD)
delivery of the drug to the middle passages (8.8 (1.2) %, 11.6 (6.1) % and 14.4 % (2.3) %) when
the model tilt angle increased from 30° to 40° and 50°. CFD simulation (Figure 3.13) results
showed reduced anterior drug deposition of 78.5 % and 76.2 %, respectively, when the head angle
tilted to 40º and 50º with increased middle passage drug deposition to 21.1 % and 23.6 %,
respectively, which suggests the importance of head angle in determining nasal spray deposition.
Reviewing directions and illustrations provided in packaging inserts for a series of
corticosteroid nasal spray products, patients are mostly advised to tilt their head forward and this
angle varies between 30° to 50° [138]. For example, in directions for use of Nasonex®, Flonase®
and Beconase® subjects are advised to tilt their head forward. However, in case of Nasacort®, the
patient is directed to tilt the head backward [139]. Foo et al. [42] changed the nasal spray angle
and defined an “administration angle” based on a triangle that has one side parallel to the coronal
plane of the head and a horizontal plane perpendicular to it (Figure 3.14). They showed that tilting
the nasal spray at lower “administration angle” of 30° provided increased middle turbinate
deposition compared to 40° and 50° angles. However, based on their definition, it can be observed
that increasing the “administration angle” is equivalent to decreasing the head angle in our studies.
It is important to note that the studies by Foo et a. contradict the prescribing information for
Nasonex®, which state that the nasal spray product needs to be kept in the upright position to
deliver the label claim [138]. Kundoor et al. [37] showed that greater deposition in the middle
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passages can be achieved by tilting the model 30° back from horizontal compared to 30° forward.
Tilting the nasal model back from horizontal can also significantly reduce the amount of
formulation that drips from the nose following actuation.

Deposition fraction (%)

100
AD: in vitro
AD: CFD
MP: in vitro
MP: CFD

80
60
40
20
0

30 degrees

40 degrees

50 degrees

Figure 3.13. Comparison of in vitro (mean (error bars are SD)) regional nasal deposition for
Nasonex® nasal spray product in the VCU model 1 obtained from experimental data and CFD
simulation. AD: Anterior + drip, MP: Combined middle passage and nasopharynx region. The
nasal spray is positioned at 9 mm distance from the tip of the nose at the head angle of 30º
forward and in the absence of the airflow

(a)

(b)

Figure 3.14. Nasal model head angle representations (a) 30º forward from horizontal defined in
present study, (b) administration angle defined by Foo et al. [138]

62

Table 3.4. Mean (SD) in vitro regional nasal deposition of mometasone furoate (expressed as a percentage of recovered dose) and
total recovery (expressed as percentage of the label claim) for the Nasonex ® nasal spray following actuation into the left nostril of
VCU nasal model 1 (n=4 – 10)
Flow
Profile

Position#
(mm)

NSP (%)

AD (%)

MP (%)

F (%)

Recovery
(%)

4.5

Head
angle
(º)
30

NI

9

0.7 (0.4)

85.2 (6.2)

7.8 (3.3)

0.0 (0.0)

93.0 (4.8)

2

4.5

30

NI

9

1.3 (2.1)

89.9 (2.5)

8.8 (1.2)

0.0 (0.0)

96.2 (3.1)

3

1

5.8

30

NI

9

1.4 (2.1)

81.9 (11.5)

11.7 (3.9)

0.0 (0.0)

97.5 (7.1)

4

2

4.5

40

NI

9

2.5 (1.2)

85.0 (5.7)

11.6 (6.1)

0.9 (0.5)

93.3 (6.6)

5

2

4.5

50

NI

9

1.5 (2.1)

83.8 (4.3)

14.4 (2.3)

0.3 (0.1)

90.8 (3.1)

6

2

4.5

30

NI

5

0.2 (0.4)

80.9 (4.3)*

18.9 (4.1)*

0.0 (0.0)

101.8 (17.1)

7

2

4.5

30

NI

11

1.3 (0.6)

90.1 (0.8)

8.6 (1.2)

0.0 (0.0)

95.8 (4.0)

8

2

5.8

30

NI

9

0.5 (0.7)

86.4 (4.1)

13.1 (3.7)

0.0 (0.0)

98.8 (10.3)

9

2

7.5

30

NI

9

1.4 (1.9)

85.6 (3.3)

13.0 (4.3)

0.0 (0.0)

87.7 (3.4)

10

2

4.5

30

SI

9

0.8 (1.1)

70.2 (10.6)** 28.9 (10.9)**

0.1 (0.4)

92.8 (7.3)

11

2

4.5

30

FI

9

0.6 (0.9)

67.3 (7.4)**

0.0 (0.0)

91.5 (7.3)

12

2

4.5

30

Exp.

Actuation
force (kg)

1

Number
of
actuation
1

2

†

32.1 (8.0)**

FI9
0.4 (0.5) 71.9 (6.5)** 27.3 (4.3)** 0.5 (0.0)
97.4 (4.3)
Coated
NSP: Nasal spray, AD: Anterior + drip, MP: Combined middle passage and nasopharynx region, F: Filter, NI: No Inhalation, SI:
Slow Inhalation, FI: Fast Inhalation
# P<0.05, significant effect of position (one-way ANOVA); *: P<0.05, Significant difference compared to positioned at 11 and 9
mm, no inhalation airflow (Tukey’s HSD)
† P<0.05, significant effect of flow profile (ANOVA); **: P<0.05, Significant difference compared to no inhalation airflow,
positioned at 9 mm (Tukey’s HSD)
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3.3.3.3 Effect of nasal spray positioning on the regional nasal deposition of the Nasonex® in
the VCU nasal model 1
The release point position of the nasal spray product in the airway model is considered to
be one of the greatest sources of experimental variability that can have significant effects on the
observed nasal spray deposition [15]. The release point position of the spray is defined by a
combination of the model position and the nasal spray position in the nostril, all of which can be
defined by the operator. However, in previous in vitro studies a fixed nasal position in the nostril
(using nozzle locator) was used or only the information about the insertion depth provided [31, 42,
140]. Variables which can be controlled include nasal model angle, the geometric position of the
nasal spray tip within the nostril, the insertion depth and the coronal and sagittal insertion angles.
Insertion depth is not usually defined in the patient information leaflet; however, a commonly used
value of 10 mm has been widely studied using in vivo, in vitro and computational fluid dynamic
(CFD) models and shown to produce effective delivery to the nose [15, 16, 37, 136].
Three nasal spray positions were defined in our studies which were feasible based upon the
nostril hydraulic diameter of VCU nasal model 1 and the geometry of Nasonex® nasal spray nozzle.
Considering the results summarized in Table 3.4, small changes of 2-6 mm, (by changing the nasal
spray position from 11 mm to 9 mm and 5 mm) in the spray release point were observed to
significantly alter deposition, with the middle passage deposition increasing when the spray release
point was closer to the front of the nostril. Positioning the nasal spray closer to the front of the
nostril at the 5mm distance resulted in more than 2-fold increase in middle passages drug delivery
compared to other positions (9 and 11 mm) (mean (SD) = 18.9 (4.1) % (Exp. 6) versus 8.8 (1.2)
% (Exp. 2) and 8.6 (1.2) % (Exp. 7) (p-value = 0.0004 and 0.0003, respectively)). Correspondingly
there was lower anterior nose deposition for the 5 mm position compared to the 9 and 11 mm
positions (mean (SD) = 80.9 (4.3) % (Exp. 6) versus 89.9 (2.5) % (Exp. 2) and 90.1 (0.8) % (Exp.
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7) (p–value = 0.0030 and 0.0024, respectively)) when tested in the absence of inhalation airflow.
It appears that at a position closer to the tip of the nostril of the VCU nasal model 1, spray droplets
can be release and develop from the spray pump producing less impaction on the walls of the
anterior nose before reaching to the middle passages.
3.3.3.4 Effect of actuation force on the regional drug deposition of Nasonex® nasal spray
Nasal spray generation is dependent on a combination of actuation force, pump design,
viscosity and rheological properties of nasal spray formulation. Doughty et al. [141] investigated
the effect of variability in actuation force and the force profile observed in adults and children
during hand spraying of Flonase® with an instrumented nasal spray. They observed a significant
difference in spray weight (especially in pediatrics) and spray plume properties such as droplet
size diameter with respect to the manual spray condition applied. In our studies, increasing
actuation force from 4.5 kg to 7.5 kg was associated with reducing the mean volume droplet size
of Nasonex® nasal spray from 57.2 µm to 47.0 µm measured using Malvern Spraytec. The droplet
size measurements are described in details in Section 4.2.7.1. However, despite changes in droplet
size, the in vitro realistic nasal deposition profiles remained similar (Exp. 2, 8, and 9) when tested
using actuation forces of 4.5, 5.8 and 7.5 kg with the nasal spray positioned at 9 mm distance from
the front of the nostril. Deposition in the middle passage region was around 10 % of the recovered
dose in all cases. Perhaps, the magnitude of change in droplet size distribution of Nasonex ® was
not large enough to change the regional deposition profile of the formulation due to the initial high
velocity of the spray plume and the presence of the nasal valve region in the anterior nose.
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3.3.3.5 Effect of inhalation airflow on regional drug deposition of Nasonex® nasal spray
Previous studies have shown that in the absence of an inhalation airflow, the majority of
the delivered dose (80 - 90%) was deposited on the anterior nose region and less than 10 - 15% of
the formulation penetrated to the posterior part of the nasal cavity. However, employing nasal
inhalation in combination with nasal spray administration significantly increased the combined
middle passage and nasopharynx deposition and decreased anterior nose losses. The slow and fast
breathing profiles investigated (PIFR of 20.2 Lmin-1 and 35.8 Lmin-1, respectively) produced mean
(SD) anterior nose depositions which were reduced significantly from 89.9 (2.5) % (Exp. 2) to
70.2 (10.6) % (Exp. 10) and 67.3 (7.4) % (Exp. 11), respectively (p-value = 0.0083 and 0.0044,
respectively). As a result, the mean (SD) middle passage drug deposition was observed to be
significantly higher (almost 4-fold) when an inhalation flow was used (28.9 (10.9) % and 32.1
(8.0) % for slow and fast, respectively) compared to the same experiment performed with the
absence of the airflow (8.8 (1.2) %) (p-value = 0.0009 and 0.0010, respectively). The flow rate
employed during inhalation in the range of 20 - 35 Lmin-1 did not significantly affect the regional
nasal deposition. Possible explanations for this improved delivery include that an increased
fraction of small sized droplets is entertained by air flow and that travel further distance inside the
nasal passages or that spray formulation deposited in the anterior nose is moved as liquid on the
surface of the airway into the middle passage region with the inhalation flow. These results appear
to demonstrate the significance of inhalation airflow during nasal spray administration to improve
delivery to the middle passages. The in vitro results were compared to CFD simulations (Figure
3.15) where the flow rate was also shown to significantly increase the middle passage drug
deposition. It was also noted that there was no difference observed in the nasal deposition patterns
for the slow and fast inhalation flow rates in the CFD results. The use of an inhalation during nasal
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spray administration is not clearly stated in patient information leaflet. However, the experimental
and CFD results show the importance of the nasal inhalation for improved drug delivery to the
middle passages.
These results for middle passage drug deposition in the presence of the airflow are similar
to those obtained by Shah et al. [34] using a nasal spray formulation and the Bespak in vitro nasal
model. They reported middle passage deposition of 28.5% using a post actuation flow of 16 Lmin-1
for 12 sec. Also, they observed that there was no change in middle turbinate drug deposition when
changing the flow rate from 8 Lmin-1 to 16 Lmin-1. Trows et al. [35] employed the Boehringer
Ingelheim in vitro nasal model and also reported higher deposition in the nasal vestibule, middle
and upper turbinates employing 15 and 30 Lmin-1 constant air flow compared to no air flow.
Kimbell et al. [15] used a CFD simulation model to report a significant increase in number of
particles that pass the nasal valve region when employing a nasal flow of 15 Lmin-1 for a nasal
spray with spray velocity of 1m/sec. No change in formulation penetration through and beyond
the valve region was observed when the flow increased from 15 Lmin-1 to 30 Lmin-1 similar to our
observations in the present study. In contrast, there are also a number of other in vitro studies that
have failed to show any change in in vitro deposition using both constant air flow and realistic
inhalation profiles [36, 38, 42]. Possible reasons for these discrepancies maybe related to the
experimental protocols employed.
3.3.3.6 Effect of surface coating on the regional drug deposition of Nasonex® nasal spray
The presence of the lining fluid did not result in any significant change in either the mean
(SD) middle passage (27.3 (4.3) % (Exp. 12) vs 32.1 (8.0) % (Exp.11)) or mean (SD) anterior nose
drug deposition (71.9 (6.5) % vs 67.3 (7.4) %) for Nasonex® compared to studies performed in the
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absence of a mucus lining fluid. The results demonstrated that coating the nasal model will not
change the distribution pattern of Nasonex® formulation in the nasal model cavity. Hence, in order
to simplify studies, future studies did not employ surface coating.

Deposition fraction (%)

100

AD: in vitro
AD: CFD
MP: in vitro
MP: CFD

80
60
40
20
0
Slow

Fast

Figure 3.15. Comparison of in vitro regional nasal deposition for Nasonex® nasal spray product
in the VCU model 1 obtained from experimental data and CFD simulation. AD: Anterior + drip,
MP: Combined middle passage and nasopharynx region. The nasal spray is positioned at 9 mm
distance from the tip of the nose at the head angle of 30º forward and in the presence of the slow
inhalation (20.5 Lmin-1) and fast inhalation (35.8 Lmin-1) airflow

3.3.4 Full factorial design of experiment (DOE) to assess the effect of patient use variables
on the regional drug deposition of Nasonex® nasal spray
The four variables of actuation force, head angle, inhalation and actuation timing and nasal
spray position at two levels were selected to be investigated for their effects on regional nasal drug
deposition of the Nasonex® nasal spray product. Our preliminary studies demonstrated that
changing actuation force can result in the generation of a spray plume with small differences in
droplet size distributions (described in Section 4.2.7.1) however, these differences resulted in no
change in middle passage drug delivery. Varying the nasal head angle from 30º to 50º forward
from horizontal and nasal spray position from 11 to 5 mm from the tip of the nostril were both
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associated with changes in drug deposition in VCU nasal model 1. Lastly, we observed a
significant effect for the presence of inhalation airflow which increased drug delivery beyond the
nasal valve region. Therefore, the presence of inhalation airflow seemed to be necessary for the
further assessment. Based on literature data and our preliminary studies, timing of nasal inhalation
with respect to nasal spray actuation also seemed to be important and was considered for
investigation.
The preliminary studies considered each variable in isolation and did not consider the
effect that one variable may change as the level of other variables are change. Therefore, a full
factorial DOE was performed including two-way interactions which could identify the most
important variables influencing regional nasal drug deposition of the Nasonex® nasal spray. Table
3.5 shows the mean (SD) drug deposition for the Nasonex® nasal spray on the nasal spray device
(NSP), anterior + drip (AD), combined middle passages and nasopharynx area (MP) and filter (F)
as well as the total recovery for the 4-factor full factorial design of experiment performed at two
levels (high and low). As demonstrated in Table 3.5, total recovery was similar to previous studies
and ranged from 87.3 % - 100.6% of the label claim. Overall, drug deposition on the nasal spray
was low, ranging from 0.0 - 5.2 % of the recovered dose. The drug recovery from the respiratory
filter at the end of the throat was less than 0.5 % of the label claim for each of the experiments.
Depending on the experimental conditions, the mean anterior passage + drip deposition ranged
from 42.3 to 81.8 % of the recovered dose. Similarly, the combined middle passage and
nasopharynx deposition ranged from 16.6 % to 57.1 %. A combination of an optimal position for
spray plume release with the nasal spray positioned close to the nostril tip (5 mm), head angle of
50º and nasal inhalation during nasal spray actuation showed the highest middle passage drug
delivery for Nasonex® with 57.1 % of the dose. Figure 3.16 show the results of drug deposition
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for 16 different experimental conditions. It appears that coordination of nasal inhalation with nasal
spray actuation (D) consistently will result in higher middle passage drug delivery and lower
anterior nose deposition. In contrast, lower middle passage deposition was observed when nasal
inhalation began at the end of nasal spray actuation (E). Kimbell et al. [15] using CFD simulations
also showed that penetration of 20 µm particles from a nasal spray using a 1 sec delay between
nasal spray actuation and the start of inhalation was equivalent to no inhalation flow, suggesting
that coordination of inhalation and actuation is critical for delivery of drug to the middle passages.
Tables 3.6. and 3.7 show the results of the ANOVA statistical analysis, the estimates for
coefficients (the values of the regression coefficient for each variable) and their significance level.
The Prob > F gives the p-value for the ANOVA effect test where p-value of 0.05 or less and
indicates that there is at least one variable that has significant effect on middle passage drug
deposition. Coefficients (Figure 3.7) with more than one factor term represent the interaction terms
which demonstrate how the response (combined middle passage and nasopharynx drug deposition)
changes when the two factors were simultaneously changed. A positive value of coefficient
indicates an effect that helps to enhance the response value; conversely a negative sign value
represents an inverse relationship between the response and the factor. The higher the absolute
value the greater the effect of that factor on the response.
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Table 3.5. Mean (SD) in vitro regional nasal deposition of mometasone furoate (expressed as a percentage of recovered dose) and
total recovery (expressed as percentage of the label claim) for the Nasonex® nasal spray following actuation of 2 sprays into the left
nostril of VCU nasal model 1 in the full factorial design of experiments (n=4)
Actuation
Force (kg)
(X1)

Head
Angle
(X2)

4.5
4.5
4.5
4.5
7.5
7.5
7.5
7.5
4.5
4.5
4.5
4.5
7.5
7.5
7.5
7.5

30
30
30
30
30
30
30
30
50
50
50
50
50
50
50
50

Inhalationactuation
Timing
(X3)
D
E
D
E
D
E
D
E
D
E
D
E
D
E
D
E

Nasal
Spray
Position
(X4)
9
9
5
5
9
9
5
5
9
9
5
5
9
9
5
5

NSP

AD

MP

F

Recovery
(%)

0.6 (0.9)
1.2 (0.9)
0.5 (0.7)
1.9 (2.1)
0.0 (0.0)
1.3 (0.7)
2.5 (2.6)
0.1 (0.2)
2.7 (1.7)
5.2 (5.7)
1.7 (1.5)
3.1 (4.4)
1.5 (0.8)
1.2 (1.1)
0.6 (0.7)
2.0 (1.2)

67.3 (7.4)
73.3 (9.2)
58.1 (3.3)
68.2 (8.5)
55.4 (7.6)
78.8 (5.1)
63.5 (5.5)
70.2 (10.8)
51.3 (8.2)
76.4 (4.8)
48.8 (7.3)
76.3 (3.5)
48.7 (5.9)
81.8 (1.7)
42.3 (8.9)
68.9 (4.5)

32.1 (8.0)
25.1 (9.4)
40.9 (2.8)
29.9 (7.5)
44.6 (7.6)
19.8 (4.7)
34.1 (3.1)
29.7 (10.6)
45.8 (7.3)
18.4 (3.8)
49.1 (6.6)
20.6 (4.4)
49.8 (5.2)
16.6 (2.5)
57.1 (9.5)
29.2 (3.4)

0.0 (0.0)
0.0 (0.0)
0.0 (0.0)
0.0 (0.0)
0.0 (0.0)
0.3 (0.6)
0.0 (0.0)
0.0 (0.0)
0.2 (0.3)
0.0 (0.0)
0.4 (0.8)
0.0 (0.0)
0.0 (0.0)
0.4 (0.7)
0.0 (0.0)
0.0 (0.0)

91.5 (7.3)
87.3 (1.7)
89.2 (8.5)
92.7 (5.4)
88.9 (3.2)
92.4 (3.6)
100.5 (4.7)
95.6 (4.2)
92.4 (5.3)
89.7 (12.4)
95.2 (6.7)
90.7 (7.3)
93.1 (5.6)
100.6 (5.8)
95.1 (4.5)
93.6 (5.7)

NSP: Nasal spray, AD: Anterior + drip, MP: Combined middle passage and nasopharynx region, F: Filter
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Figure 3.16. Mean (error bars are SD) combined middle passage and nasopharynx regions drug deposition (expressed as % of
recovered dose) for Nasonex® nasal spray in the VCU model 1. X-axis represents the combined experimental conditions of head angle
(30 º or 50º), nasal spray position (9 or 5 mm), actuation force (4.5 or 7.5 kg) and nasal inhalation – nasal spray actuation timing (D:
Nasal inhalation during nasal spray actuation, E: nasal inhalation at the end of nasal spray actuation, inhalation rate of 35.8 Lmin-1,
(n=4)
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Table 3.6. Summary of ANOVA parameters for full factorial design of experiment
DF

Sum of Square

Mean Square

F Ratio

Prob> F

Model

10

8870.3

8870.0

17.8

<0.0001

Error

53

2646

49.9

Table 3.7. Estimates of coefficients for the predicted model and the significance of each
variable and two variables interaction
Source
Intercept
Inhalation timing (D)
Inhalation timing (E)
Angle*Inhalation timing (D)
Angle*Inhalation timing (E)
Position (5)
Position (9)
Angle (30, 50)
Inhalation timing (E)*Position (5)
Inhalation timing (D)*Position (9)
Inhalation timing (E)*Position (9)
Inhalation timing (D)*Position (5)
Force*Angle
Force*Inhalation timing (D)
Force*Inhalation timing (E)
Force (4.5, 7.5)
Angle*Position (5)
Angle*Position (9)
Force*Position (5)
Force*Position (9)
* P < 0.05

Estimate of
Coefficient
34.12
10.06
-10.06
4.56
-4.56
2.60
-2.60
1.69
1.50
1.50
-1.50
-1.50
1.39
1.22
-1.22
0.97
0.58
-0.58
-0.18
0.18
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t Ratio

Prob>|t|

38.62
11.39
-11.39
5.17
-5.17
2.94
-2.94
1.91
1.70
1.70
-1.70
-1.70
1.57
1.38
-1.38
1.10
0.65
-0.65
-0.20
0.20

<0.0001*
<0.0001*
<0.0001*
<0.0001*
<0.0001*
0.0048*
0.0048*
0.0618
0.0949
0.0949
0.0949
0.0949
0.1213
0.1726
0.1726
0.2749
0.5164
0.5164
0.8389
0.8389

Figure 3.17. Plot of actual (observed) values versus predicted values for combined middle
passage and nasopharynx regions deposition. The horizontal broken line shows the mean
velocity, the solid line is the line of fit, and the two broken curve lines describe the 95%
confident region relative to the line of fit. RSq: correlation coefficient; RMSE: root mean square
error
As shown in Table 3.6, analysis of variance of the overall model reports a significant model
with p-value < 0.0001. Based on the p-value reported for the variables in Table 3.7, inhalation –
actuation timing and nasal spray position have significant effects on middle passage drug
deposition with inhalation timing being the more influential factor as shown by larger estimated
coefficient. Coordination of inhalation and nasal spray actuation (D) was shown to produce higher
middle passage drug deposition (increased by 10.1 %, holding all variables constant, equation 3.6),
while conversely, nasal inhalation after nasal spray actuation (E) results in lower drug delivery to
the middle passages (decreased by 10.1%, assuming all variables are constant). In addition,
positioning the nasal spray closer to the nostril tip (5 mm compared to 9 mm) also resulted in
greater delivery efficiency to the middle passages.
In addition to these individual significant variables, there was a significant interaction
between the effect of inhalation timing and the head angle of the nasal airway model (p-value <
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0.0001). This interaction reveals that the effects of individual variables are not independent and
have a combined effect on middle passage drug deposition. The higher head angle of 50º when
combined with coordination of nasal inhalation and nasal spray actuation increases middle passage
drug delivery. However, nasal inhalation following spray actuation combined with a head angle of
50º lowers middle passage drug deposition.
Based on the experimental data for regional drug deposition of Nasonex® in the DOE study,
the following model including the four patient use variables and their interaction (two-way) was
developed to predict middle passage drug deposition. It was of interest to observe the effects of
individual variables and two variable interactions, therefore all variables were included in the
model. JMP uses scaled factor values for the continuous variables (angle and force) to develop an
equation that predict responses based on the input parameters. A scaled factor is mean-centered
and scaled by range/2.
2 (𝑋−𝑋𝑐𝑒𝑛𝑡𝑒𝑟)

Scaled factor=

Equation 3.5

𝑋𝑚𝑎𝑥−𝑋𝑚𝑖𝑛

Scaled factor for angle was calculated as: 2*(input value of angle - 40)/20
Scaled factor for actuation force was calculated as: 2*(input value of force- 6)/3
The built model equation is presented below and Y represents the response factor (middle
passage deposition):
Y=34.1+(0.97*(
10.1)+(Match
(

𝑓𝑜𝑟𝑐𝑒−6

𝑎𝑛𝑔𝑙𝑒−40

1.5

10

position

))+(1.69*(

if

5

then

))+(Match inhalation if “D” then 10.1 or E 2.60

or

9

then

-2.6)+

((1.39 ∗

𝑓𝑜𝑟𝑐𝑒−6

𝑎𝑛𝑔𝑙𝑒−40

𝑓𝑜𝑟𝑐𝑒−6

𝑓𝑜𝑟𝑐𝑒−6

1.5

10

1.5

1.5

)*(

))+((

)*(Match inhalation if “D” then 1.2 or E -1.2))*+((

Match position if 5 then -0.2 or 9 then 0.2))+((

𝑎𝑛𝑔𝑙𝑒−40
10
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)*(

)*( Match inhalation if “D” then 4.6 or E -

4.6))+((

𝑎𝑛𝑔𝑙𝑒−40
10

)*( Match position if 5 then 0.58 or 9 then -0.58))+(Match timing if D then (Match

position if 5 then -1.5 or 9 then -1.5), if timing E (Match position if 5 then 1.5 or 9 -1.5))
Equation 3.6
Using this model, predicted and observed response values were in the good agreement (R2=
0.77) (Figure 3.17). The R2 of 0.77 means that 77% of variability in the response can be explained
with the model which was relatively high. The model assumptions of normality for residuals and
homogeneity of variances for the ANOVA test were also tested and demonstrated in Figures 3.18,
3.19 and 3.20. Looking at normal quantile plot presented in Figure 3.18 it seems data are normally
distributed. For residual plot, graphically shown in Figures 3.19 and 3.20, the equal amount of
spread above and below the line is desirable meaning that there is no heteroscedasticity observed
(no change in variance of the error term across the observations). Brown-Forsythe among with
three other tests were used to check the equality of variances and the result is shown in Table 3.8.
The p-value greater than 0.05 demonstrated equality of variances among groups. The p-value for
the Brown-Forsythe test was 0.2418.

Table 3.8. Results of statistical analysis for testing unequal variances
Test
F Ratio
DF Num
DF Den
O'Brien
1.0979
15
48
Brown-Forsythe
1.2957
15
48
Levene
1.7689
15
48
Bartlett
1.1093
15
.
DF NUM: degrees of freedom in the numerator for each test
DF Den: the degrees of freedom used in the denominator for each test.
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Prob > F
0.3834
0.2418
0.0685
0.3408

Figure 3.18. Normal quantile plot used to assess the normality of the data for the linear model

Figure 3.19. Plot of residuals used to assess the normality for the linear model
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Figure 3.20. Plot of standard deviation for each group constructed by actuation force, head
angle, timing and nasal spray position

This study has illustrated the use of in vitro realistic testing methods to simulate patient use
parameters and their effects on the regional nasal deposition of the Nasonex® nasal spray product.
In vivo deposition studies with Nasonex® have shown that the mean anterior nose and middle
passage deposition healthy volunteers was 26.0 % and 60.1 % [137]. In another in vivo study in
patients with allergic rhinitis, different results of approximately 65% and 35%, respectively, were
reported [18]. Unfortunately, details regarding the controlled administration of the nasal spray and
associated patients use variables were not reported. This prevents a direct comparison with similar
administration conditions using the developed in vitro realistic deposition test method. These in
vivo results were in line with the results that we observed for Nasonex ® in our developed realistic
testing condition. Without this in vitro – in vivo correlation, the conclusions of this in vitro study
and their significance with respect to optimizing delivery remain to be confirmed. If these
developed in vitro methods are capable of simulating in vivo deposition, then this approach offers

78

a powerful technique of rapidly screening both formulation and administration variables and their
effects on regional nasal deposition.
The results of this study demonstrated that the way the patient administers the nasal spray
can result in high drug deposition in the anterior nose which is a non-ciliated region where no drug
absorption can take place with corresponding poor drug delivery to the site of action in middle
passages. Conversely, there are patient use conditions that can be recommended that appear to
significantly increase middle passage drug delivery for this nasal spray product. It should be noted
that the conclusions regarding patient use parameters have only been tested using one spray device
and formulation (Nasonex®) and may not be applicable to other nasal spray products.

3.4 Conclusions
In this chapter, a realistic in vitro deposition testing method was developed for the
Nasonex® nasal spray product based on realistic patient use conditions (Specific Aim1-1). The
effects of patient use factors on regional nasal deposition of the Nasonex® nasal spray product was
investigated (Specific Aim 1-2). The overall deposition pattern within the nasal cavity and the
potential for the lung deposition were found to be similar to previous in vivo studies which
indicated that the developed method may be used as a tool for estimating the initial sites of regional
nasal drug deposition, although a prospective in vitro and in vivo study with identical patient use
conditions would be desirable.
The results suggest that the presence of the nasal inhalation and its timing with respect to
the nasal spray actuation is crucial for enhanced nasal valve penetration of the formulation. The
effect of head angle was also found to be significant. Significant drug losses in anterior nose region
can be observed under certain patient use conditions. Based on the DOE studies, nasal drug
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delivery to the middle passages could be increased up to 3-fold by a combination of patient use
parameters in a single nasal geometry. Realistic nasal airway models can be used to identify the
key administration technique factors required to maximize drug delivery to the site of action.
This study has demonstrated that when comparing in vitro nasal deposition studies, it is
important to control and report the spray administration experimental variables used to simulate
patient use conditions if comparable results are to be obtained. It should also be observed that the
conclusions made in the chapter are specific to the Nasonex® nasal spray tested in a single airway
nasal geometry. Studies should also consider comparisons between a series of innovator and
generic nasal spray products, rather than a single test product if this method is to be utilized to
accelerate regulatory reviews of nasal sprays. It is also important to evaluate the role of intersubject nasal geometry on the regional deposition of nasal sprays if these methods are to be used
to simulate variability observed in the population.
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CHAPTER 4
ASSESSMENT OF THE EFFECTS OF PATIENT-USE VARIABLES,
NASAL GEOMETRY AND FORMULATION / DEVICE COMBINATION
ON REGIONAL DEPOSITION OF NASAL SPRAY PRODUCTS IN THE
REALISTIC NASAL GEOMETRIES

4.1 Introduction
Drug delivery to the posterior part of nasal cavity from a nasal spray product is dependent
upon a number of factors including patient use factors, the geometry of nose and nasal cavity, and
the formulation/device characteristics [2, 9]. Investigations of drug delivery efficiency and
assessments of bioequivalence of nasal spray products may be aided by the use of physically
realistic nasal airway models in combination with simulated patient use to determine in vitro spray
deposition patterns within the nose as described in the previous chapter. These realistic in vitro
tests may provide an improved means of comparing innovator and generic nasal spray products
compared to traditional droplet size and plume geometry tests. In this chapter, we have investigated
the effects of inter-subject variability in nasal geometry on the in vitro regional drug deposition of
Nasonex® nasal spray product by comparing its regional nasal deposition in two nasal airway
geometries. In addition, this chapter also describes studies assessing the utility of the developed
realistic deposition test methods to discriminate between products when changing the formulationdevice combination and comparing innovator and generic nasal spray products. This capability of
the developed realistic test methods to discriminate between nasal spray products was also assessed
by comparing the regional nasal deposition of nasal spray formulations with different spray plume
characteristics.
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4.2

Material and Methods
VCU nasal model 2
The VCU nasal model 2 was previously developed by Walenga [48]. The computerized

tomography (CT) scan data of a 20-year old female was segmented using the commercial software
package Mimics 16.0 (Materialise, Belgium). The 3D file was then converted to an .stl file and
imported to a CAD software package, SolidWorks 2011 (Dassault Systèmes Solidworks Corp.,
Waltham, MA). Finally, the file was converted into a volumetric file type (.igs) using the mesh
development software 3-Matic (Materialise, Belgium).
The VCU nasal model 2, shown in Figure 4.1, was characterized by a nasal cavity with a
surface area to volume ratio (SA/V) of 0.75 mm-1 in the anatomical left side of the posterior part
of the nasal cavity and 1.33 mm-1 on the right side, indicating that significant nasal cycling was
present, a phenomenon described in more detail by Gungor et al. [142]. However, in this study
drug deposition was investigated using the right side of the nasal cavity and the left side was
blocked. Table 4.1 describes the geometric characteristics of the VCU nasal model 2 and compares
with the corresponding features in VCU nasal model 1. For these studies VCU nasal model 2 was
incorporated to the experimental setup in the similar fashion as VCU nasal model 1 as depicted in
Figure 4.2.
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Figure 4.1. Realistic nasal model (VCU nasal model 2) developed at Virginia Commonwealth
University

Figure 4.2. Experimental setup for realistic testing of regional nasal deposition of the Nasonex®
nasal spray product in VCU nasal model 2
Table 4.1. Geometric measurements of the nasal cavity for the left side of VCU nasal model 1
and right side of VCU nasal model 2. The dimensions tabulated are the posterior surface area-tovolume ratio (SA/V), the average nostril hydraulic diameter (dh, nostril), the nasopharynx exit
hydraulic diameter (dh, nasopharynx), anterior nose volume, and surface area of the nasal
vestibule (SA).
VCU
nasal
model
1
2

SA/V
(mm-1)

Dh, nostril
(mm)

Dh, nasopharynx
(mm)

Anterior nose
volume (mL)

SA of the anterior
nose (mm2)

0.74
1.33

12.1
10.6

5.9
4.5

3.2
2.2

1153
1493
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Selection of inhalation flow rate to be employed using VCU nasal model 2
The resistance of VCU nasal models 1 and 2 against the incoming airflow was determined
by measuring the pressure drop across the models at a series of flow rates in the range of 5 to 50
Lmin-1. The assembled nasal models were sealed air-tight completely with only one nostril open
to air flow. Pressure drop across the model was measured using a digital manometer (Air Neotronics Ltd., Oxford, England). Air flow was drawn through the nasal model via the throat
which was connected to the vacuum pump capable of pulling constant flows of between 5 and 50
Lmin-1 through the model. Air flow rate was varied and plotted against the measured square root
of the pressure drop to calculate the air flow resistance through the nasal model. Assuming
frictionless flow through the nasal models, the relationship between the volumetric flow and
pressure drop is based on the following equation [143]:

√𝛥𝑃𝐷 = √𝑃𝑎 − 𝑃1 = RDQ

Equation 4.1

In which Pa is the ambient pressure, P1 is the pressure measured at the nasal airway model
tracheal pressure tap at the entrance of nasal airway model, and Q is the volumetric flow.
Therefore, RD or model related resistance can be calculated form the slope of the linear line.
Following calculation of resistance of VCU nasal models 1 and 2, flow rates with
equivalent pressure drops were evaluated in the in vitro test setup.
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Figure 4.3. √(Pressure drop ) - flow rate relationship in VCU nasal models 1 and 2. The line
equation and correlation coefficient (R2) were calculated for each nasal model. The resistance
was calculated as 0.046 (cmH2O1/2/(Lmin-1)) for VCU nasal model 1 and 0.073 (cmH2O1/2/
(Lmin -1)) for VCU nasal model 2

The resistance calculated for VCU nasal model 2 was compared to that of determined for
VCU nasal model 1. As demonstrated in Figure 4.3, VCU nasal model 2 has a higher airflow
resistance of 0.073 (cmH2O1/2/(Lmin-1)) compared to VCU nasal model 1 with 0.046
(cmH2O1/2/(Lmin-1)). This difference in resistance can be explained by variability in the model
geometries with VCU nasal model 2 being more constricted in the right side of the nasal cavity as
shown previously by large SA/ V ratio in the middle passage region (1.33 mm-1) compared to the
left side of VCU nasal model 1 (0.74 mm-1) (Table 4.1).
It was important to test the two nasal models at equivalent realistic flows if flow rates are
important in determining the regional drug deposition. Initial studies examined the regional drug
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deposition of Nasonex® in VCU nasal model 1 at two flow rates of 20.5 Lmin-1 (equivalent to a
square root of pressure drop of 1.01 cmH2O1/2) and 35.8 Lmin-1 (equivalent to a square root of
pressure drop of 1.65 cmH2O1/2). However, those studies indicated that there was no difference in
the regional nasal deposition at those two flow rates. The higher flow rate (35.8 Lmin-1) was
therefore selected for comparison in VCU nasal model 2. This flow in VCU nasal model 1
generated a pressure drop of 1.65 cmH2O1/2. The equivalent flow at this pressure drop in VCU
nasal model 2 was determined as 20.5 Lmin-1. Studies in VCU nasal model 2 were then performed
i) using an identical flow rate of 35.8 Lmin-1 compared to VCU nasal model 1 (with a higher
resulting pressure drop) and with an identical pressure drop of 1.65 cmH2O1/2 to VCU nasal model
1 (with a lower resulting flow rate of 20.5 Lmin-1). The mean (SD) total drug recovery was similar
for both experiments with 88.2 (1.8) % recovered at 35.8 Lmin-1 and 90.7 (2.5) % recovered at
20.5 Lmin-1 as shown in Figure 4.4. It is evident that there is no significant difference between the
amount of the drug deposited on the nasal spray device and in the regional nasal drug deposition
for Nasonex® when using the different flow conditions in VCU nasal model 2. The experimental
conditions used an actuation force of 4.5 kg, nasal spray position at 5 mm from the front of the
nasal tip and nasal spray actuation during nasal inhalation (D).
This indicated that changing flow rates from 20.5 Lmin-1 to 35.8 Lmin-1 did not affect the
regional drug deposition of Nasonex® in VCU nasal model 2. We observed similar findings of no
change in the regional drug deposition of the Nasonex® in VCU nasal model 1 with respect to the
flow rates used despite differences in model airway resistance.
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Figure 4.4. Regional nasal drug deposition of Nasonex® in the VCU nasal model 2 tested at flow
rates of 20.5 Lmin-1 and 35.8 Lmin-1. Data presented as mean (error bars are SD) (n=4). NSP:
nasal spray device, AD: Anterior + drip, MP: Combined middle passage and nasopharynx region,
F: Filter. Recovery is presented based on the label claim. Device deposition and regional drug
deposition data are presented based on the recovered dose.

Assessing the effects of patient use variables on the regional drug deposition of
Nasonex® in VCU nasal model 2 using a full factorial design of experiment
A full factorial DOE for 3 factors at 2 experimental levels was conducted (for a total of 32
experiments) to explore the influence of patient use factors and the interactions among the factors
in the VCU nasal model 2. Similar to the variables that were tested in the VCU nasal model 1,
three independent variables of actuation force, head angle and inhalation timing at two levels were
selected to perform the regional nasal deposition studies in VCU nasal model 2. The smaller
hydraulic diameter of the nostril for VCU nasal model 2 compared to VCU nasal model 1 allowed
defining only one nasal spray position within in the nostril as 5 mm distance from the tip of the
nostril. Nasal spray insertion depth of 1 cm was kept constant. The previously defined nasal
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breathing profile with the PIFR of 35.8 Lmin-1 was used. Two doses of the Nasonex® nasal spray
were administered in the right nostril while the other nostril was blocked. The amount of drug
deposited on the i) the nasal spray device (NSP), ii) amount that dripped from the nose + anterior
nose (AD), iii) combined middle passage and nasopharynx (MP), iv) respiratory filter + throat (F)
were quantified. Samples were assayed for mometasone furoate content by a validated HPLC
method and using methanol and water (50:50 %v/v) as the wash solution (Sections 3.1.3 and 3.2.1).
In order to compare, the inter-subject variability between the two nasal airway models, the
regional nasal drug deposition of Nasonex® nasal spray product obtained from VCU nasal model
1 (Section 3.2.4) and 2 were compared under identical experimental conditions.
Statistical analysis for full factorial design of experiment
Results were processed as a percentage of the recovered dose. The ANOVA assumption of
normality of data was assessed using normal quantile plot. The model assumptions of normality
for residuals and homogeneity of variances for the ANOVA test were tested using residual plot.
Brown-Forsythe test was used to check the equality of variances where a p-value greater than 0.05
demonstrated equality of variances among groups. Variables of inhalation-actuation timing and
nasal spray position were defined as categorical variables whereas actuation force was defined as
continuous. The response for the DOE analysis was defined as the combined middle passage and
nasopharynx deposition. The influence of each factor and two factor interactions on the response
was analyzed using full factorial ANOVA and significant main effects or any interactions between
these effects was recognized by p-value<0.05. The linear regression equation employed was:
Y= b0+b1x1+b2x2+b3x3+b4x1x2+b5x1x3+b6x2x3
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Equation 4.2

where, b0 is the line intercept, and Y is the measured response (combined middle passage and
nasopharynx deposition) associated with the factors (x1, x2, and x3) and their interactions (x1x2,
x1x3, and x2x3). The p-values related to the regression coefficients indicated the significance of
each factor on the response.
Student t-test was used to compare the regional drug deposition obtained using VCU nasal
models 1 and 2 using identical experimental conditions and significance was assessed using a pvalue < 0.05 (JMP Pro 12 software). Finally, a linear equation model was built to include the
independent variables of nasal model geometry, nasal model head angle, nasal spray position and
inhalation-actuation timing to predict the regional nasal drug deposition of Nasonex ® nasal spray
product. The model was evaluated based on the goodness of fit criteria (Akaike information
criterion (AIC), Bayesian information criterion (BIC) and Root Mean Square Error (RMSE)).
Evaluating the developed realistic in vitro test method using innovator and generic
nasal spray products
To test the utility and reproducibility of the developed realistic test methods for evaluation
of regional nasal drug deposition of nasal spray products, the regional nasal drug deposition of
formulations designed to be ‘generic’ copies were compared to their innovator products.
4.2.5.1

Mometasone furoate nasal spray products
Commercially sourced Nasonex® (Merck & Co. Inc., Whitehouse Station, NJ) nasal spray

product was identified as the innovator product for mometasone furoate nasal sprays. “In house”
mometasone furoate formulations were manufactured by the University of Bath (Bath, UK) to be
generic copies of the Nasonex® product and contained 50 µg of mometasone furoate in each
metered spray. Two batches of the “in house” mometasone furoate nasal sprays (batch #s
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MFM11TF5 and MFM13F2) were characterized and compared to the innovator product, in VCU
nasal models 1 and 2 using the previously described methods. The “in house” nasal spray
formulations were developed to be qualitatively (Q1) and quantitatively (Q2) equivalent to the
innovator product [144]. The batches differed only in the particle size of the drug product included
(
in the formulation. Batch
MFM11TF5 had a mean diameter of 1.9 µm and MFM13F2 had a
!

diameter of 1.07 µm, however this change did not affect the spray characteristics of the nasal spray.
The container closure system for the “in house” generic was different from Nasonex® and included
a bottle and nasal pump (Figure 4.5). The nasal spray pump was an Aptar VP3/93 pump
(AptarGroup, Inc., Le Vaudreuil, France) with 404E/A4 internal gasket, 908 EVA neck gasket and
40 mm visible dip tube. This nasal pump was not crimped onto the bottle and employed a screw
on mechanism. The bottle! was a standard HDPE container which was sourced from Gerresheimer
(Chalon-sur-Saône, France) (Figure 4.5).

(a)

(b)

(c)

(d)

Figure 4.5. Images of (a) Nasonex® nasal spray product (Merck & Co. Inc., Whitehouse Station,
NJ) and the “in house” mometasone furoate nasal spray (b) (University of Bath, Bath, UK). Also,
shown here container closure system for the “in house” mometasone furoate nasal spray products
(c) bottle and (d) pump
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4.2.5.2 Fluticasone propionate nasal spray products
Commercially sourced Flonase® (GlaxoSmithKline, Research Triangle Park, NC) nasal
spray product was identified as the innovator product for fluticasone propionate nasal sprays. A
previously FDA approved and commercially available generic fluticasone propionate (Roxane
Laboratory, Columbus, OH) was obtained as the generic comparator (Figure 4.6). Based on FDA
guidance for the development of the generic fluticasone propionate nasal sprays, the generic
formulation should have both qualitatively quantitatively within ± 5% similar ingredients
compared to the innovator product [56]. The device should deliver the same number of doses as
the reference listed product, and should be similar in shape, size, and external operating principles.
In addition patients should not need to retrain or take more steps to use the generic product
compared to the innovator product [144].

(a)

(b)

Figure 4.6. Images of (a) Flonase® nasal spray product (GlaxoSmithKline, Research Triangle
Park, NC) and (b) the generic fluticasone propionate nasal spray (Roxane Laboratory, Columbus,
OH)
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4.2.5.3

In vitro realistic deposition test conditions
The experimental conditions for the in vitro regional drug deposition tests using the two

airway models were designed to reflect the possible in vivo variability that can be associated with
patient use factors. The design of experiment approach described previously revealed the influence
of patient use factors when implemented in vitro on nasal deposition within the middle passage
region. An attempt was made to select a manageable series of in vitro experiments that reflect the
potential inter-subject and patient use factors that could affect the deposition of the test nasal spray
products. The approach sought to identify in vitro test conditions from the DOE experiments that
produce low, intermediate and high drug deposition in combined middle passage and nasopharynx
regions in each of the two airway models as shown in Table 4.2.
For Flonase® nasal spray, an “in use” measurement of actuation force was obtained from
the literature [121] and therefore only one actuation force of 5.8 kg was employed in those studies.
The remaining test conditions for “low”, “medium” and “high” deposition experiments were based
upon the Nasonex® DOE experimental conditions. The previously described HPLC quantitative
analysis method for mometasone furoate (Sections 3.1.3 and 3.2.1) was also used for fluticasone
propionate and validated to ensure drug mass balance and recovery from the nasal models in the
in vitro experiments.
For each of the test nasal spray products, the droplet size distribution was characterized
using the method described in Section 4.2.7.1.
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4.2.5.4 Statistical analysis for innovator and generic comparison
Student t-test was used to compare the regional drug deposition of the “in house”
mometasone furoate nasal spray with Nasonex® nasal spray product and the generic fluticasone
propionate with Flonase® nasal spray product across the range of experimental conditions in the
two nasal models (JMP Pro 12 software; p-value < 0.05).

Table 4.2. Experimental conditions for testing of innovator and generic nasal spray products
using VCU nasal models 1 and 2
Expected combined middle
passage and nasopharynx regions
drug deposition

Actuation
force
(kg)3

Nasal spray
position
(mm)1

Head
angle

Inhalation
and actuation
timing2

7.5
7.5
7.5

9
5
5

50°
30°
50°

E
D
D

7.5
4.5
4.5

5
5
5

30°
30°
50°

E
D
D

VCU Model 1
Level 1 - Low (~ 20 %)
Level 2 - Intermediate (~ 40 %)
Level 3 - High (~ 60 %)
VCU Model 2
Level 1 - Low (~ 50 %)
Level 2 - Intermediate (~60 %)
Level 3 - High (~77 %)
1

Distance between nasal spray applicator and the tip of the nose
E: inhalation followed by actuation, D: actuation during inhalation
3
Fluticasone propionate products were tested using only an actuation force of 5.8 kg
2

Evaluating the developed realistic in vitro test method using nasal spray products with
varying spray plume properties
A series of nasal spray products with differing in vitro spray properties were tested to assess
their regional drug deposition in VCU nasal model 1. Four products were considered, two custommade mometasone furoate nasal sprays (Batches No: A and B), and two commercial Nasonex ®
nasal sprays with expiration dates of Feb 2007 (expired) and Oct 2015 (in-date), respectively.
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The regional nasal drug deposition of the custom-made mometasone furoate nasal sprays
and Nasonex® nasal sprays were tested using the VCU nasal model 1. The experimental conditions
used to test the in vitro nasal sprays are nasal spray position of 9 mm from front of the nostril, head
angle of 30º forward from horizontal, and nasal spray actuation during nasal inhalation (D). The
regional drug deposition tests were performed at two actuation forces of 4.5 and 7.5 kg. The in
vitro spray plume properties of these products was also characterized by examining the droplet
size distribution and spray pattern and plume geometry tests (as described in Section 4.2.7) based
on FDA recommended in vitro tests for establishing BE for nasal spray products [131].
In vitro nasal spray characterization methods
4.2.7.1

Droplet size distribution measurements (DSD)
Droplet size distribution (DSD) measurement for nasal spray products was conducted by

laser diffraction technique using a Malvern Spraytec (Malvern Instruments Ltd, Worcestershire,
UK) equipped with 100 mm focal lens. The spray nozzle was positioned below the laser beam,
aligned vertically at the specified distance (2 cm mostly based on FDA guidance below the center
of laser sensing zone [144]. The distance between nasal spray and detector was 9 cm. Data
collection was initiated when the percent laser light transmittance falls below 99.0% and
acquisition continued for 2000 ms. Data analysis of the droplet size distribution was performed on
the average of all scans collected in the fully developed phase of the nasal spray, that is indicated
by the entire plateau region for the transmittance plot. The data were reported as volume diameters
at the 10th, 50th and 90th percentile as Dv10, Dv50, and Dv90, respectively, together with the span
which is defined as below:

Span =

(𝐷𝑣90−𝐷𝑣10)

Equation 4.3

𝐷𝑣50
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4.2.7.2

Spray pattern measurement
Spray pattern tests were performed from the analysis of a two-dimensional image of the

emitted plume using a SprayVIEWTM NSP system (Proveris Scientific Corporation, Sudbury,
MA). This system includes a laser light sheet, high-speed digital camera, and SprayVIEWTM NSx
automated actuation force system. For spray pattern measurements, the distance of nasal spray
nozzle to the laser beam was 30 mm. The laser light illuminates the spray horizontally and images
are taken from the above. The automated actuator is a velocity control actuator and actuation
parameters for the nasal sprays were defined as velocity 70 (mm/sec), acceleration of 5000
(mm/s2), initial and final delay of 200 (ms) and hold time of 300 (ms) generating an actuation force
of 7.5 kg. Stroke length (displacement of the nasal spray pump (mm)) for each nasal spray bottle
was automatically characterized. The SprayVIEWTM NSP software determines the outlines of the
spray pattern and reports Dmax, Dmin, ovality, and area for spray pattern measurements. Dmax
and Dmin are defined as the longest and shortest diameter that can be measured for the spray
pattern image and the ratio of the two diameters is used to calculate the ovality ratio. The area is
also calculated after defining the perimeter of the resulted spray pattern image.
4.2.7.3 Plume geometry measurement
Plume geometry measurements were also carried out using SprayVIEWTM NSP system
(Proveris Scientific Corporation, Sudbury, MA). For plume geometry measurements, the laser
sheet was positioned vertically, and the spray plume was imaged from the right side, directly above
the device tip. Plume geometry measurement was performed at distance of 30 mm from spray
orifice. Similar actuation settings as spray pattern test were employed for the nasal spray actuator.
By monitoring the intensity profile during the spray life, a single frame from the fully developed
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phase with the highest intensity was selected and the spray angle defined as the angle of the emitted
plume measured from the vertex of the spray cone and spray nozzle and plume width as the width
of the plume at a given distance from the spray nozzle.
Statistical analysis for spray plume characterization tests
Data for DSD, spray pattern test and plume geometry test results are expressed as mean
(SD) and subjected to statistical analysis of variance (ANOVA) followed by Tukey’s HSD test
using JMP software version 12.0. The analyses were done at 95% confidence limits for two-tailed
tests. Probability values of <0.05 were considered statistically significant.

4.3 Results and Discussion
Assessing the effects of patient use variables on the regional drug deposition of
Nasonex® in VCU nasal model 2 using a full factorial design of experiment
Table 4.3 shows the drug deposition results of the 2- level, 3- factor full factorial design of
experiment for the Nasonex® nasal spray tested in VCU nasal model 2. Total drug recovery along
with the drug deposition on the nasal spray device (NSP), anterior +drip (AD), combined middle
passages and nasopharynx area (MP) and filter (F) are reported. As demonstrated in Table 4.3,
mean (SD) drug recovery from VCU nasal model 2 and nasal spray device ranged from 90.9 (2.4)
% to 94.3 (7.5) % of the label claim. Drug deposition on the nasal spray device was less than 1.9
% of the recovered dose and no formulation was observed to reach the respiratory filter at the end
of the throat. Changing patient use related variables in 8 different combinations of actuation force,
head angle and inhalation - actuation timing relative to actuation for Nasonex® nasal spray product
in VCU nasal model 2 resulted in mean (SD) anterior passage + drip deposition that varied from
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21.5 (9.0) % to 53.3 (10.2) % and mean (SD) combined middle passage and nasopharynx region
ranged 46.6 (10.0) % to 77.4 (8.5) %.
A linear model including three variables and the two-way interactions was constructed and
analysis of variance (ANOVA) performed to evaluate the model significance. The model was
statistically significant as shown by p-value <0.004 in Table 4.4. The summary of the ANOVA
analysis is presented in Table 4.4. As demonstrated in Figure 4.7 and Table 4.5 the developed
model did not predict a strong correlation between predicted and observed data shown by the R2
of 0.3861 and adjusted R2 of 0.2387 meaning that there are other factors controlling the regional
drug deposition in VCU nasal model 2 that are not considered in the predicted model.
Table 4.6 illustrated the estimates (the values of the regression coefficients), t-ratio and
their significance for the constructed model. Using VCU nasal model 2, patient related parameters
of inhalation timing and angle had significant effects on middle passage drug delivery of Nasonex®
(p-value = 0.0150 and 0.0215, respectively). A positive value of estimate (4.86) for inhalation
timing (D), indicated that this effect helps to enhance middle passage drug delivery; conversely, a
negative sign value for inhalation (E) represents an inverse relationship between the response and
the factor. This is also evident by comparing the data in Table 4.3 for all the study sets that differ
only with respect to the inhalation – actuation timing condition. Experiments with coordination
between actuation and inhalation (D) had higher middle passage drug delivery and lower anterior
nose deposition compared to the studies in which there was a delay between actuating the nasal
spray and then commencing inhalation (E). In VCU nasal model 2, tilting the model to the head
angle of 50° while nasal spray is actuated during nasal inhalation, using actuation force of 4.5 kg
or 7.5 kg, resulted in drug delivery to the middle passages that ranged from 72.2 % - 77.4 % of the
recovered dose. However, nasal inhalation after nasal spray actuation at the head angle of 30° and
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actuation force of 7.5 kg resulted in the lowest middle passage drug deposition of 46.6 % which
demonstrates the significant effects of the head angle and inhalation timing. These results were
similar to the trends observed with the deposition studies using VCU model 1 (Chapter 3). As we
observed previously, actuation of nasal spray during nasal inhalation did increase middle passage
drug delivery as the larger fraction of the droplets were entrained in the airflow, perhaps traveling
deeper into the posterior region through the nasal valve from the initial release point in the nostril.
However, we did not see any significant interaction between the two variables of inhalation timing
and head angle as previously observed for VCU nasal model 1.
In addition, the extent of deposition variability that was observed due to the patient
variables differed between the two models. Middle passage drug deposition in VCU nasal model
2 varied by 1.7-fold with respect to the tested patient use parameters (46.6 % – 77.4 %). However,
varying the corresponding patient use parameters produced a 3.4-fold change in middle passage
drug delivery using VCU nasal model 1 (16.6 % - 57.1 %). This suggested that the regional nasal
drug deposition in VCU nasal model 2 was influenced more by the nasal airway geometry than by
the employed patient use variables.
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Table 4.3. Mean (SD) in vitro regional nasal deposition of mometasone furoate (expressed as a percentage of recovered dose) and
total recovery (expressed as percentage of the label claim) for the Nasonex® nasal spray following actuation of 2 sprays into the right
nostril of VCU nasal model 2 for the full factorial design of experiments (n=4)
Actuation Force
(kg)
(x1)
4.5

Head
Angle
(x2)
30

Timing
(x3)

NSP

AD

MP

F

Recovery
(%)

D

0.2 (0.2)

38.2 (9.4)

61.6 (9.6)

0.0 (0.0)

91.3 (5.6)

7.5

30

E

0.1 (0.1)

53.3 (10.2)

46.6 (10.0)

0.0 (0.0)

92.5 (11.2)

7.5

30

D

0.3 (0.6)

31.8 (3.8)

68.0 (4.2)

0.0 (0.0)

93.1 (6.3)

4.5

50

E

1.9 (2.8)

44.7 (8.2)

53.4 (9.4)

0.0 (0.0)

92.3 (5.1)

7.5

50

D

0.9 (1.4)

26.9 (4.6)

72.2 (4.7)

0.0 (0.0)

90.9 (2.4)

4.5

30

E

1.1 (1.1)

33.9 (10.4)

65.0 (9.5)

0.0 (0.0)

93.1 (10.1)

4.5

50

D

1.1 (1.1)

21.5 (9.0)

77.4 (8.5)

0.0 (0.0)

94.3 (7.5)

7.5

50

E

0.2 (0.5)

25.9 (8.7)

73.9 (8.5)

0.0 (0.0)

93.1 (9.8)

Timing; D: Nasal spray actuation during nasal inhalation, E: Nasal spray actuation followed by nasal inhalation
NSP: Nasal spray, AD: Anterior + drip, MP: Combined middle passage and nasopharynx region, F: Filter
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Table 4.4. Summary of ANOVA analysis for full factorial design of experiment including
actuation force, head angle and inhalation timing in VCU nasal model 2
DF

Sum of Square

Mean Square

F Ratio

Prob> F

Model

6

1802.9

300.5

2.6

<0.0400

Error

26

2976.7

114.5

DF: degree of freedom

Figure 4.7. Plot of actual (observed) value versus predicted values of Nasonex® middle passage
deposition in VCU model 2. The horizontal broken line shows the mean velocity, the solid line is
the line of fit, and the two broken curve lines describe the 95 % confident region relative to the
line of fit.

Table 4.5. Summary of fit for regional nasal drug deposition of Nasonex® in VCU nasal model
2 including three variables of actuation force, head angle, and timing
R2
Model

0.3861

R2 Adj

Root Mean Square
Error (RMSE)

Mean of
Response

Observations

0.2387

10.83

64.75

32

R2 Adj: Adjusted R
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Table 4.6. Estimates of coefficients for the model predicting the combined middle passage and
nasopharynx drug deposition of Nasonex® nasal spray product in VCU nasal model 2 along
with the significance of each variable and two variables interaction
Term

Estimate

t Ratio

Prob>|t|

Intercept

45.46

4.18

0.0003*

Inhalation Timing (D)

4.86

2.60

0.0150*

Inhalation Timing (E)

-4.86

-2.60

0.0150*

(Force-6.0) * (Angle-40)

0.22

1.73

0.0955

Angle

0.46

2.45

0.0215*

Force

0.20

0.16

0.8718

(Force-6.0) * Inhalation Timing (D)

0.05

0.04

0.9708

(Force-6.0) * Inhalation Timing (E)

-0.05

-0.04

0.9708

(Angle-40) * Inhalation Timing (D)

0.03

0.18

0.8556

(Angle-40) * Inhalation Timing (E)

-0.03

-0.18

0.8556

* P<0.05, significant effect
Timing; D: Nasal spray actuation during nasal inhalation, E: Nasal spray actuation followed by
nasal inhalation
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Evaluating the developed realistic in vitro test method using nasal spray products with
varying spray plume properties
The results for Nasonex® drug deposition in the two nasal geometries were compared and
shown in Table 4.7. These studies compare experiments performed using identical experimental
conditions with a nasal spray position of 5 mm from the nasal tip. Comparing the anterior nose
deposition in VCU nasal model 1 and 2, in general, there was higher drug deposition observed in
VCU nasal model 1. The extent of drug deposition in the anterior nose + drip for VCU nasal model
1 was 1.3-fold to 2.7-fold higher compared to what was observed in the VCU nasal model 2,
depending on the experimental conditions. This resulted in consistently lower middle passage
delivery to VCU nasal model 1 (1.3-fold to 2.6-fold) compared to VCU nasal model 2. The most
pronounced difference (2.7-fold increase) in the anterior nose deposition was observed when the
nasal model tilted 50º forward with a delay in nasal inhalation timing with respect to nasal spray
actuation (E). Differences in the geometry of nasal valve region between the two models may play
a significant role as VCU nasal model 2 has a wider nasal valve region compared to VCU nasal
model 1. Therefore, a larger fraction of the exiting plume can penetrate through the nasal valve
region regardless of head angle, nasal spray position and inhalation time.
In summary, it has been observed that patient use variables have less impact on the regional
nasal drug deposition pattern in the VCU nasal model 2. Differences in the regional deposition
between the two airway geometries indicated the potential effects of inter-subject nasal geometry
variability on the regional drug deposition of Nasonex® nasal spray product. Significantly higher
drug formulation was able to penetrate into the middle passages of VCU model 2 under almost all
test conditions compared to VCU model 1 (Table 4.7). Differences in the geometry of nasal valve
region between the two models may play a significant role as VCU nasal model 2 has a wider nasal
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valve region compared to VCU nasal model 1. These differences may even occur in the left and
right side of the nasal cavity of a subject. Previous studies using CFD simulations have shown
changes in the drug deposition pattern for 22 µm particles in the right and the left sides of a realistic
nasal cavity geometry and concluded that geometry is an important parameter for deposition of the
micron size particles [30]. Similar results may be found for regional nasal drug deposition of nasal
sprays when tested in different sides of the nasal cavity.
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Table 4.7. Mean (SD) in vitro regional drug deposition (standard deviation (SD)) (expressed as a percentage of recovered dose) of
Nasonex® nasal spray product in VCU models 1 and 2. Results are ranked based on increasing deposition for Nasonex® in the VCU
nasal model 1 (n=4)
Actuation force
(kg)

Head angle
(°)

Timing

VCU model 1

VCU model 2

p-value

change

Anterior + drip deposition
7.5

50

D

42.3 (8.9)

26.9 (4.6)

0.0318*

1.6-fold

4.5

50

D

48.8 (7.3)

21.5 (9.4)

0.0037*

2.3-fold

4.5

30

D

58.1 (3.3)

38.2 (9.4)

0.0187*

1.5-fold

7.5

30

D

63.5 (5.5)

31.8 (3.8)

0.0002*

2.0-fold

4.5

30

E

68.2 (8.5)

33.9 (10.4)

0.0022*

2.0-fold

7.5

50

E

68.9 (4.5)

25.9 (8.7)

0.0005*

2.7-fold

7.5

30

E

70.2 (10.8)

53.3 (10.2)

Not significant

1.3-fold

4.5

50

E

76.3 (3.5)

44.7 (8.2)

0.0020*

1.7-fold

Combined middle passage and nasopharynx deposition
4.5

50

E

20.5 (4.4)

53.4 (9.4)

0.0025*

2.6-fold

7.5

50

E

29.2 (3.4)

73.9 (8.5)

0.0007*

2.5-fold

7.5

30

E

29.7 (10.6)

46.6 (10.1)

Not significant

1.6-fold

4.5

30

E

29.9 (7.5)

65.0 (9.5)

0.0014*

2.2-fold

7.5

30

D

34.1 (3.1)

68.0 (4.2)

<0.001*

2.0-fold

4.5

30

D

40.9 (2.8)

61.6 (9.6)

0.0188*

1.5-fold

4.5

50

D

49.1 (6.6)

77.4 (8.5)

0.0022*

1.6-fold

7.5

50

D

57.1 (9.5)

72.2 (4.7)

0.0411*

1.3-fold

Timing; D: actuation during inhalation, E - inhalation followed by actuation
* P<0.05 (Student t-test)
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4.3.2.1 Combined geometry and patient variable statistical analysis
It was also of interest to develop a mathematical model to predict the in vitro middle
passage drug deposition using the data generated for Nasonex® in VCU nasal models 1 and 2
combined with the different patient use variables. The continuous predictors considered were
actuation force (4.5 kg and 7.5 kg), head angle (30º and 50º) and VCU nasal model geometry ( 1
with SA/V ratio of 0.75 mm- 1 and 2 with SA/V ratio of 1.33 mm-1), and nasal spray position (9
mm and 5 mm), and timing (D and E) were defined as categorical variables. Using JMP software,
a multiple regression approach was used to identify the significant predictors and the most
informative subset among all the combinations that could be used to estimate the middle passage
drug deposition. All the possible combinations were considered starting with addition of one
parameter at a time to the model and assessing the correlation coefficient and goodness of fit
criteria between the built models. The goodness of fit criteria included the Akaike information
criterion (AIC), Bayesian information criterion (BIC) and Root Mean Square Error (RMSE) and
can be found in the multiple regression results (Table 4.9). Both BIC and AIC attempt to resolve
this problem by introducing a penalty term for the number of parameters in the model; the penalty
term is larger in BIC than in AIC. RMSE is a measure of the difference between the predicted
values (sample and population) by the model and the observed data. The model with the lowest
AIC, BIC and RMSE is preferred. However, the predictors first assessed if there is any co-linearity
between them. If the predictors that are correlated are used in a model, the overall regression model
and the effect of individual predictors are influenced. The performed multivariate analysis from
JMP is presented in Table 4.8.. The highest correlation coefficient was found between combined
middle passage and nasopharynx drug deposition and VCU nasal model geometry, meaning that
this variable is the most impactful variable. Table 4.9 represents the goodness of fit criteria for the
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models built in this study. The numbers of variables are added one at the time and the results are
only presented for the models showing the best goodness of fit among its subset. As shown, when
including only the VCU nasal model as a predictor, the model is able to explain 55 % (R2 = 0.5513)
of the variability around the predicted mean middle passage drug deposition. Adding the timing
variable to the model, the R2 and predictability of the model increased to 0.7294. However, adding
the variables of angle and position further increased R2 to 0.7673 (shown in Table 4.9 and Figure
4.8). Using this model with R2 of 0.7673, almost 77% variability around the mean response data
can be explained. In this case, each of the goodness of fit criteria (RMSE, AIC, and BIC) showed
the lowest values. Including the two variables interaction between the predictor did not increase
the model predictability. The ANOVA summary of the model is shown in Table 4.10. All the
variables included in the model showed significant effect on combined middle passage and
nasopharynx deposition for Nasonex® (Table 4.9, p < 0.05). Based on the estimate of coefficients
for the final model presented in Table 4.11, nasal airway geometry with the absolute largest
coefficient was the most influential factor in determining the extent of drug delivery to the middle
passages for the Nasonex® nasal spray product. The second important factor was the coordination
of nasal inhalation and spray actuation as it was consistently observed previously in the results of
deposition assessments using the individual models 1 and 2.
Table 4.8. Correlations of predictors with response (middle passage drug deposition) and between
predictors of force, angle, VCU nasal model, timing and nasal spray position
Response

Angle

VCU nasal model Timing

Position

Force

VCU nasal model

0.7425

-0.0000

1.0000

-0.0000

-0.4980

-0.0000

Position

0.4658

-0.0000

-0.4980

-0.0000

1.0000

-0.0000

Timing

0.4312

-0.0000

-0.0000

1.0000

-0.0000

-0.0000

Angle

0.1345

1.0000

-0.0000

-0.0000

-0.0000

-0.0000

Force

0.0402

-0.0000

-0.0000

-0.0000

-0.0000

1.0000
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Table 4.9. Goodness of fit criteria for models built to predict the regional nasal drug deposition
for Nasonex® nasal spray product using patient use parameters of timing, nasal spray position,
actuation force and head angle together with the VCU nasal model predictor. The variables are
added one at the time and the results are only presented for the models showing the best goodness
of fit among its subset
Model

Number

R2

RMSE

AIC

BIC

VCU nasal model

1

0.5513

13.2

771

780

VCU nasal model, Timing

2

0.7372

10.1

722

732

VCU nasal model, Timing, Angle

3

0.7553

9.8

717

729

VCU nasal model, Timing, Angle, Position

4

0.7673

9.7

715

729

VCU nasal model, Timing, Angle, Position,
Actuation force

5

0.7689

9.7

716

733

Figure 4.8. Plot of actual (observed) value versus predicted values of middle passage deposition
for the model built using four predictors of VCU nasal model geometry, timing, angle and nasal
spray position. The horizontal broken line shows the mean velocity, the solid line is the line of
fit, and the two broken curve lines describe the 95% confident region relative to the line of fit.
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Table 4.10. Analysis of Variance (ANOVA) results for the model including four variables of
VCU nasal model geometry, inhalation timing, angle and position to predict middle passage
drug deposition of the Nasonex® nasal spray product
Source

DF

Sum of Squares

Mean Square

F Ratio

Prob > F

Model

4

27858.7

6964.7

75.0

<.0001*

Error

91

8450.8

92.9

C. Total

95

36309.4

DF: degree of freedom
* P<0.05

Table 4.11. Estimates of coefficients and the significance of each variables for the model
including four variables of VCU nasal model geometry, inhalation timing, angle and position
to predict middle passage drug deposition of the Nasonex® nasal spray product
Term

Estimate

Standard
Error

t Ratio

Prob>|t|

Intercept

-12.6

5.5

-0.45

<.0001*

VCU nasal model

48.3

1.2

11.6

<.0001*

Timing[D]

8.4

1.0

8.5

<.0001*

Timing[E]

-8.4

1.0

-8.5

<.0001*

Position

-2.6

1.2

-2.15

0.0344*

Angle

0.3

0.1

2.7

0.0093*

* P<0.05
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In the developed model, based on the estimated coefficient presented in Table 4.11, all the
variables have significant effects on middle passage drug deposition with the VCU nasal model
geometry having the largest effect followed by inhalation timing.
The prediction expression for middle passage drug deposition (Y) is shown below:
Y = - 12.5 + (48.3 * VCU nasal model) + (0.3 * angle) + (Match inhalation,
if D then 8.3, or E then -8.6) – (Match position,
if 5 mm then 2.6, or 9 mm then – 2.6)

Equation 4.4

Based on the above equation, having a geometry similar to the VCU nasal model 2 with
coordination of nasal inhalation and spray actuation, nasal spray positioning closer to the tip of the
nostril and higher head angle of 50º forward from horizontal results in higher drug delivery to the
middle passages for the Nasonex® nasal spray product.
The model assumptions of normality of residuals and homogeneity of variances for the
ANOVA test were also tested and presented in Figures 4.9, 4.10 and 4.11 as well as Table 4.12.
Looking at the normal quantile plot presented in Figure 4.9, it appears that the data are normally
distributed. For the residual plot, graphically shown in Figures 4.10 and 4.11, equal amount of
spread above and below the line is observed with no sign of heteroscedasticity. Tabulated in Table
4.12, the Brown-Forsythe test was used to check the equality of variances with a p-value of less
than 0.05 indicating statistical significance. Table 4.12. shows that a p-value of 0.4758 and
confirms the equality of variances among the groups that were studied.
In summary, using realistic in vitro developed method, it seems the geometry of the nasal
cavity and patient use parameters such as head angle and nasal spray position in the nostril are
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influential in the delivery efficiency of the Nasonex ® nasal spray product and the developed
mathematical model can predict the range of variability for the drug delivery beyond the nasal
valve region. The actuation force for the nasal spray in the tested range for this nasal spray did not
result in change in drug delivery due to the presence of the nasal value and large droplet size of
the spray plume. It seems the positioning of the nasal spray with respect to the nasal valve and the
nasal valve geometry determine the extent of the penetration for the exiting plume into the
posterior region of the nasal cavity. This can be effected by patient use technique including head
angle and nasal spray position in the nostril. These results show the utility of the nasal airway
models in the development and screening of the nasal spray products.

Figure 4.9. Normal quantile plot used to assess the normality of the data for the linear model
built using the predictors of VCU nasal model geometry, timing, angle and nasal spray position

110

Figure 4.10. Plot of residual used to assess the normality of the residual for the linear model
built using the predictors of VCU nasal model geometry, timing, angle and nasal spray position

Figure 4.11. Plot of standard deviation for each of the group constructed using the variables of
actuation force, head angle, timing and VCU nasal model geometry
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Table 4.12. Results of statistical analysis for testing equality of variances among groups
Test

F Ratio

DFNum1

DFDen2

Prob > F

Brown-Forsythe

1.0009

23

71

0.4758

1
2

Degrees of freedom in the numerator
Degrees of freedom in the denominator

Evaluating the developed realistic in vitro test method using innovator and generic
nasal spray products
To assess the utility of the developed in vitro test method for characterizing regional nasal
drug deposition of nasal spray products, innovator and generic nasal spray products were
characterized and compared. Two innovator products, Flonase® and Nasonex® were tested
alongside their respective generic or “in house” nasal spray products, respectively. Specifically,
the capability and reproducibility of the developed in vitro deposition test method in characterizing
equivalent formulations and products was assessed. Generic nasal spray products are formulated
to have an equivalent in vitro and in vivo performance compared to the innovator product.
Therefore, it was expected that using this new in vitro realistic test method, the regional nasal drug
deposition for the generic nasal spray will not be statistically different from the innovator product
when tested under identical conditions in VCU nasal models 1 and 2. Based on previous studies
performed for the Nasonex® nasal spray product, test conditions for VCU nasal model 1 and 2
were selected by varying patient use parameters to produce low, intermediate and high combined
middle passage and nasopharynx drug deposition (Table 4.2). For VCU model 2, only one nasal
spray position was identified for testing due to its smaller nostril hydraulic diameter.
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4.3.3.1 Mometasone furoate nasal spray products
Conventionally, to develop generic solution or suspension nasal spray products, the
establishment of the equivalent in vitro performance between test and innovator is one of the
requirements. The droplet size distribution (DSD) measurement is one of the in vitro spray plume
characteristic tests that needs to be conducted. Similarity in DSD between products is evaluated
using the population bioequivalence approach.
The DSD for Nasonex® and the mometasone furoate “in house” formulations used in this
study was determined using two actuation forces of 4.5 kg and 7.5 kg. The results are shown in
Figure 4.12. At an actuation force of 4.5 kg and a distance of 2 cm between the nasal spray orifice
and the laser sensing zone, the mean (SD) of Dv10 for Nasonex® and “in house” formulation batch
#s of MFM11TF5 and MFM13F2 were measured as 19.4 (0.4) µm, 17.9 (0.3) µm and 17.2 (0.4)
µm, respectively. The Dv10 was significantly different for the two “in house” mometasone furoate
formulations compared to the Nasonex® nasal spray product (p-value = 0.008 <0.0001,
respectively) and there was also a significant difference observed in Dv10 between the two “in
house” formulations (p-value = 0.0261).
For Dv50, the mean (SD) measured values were 57.2 (1.4) µm, 54.0 (1.3) µm and 49.0
(1.3) µm for the Nasonex® and “in house” formulation batch #s of MFM11TF5 and MFM13F2,
respectively. Similar to the Dv10, the mean Dv50 was smaller for the two “in house” formulations
compared to Nasonex® (p-value = 0.0018 and <0.0001, respectively) and they were significantly
different from each other (p-value = 0.0290). Similar observations made for Dv90 with
corresponding mean (SD) values for the nasal spray products of 126.7 (4.0) µm, 96.4 (1.9) µm and
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90.7 (1.3) µm, respectively (p< 0.0001, < 0.0001 and 0.0116, respectively). The mean (SD) span
for these products were 1.9 (0.1), 1.5 (0.1) and 1.5 (0.1), respectively.
The two “in house” generic formulations were developed to have identical spray characteristics
with only the drug particle size differing, however there did appear to be some statistically
significant differences in the droplet size distributions both between the “in house” generic
formulations and with the Nasonex® product. This demonstrates the difficultly generic
manufacturers currently encounter when attempting to produce statistically equivalent
formulations with respect to their in vitro droplet / spray characteristics. The experimental
significance of these small, but statistically significant droplet size differences were evaluated
using the realistic in vitro deposition test method.
Increasing the actuation force from 4.5 kg to 7.5 kg resulted in a reduction in the DSD for
all three nasal sprays, with the more pronounced effect being on the Dv50 and Dv90 parameters.
For Nasonex® the mean (SD) Dv50 and 90 were reduced from 57.2 (1.4) µm to 47.0 (1.0) µm and
126.7 (4.0) µm to 109.8 (1.7) µm, respectively. For the “in house” generic formulation
(MFM11TF5) at 7.5 kg it showed a similar mean (SD) Dv50 of 47.2 (1.7) µm but smaller Dv90
of 91.2(1.7) µm (p<0.001) compared to Nasonex®. The other “in house” formulation (MFM13F2)
tested at 7.5 kg was observed to have even smaller mean (SD) values for Dv50 and Dv90 of 36.7
(0.5) µm and 80.3 (1.5) µm (p<0.001, <0.001, respectively, compared to Nasonex®).
The results for comparison of in vitro regional nasal drug deposition of Nasonex® nasal
spray and the “in house” generic mometasone formulations are shown in Tables 4.13 and 4.14 in
VCU nasal models 1 and 2, respectively. In these studies, the recovery of the “in house”
mometasone furoate formulation from VCU nasal models 1 and 2 was in the acceptable range of
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86.5 (3.5) % to 102 (11.9) % with no difference in the drug recovery between the two “in house”
formulations.
As shown in Table 4.13, the mean (SD) % drug delivery to the middle passages of VCU
nasal model 1 for the two “in house” generic mometasone furoate formulations varied from 20.2
(3.2) % to 59.1 (6.8) % for batch # MFM11TF5 and 19.5 (2.2) % to 47.9 (8.7) % for batch #
MFM13F2 which was similar to the results obtained for the Nasonex® nasal spray product (16.6
(2.4) % to 57.1 (9.4) %). Comparing the regional drug deposition for the two “in house”
mometasone furoate nasal formulations and the innovator product, there was no significant
differences in drug deposited in the anterior nose region and combined middle passage and
nasopharynx regions, when they were compared at three levels of low, intermediate and high
middle passage drug delivery in the VCU nasal model 1.
Similarly, using VCU nasal model 2, the in vitro regional nasal drug deposition of “in
house” generic mometasone furoate formulation (batch #MFM11TF5) was compared with
Nasonex® nasal spray product in Table 4.14 (insufficient product was available to test batch #
MFM13F2). The mean (SD) middle passage drug deposition for the “in house” mometasone
furoate formulation varied from 49.6 (10.7) % to 70.9 (6.5) % with the change in the experimental
conditions which was comparable with the observations for Nasonex® of 46.6 (10.0) % to 77.4
(8.5) %. It was concluded that there were no statistical differences in in vitro regional drug
deposition for the “in house” mometasone furoate formulation of MFM11TF5 and Nasonex ®
measured in VCU nasal model 2 and across the three different experimental conditions.
With respect to the comparison between the conventional spray characterization methods
and the realistic deposition method for comparing nasal spray products, it appears that marginal
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but statistically significant differences in DSD were not important with respect to the regional
deposition profile in the in vitro nasal airway models. Similar results were observed by Suman et
al. [52]. They compared the regional nasal deposition, rate and extent of absorption for nicotine
administered to 9 healthy subjects by two nasal spray pumps producing statistically different
droplet size (Dv50 of 37.3 vs 48.2 µm measured at distance of 2.5 cm) and spray plume
characteristic. However, they reported these in vitro differences did not alter the site of drug
deposition or the rate and extent of nicotine absorption. The in vitro characterization tests for nasal
sprays products such as DSD and spray plume characterizations are appropriate as quality control
tests but a more realistic and clinically relevant test may be necessary if an assessment of clinical
equivalence is to be made for comparison generic and innovator suspension nasal spray products
using in vitro testing.
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Nasonex®
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“In house” mometasone furoate
Batch MFM11TF5
In house” mometasone furoate Batch
MFM13F2
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Actuation force: 4.5 kg
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Figure 4.12. Mean (error bars are SD) droplet size distribution results for a single actuation of
the Nasonex® and “in house” mometasone furoate nasal spray products at actuation force of and
7.5 kg and 4.5 kg at 2 cm distance between the tip of the nasal spray and laser sensing zone.
These measurements performed in the beginning of the nasal spray life. Data represent mean
(SD) (n = 4)
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Table 4.13. Mean (SD) in vitro regional nasal drug deposition (expressed as a percentage of recovered dose) and total recovery
(expressed as percentage of the label claim) for the “in house” generic mometasone furoate (batches #MFM11TF5 and
MFM13F2) and Nasonex® nasal spray products in VCU nasal model 1 at three different experimental conditions (n=4).
Expected combined middle passage and
nasopharynx deposition
“In house” mometasone furoate #MFM11TF5
Level 1 - Low (~ 20 %)
Level 2 - Intermediate (~ 40 %)
Level 3 - High (~ 60 %)
“In house” mometasone furoate #MFM13F2
Level 1 - Low (~ 20 %)
Level 2 - Intermediate (~ 40 %)
Level 3 - High (~ 60 %)
Nasonex®
Level 1 - Low (~ 20 %)
Level 2 - Intermediate (~ 40 %)
Level 3 - High (~ 60 %)

NSP

AD

MP

F

Total recovery
(%)

1.5 (1.7)
1.7 (0.9)
0.8 (1.3)

78.3 (12.6)
62.4 (11.5)
40.0 (5.5)

20.2 (3.2)
37.0 (9.9)
59.1 (6.8)

0.0 (0.0)
0.0 (0.0)
0.0 (0.0)

97.3 (7.4)
102.0 (3.4)
86.5 (3.5)

1.8 (1.3)
1.1 (1.4)
0.4 (0.6)

78.7 (2.0)
70.4 (3.7)
51.6 (8.7)

19.5 (2.2)
28.5 (3.6)
47.9 (8.7)

0.0 (0.0)
0.0 (0.0)
0.0 (0.0)

92.5 (1.8)
96.2 (7.0)
100.2 (11.9)

1.2 (1.1)
2.5 (2.6)
0.6 (0.7)

81.8 (1.7)
63.5 (5.5)
42.3 (8.9)

16.6 (2.4)
34.1 (3.1)
57.1 (9.4)

0.0 (0.0)
0.0 (0.0)
0.0 (0.0)

100.6 (5.8)
100.5 (4.7)
95.1 (4.1)

NSP: Nasal spray, AD: Anterior + drip, MP: Combined middle passage and nasopharynx region, F: Filter NSP: Nasal spray, AD:
Anterior + drip, MP: Combined middle passage and nasopharynx region, F: Filter
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Table 4.14. Mean (SD) in vitro regional nasal drug deposition (expressed as a percentage of recovered dose) and total recovery
(expressed as percentage of the label claim) for the “in house” generic mometasone furoate (batch# MFM11TF5) nasal spray
formulation and Nasonex® nasal spray product in VCU nasal model 2 at three different experimental conditions (n=4)
Expected combined middle passage and
nasopharynx deposition

NSP

AD

MP

F

Total recovery
(%)

Level 1- Low (~ 50 %)

1.2 (1.3)

49.2 (9.5)

49.6 (10.7)

0.0 (0.0)

98.2 (7.9)

Level 2- Intermediate (~ 60 %)

2.4 (1.0)

35.5 (13.4)

62.1 (13.8)

0.0 (0.0)

88.7 (3.2)

Level 3- High (~77 %)

1.2 (0.7)

28.0 (5.8)

70.9 (6.5)

0.0 (0.0)

86.8 (4.1)

Level 1- Low (~ 50 %)

0.1 (0.1)

53.3 (10.2)

46.6 (10.0)

0.0 (0.0)

92.5 (11.2)

Level 2- Intermediate (~ 60 %)

0.2 (0.2)

38.2 (9.4)

61.6 (9.6)

0.0 (0.0)

91.3 (5.6)

Level 3- High (~ 77 %)

1.1 (1.1)

21.5 (9.0)

77.4 (8.5)

0.0 (0.0)

94.3 (7.5)

“In house” mometasone furoate #MFM11TF5

Nasonex®

NSP: Nasal spray, AD: Anterior + drip, MP: Combined middle passage and nasopharynx region, F: Filter
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4.3.3.2 Fluticasone propionate nasal spray products
For the Flonase® nasal spray product, as shown in Figure 4.13, the mean (SD) Dv10, Dv50
and Dv90 using an actuation force of 5.8 kg was measured as 20.9 (1.1) µm, 72.0 (1.7) µm and
120.4 (0.6) µm, respectively. Similar results were observed for the generic fluticasone propionate
spray product with mean (SD) values of 21.9 (0.2) µm, 69.4 (2.1) µm and 118.6 (2.8) µm,
respectively. Increasing the actuation force for the fluticasone products from 5.8 kg to 7.5 kg, did
not product the same magnitude of changes in DSD that was observed for the mometasone furoate
nasal spray products. The values of Dv50 were 67.2 (1.7) µm and 65.6 (1.1) µm and DV90 of
115.4 (1.1) µm and 114 (1.3) µm for Flonase® and the generic product, respectively using an
actuation force of 7.5 kg. Similar results were observed by Doughty et al. [141] when increasing
actuation force from 5.8 kg to 7.5 kg did not result in any change in DSD for Flonase® nasal spray
product. However, it was noted that reducing the actuation force to 3 kg (pediatric force) resulted
in a significant increase in DSD. This suggests that at higher actuation forces, formulation
properties (such as viscosity) are not significantly affected for the fluticasone propionate nasal
spray product.
The in vitro regional nasal drug deposition was investigated for the Flonase® (innovator
product) and a marketed generic fluticasone propionate nasal spray product. The results are
presented in Table 4.15 when performed using VCU nasal model 1 and in Table 4.16 for VCU
nasal model 2. For experiments performed using VCU nasal model 1, mean (SD) drug recovery
ranged from 97.4 (8.5) % to 99.9 (6.2) % for the generic formulation and 92.6 (5.9) % to 100.3
(10.7) % for Flonase® nasal spray product. Similar results in VCU nasal model 2 were 88.8 (3.6)
% to 102.2 (6.3) % and 90.5 (10.0) % to 94.4 (2.4) %, respectively.
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Table 4.15 shows that the mean (SD) amount of drug deposited on the device and the
regional drug deposition in the anterior nose and combined middle passages were similar for
Flonase® and the generic fluticasone propionate nasal spray product. There were no statistical
differences when comparing the two formulations at three different levels of low, intermediate and
high expected middle passage drug delivery. The mean (SD) combined middle passage and
nasopharynx deposition ranged from 17.5 (1.0) % to 39.5 (5.9) % for generic fluticasone
formulation and 21.0 (3.8) % to 47. 2 (10.4) % for the Flonase® in the VCU nasal model 1. It was
noted that the drug deposition in middle passages at level 3 appeared to be lower (40 - 50%)
compared to the deposition observed with the Nasonex® and mometasone furoate formulations (50
- 60%). It appeared that the level 3 - “high” conditions that were derived from the Nasonex® DOE
experiments may not have translated to “high” deposition for the fluticasone propionate products
due to differences in the spray characteristics of the different drug formulations and nasal sprays.
It would be ideal to investigate using a DOE type approach the effect of patient use variables in
the in vitro testing specifically for the individual test drug product (in this case fluticasone
propionate) in any future application of these methods. This would allow identification of study
conditions for the particular test nasal spray that produce the range of low, intermediate and high
deposition.
For the fluticasone products tested in VCU nasal model 2, there was no significant
differences in the deposition pattern for the two formulations inspected at three different
experimental conditions (Table 4.16). Using the VCU nasal model 2 and three experimental
conditions, for these formulations we observed a similar trend in the mean (SD) middle passage
drug deposition ranging from 64.6 (4.8) % to 78.6 (5.6) % for the generic fluticasone propionate
and 55.6 (7.3) % to 79.6 (0.3) % for the Flonase® nasal spray product.
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Droplet size (µm)

Flonase®
100

Generic fluticasone propionate
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40
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Dv10

Dv50

Dv90

Dv10

Actuation force: 5.8 kg

Dv50

Dv90

Actuation force: 7.5 kg

Figure 4.13. Mean (SD) droplet size distribution results for a single actuation of the Flonase®
and generic fluticasone propionate nasal spray products at actuation force of and 7.5 kg and 5.8
kg at 2 cm distance between the tip of the nasal spray and laser sensing zone. These
measurements performed in the beginning of the nasal spray life. Data represent mean (SD), (n =
4)
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Table 4.15. Mean (standard deviation) in vitro regional nasal drug deposition (expressed as a percentage of recovered dose) and total
recovery (expressed as percentage of the label claim) for the fluticasone propionate generic and Flonase® nasal spray products in VCU
model 1 at three different experimental conditions (n=4)
Expected combined middle passage and
nasopharynx deposition

NSP

AD

MP

F

Total recovery
(%)

Generic fluticasone propionate
Level 1 - Low (~ 20 %)

1.2 (0.8)

81.3 (0.9)

17.5 (1.0)

0.0 (0.0)

99.7 (5.4)

Level 2 - Intermediate (~ 40 %)

1.2 (0.5)

56.0 (3.6)

42.7 (4.1)

0.0 (0.0)

99.9 (6.2)

Level 3 - High (~ 60 %)

1.1 (0.5)

59.4 (5.9)

39.5 (5.9)

0.0 (0.0)

97.4 (8.5)

Level 1 - Low (~ 20 %)

2.4 (2.5)

78.0 (3.4)

21.0 (3.8)

0.0 (0.0)

97.7 (4.4)

Level 2 - Intermediate (~ 40 %)

1.6 (0.5)

56.6 (8.9)

41.7 (8.4)

0.0 (0.0)

92.6 (5.9)

Level 3 - High (~ 60 %)

1.1 (0.7)

51.7 (10.3)

47.2 (10.4)

0.0 (0.0)

100.3 (10.7)

Flonase®

NSP: Nasal spray, AD: Anterior + drip, MP: Combined middle passage and nasopharynx region, F: Filter
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Table 4.16. Mean (standard deviation) in vitro regional nasal drug deposition (expressed as a percentage of recovered dose) and total
recovery (expressed as percentage of the label claim) for the fluticasone propionate generic and Flonase® nasal spray products in VCU
model 2 at three different experimental conditions (n=4)
Expected combined middle passage and
nasopharynx deposition

NSP

AD

MP

F

Total recovery
(%)

Level 1 - Low (~ 50 %)

1.4 (1.0)

34.0 (4.1)

64.6 (4.8)

0.0 (0.0)

95.3 (6.2)

Level 2 - Intermediate (~ 60 %)

0.7 (0.5)

24.9 (3.2)

74.5 (3.3)

0.0 (0.0)

102.2 (6.3)

Level 3 - High (~77 %)

0.8 (0.9)

20.6 (6.2)

78.6 (5.6)

0.0 (0.0)

88.8 (3.6)

Level 1 - Low (~ 50 %)

1.1 (1.3)

43.3 (6.4)

55.6 (7.3)

0.0 (0.0)

93.4 (7.5)

Level 2 - Intermediate (~ 60 %)

1.3 (1.7)

30.6 (11.6)

68.1 (10.8)

0.0 (0.0)

94.4 (2.4)

Level 3 - High (~ 77 %)

2.7 (0.7)

17.8 (0.9)

79.6 (0.3)

0.0 (0.0)

90.5 (10.0)

Generic fluticasone propionate

Flonase®

NSP: Nasal spray, AD: Anterior + drip, MP: Combined middle passage and nasopharynx region, F: Filter

124

4.3.3.3 Summary of innovator and generic comparison studies and comparison with in vivo
deposition data
To assess the utility of the developed in vitro test methods using VCU nasal models of 1
and 2 for characterization of regional nasal drug deposition of nasal spray products, two innovator
spray products (Flonase® and Nasonex®) and their respective generic and “in house” products were
characterized. No statistical differences were observed for regional nasal drug deposition of the
Flonase® and the generic copy of the product in the VCU nasal model 1 and 2 for three different
experimental deconditions. These two formulations had no statistical differences in their spray
plume DSD. Similar observation was made for Nasonex® and the “in house” mometasone furoate
formulations, despite their small differences in the DSD.
The experimental condition was selected based on the extent of drug delivery to the
combined middle passage and nasopharynx regions of Nasonex® nasal spray products. Despite the
differences in the DSD of Nasonex® and Flonase® (Dv50 of 57 µm vs 70µm) the range of drug
delivery to the posterior nose region almost remained the same for three different experimental
conditions reflecting different patient use conditions (Similar trend observed) in the two VCU
nasal model 1and 2 (Except level 1 in VCU nasal model 1). It seems the combination of patient
use variables of inhalation-actuation timing, head angle and actuation force has similar effects as
observed for Nasonex® on regional drug deposition profile of Flonase®. Moreover, the effect of
inter-subject variability in the geometry of the nasal cavity was also profound for Flonase® nasal
spray product.
An in vivo study was performed to characterize the regional nasal drug deposition in 9
human subjects with allergic rhinitis for the Nasonex® and Flonase® nasal spray products [18]. In
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this open-label, nonrandomized, crossover study subjects were administered one dose of

99m

TC

radiolabeled Nasonex® or Flonase® to one nostril using the method described in the patient
information package insert. Deposited drug in the nasal cavity were quantified by merging the
gamma camera images with magnetic resonance images. Evaluating the 3D data obtained from
this study, shown in Figure 4.14, it appears that the mean deposition of the drug in the posterior
part of nasal cavity is about 30 % and 35 % (of the administered dose) for Nasonex® and Flonase®,
respectively. However, considering the variability the drug deposition could be increased up to 60
% and 70 %, respectively. The mean results are similar to our reported in vitro deposition findings
for Nasonex® and Flonase® when they tested in VCU nasal model 1 at intermediate or level 2.
Also, the range of drug deposition produced in VCU nasal model 1 and 2 can be observed in vivo.
Similarly, in a separate clinical study the regional drug deposition for Nasonex ® nasal spray
product was tested in 12 healthy subjects. Based on scintigraphy results, the author reported that
60 (9.1) % of the formulation deposited into the posterior part of the nasal cavity which is almost
twice as the result for the previous observation. In both studies drug was administered based on
information provided in the packaging insert [140]. The effect of different patient use technique
and geometry of the nasal cavity may be the reason for the observed different extent of drug
delivery to the middle passages. In addition, failure to accurately define the separation line between
anterior and middle passages for MRI image of subjects may result in inaccurate segmentation of
the nasal cavity which might be another source of observed high middle passage drug deposition
in the later in vivo study [145]. Overall, this range of variability was also seen with our developed
technique in the two nasal airway models.
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Figure 4.14. Image of the 3D SPECT data for the regional nasal drug deposition of Nasonex®
and Flonase® nasal spray products administered to 9 subjects with allergic Rhinitis [18] (top),
box and whisker diagram showing deposition fraction of mometasone furoate in the nasal cavity
based on the percentage of the label claim administered to 12 healthy volunteers (bottom) [140]
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A series of nasal spray products with differing in vitro spray properties were tested to assess
their regional drug deposition in VCU nasal model 1 and to characterize their differing spray plume
properties. Four products were considered, two custom-made mometasone furoate nasal sprays
(Batch: A and B), and 2 commercial Nasonex® nasal sprays with expiration dates of Feb 2007
(expired) and Oct 2015 (in-date), respectively.
A summary of spray pattern test characteristics (Dmin, Dmax, Ovality ratio, and area) is
presented in Table 4.17 using an actuation force of 7.5 kg. For the illustration purposes, Figure
4.15 shows the images obtained from spray pattern tests for the four nasal spray products.
Nasonex® 2015, the reference product that was in-date when tested appeared to have the smallest
Dmin, Dmax, area and a more circular shape as shown by its ovality ratio of 1.1 compared to the
other formulations. The custom-made mometasone furoate formulation batch A showed a
significantly larger Dmin, Dmax, ovality ratio and area compared to the other formulations. Its
area of 755.9 mm2 was almost double the area measured for Nasonex® 2015 with area of 363.4
mm2 (p-value<0.0001). The expired Nasonex® 2007 showed a larger Dmin, Dmax and area
compared to the in-date formulation (p-value<0.0001). It is unclear as to the reasons for these
changes, possible reasons include alteration in the formulation rheology and viscosity. However,
a previous in vitro study showed changes in spray dimensions and properties depended on the type
of viscosity enhancer polymer. For example, addition of Avicel FMC (microcrystalline cellulose
and sodium carboxymethylcellulose) increased formulation viscosity without a pronounced
change in spray plume characteristics. Spray dimensions for a formulation without a viscosity
enhancer polymer revealed that increasing the percentage of the polymer reduced the spray
dimensions. It has been suggested that modification of these characteristics can be used to enhance
the retention of the formulation in the nasal cavity and reduce drainage from anterior nose [19].
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Table 4.17. Mean (SD) spray pattern data for a single actuation of Nasonex® 2015 and 2007
nasal spray products and custom-made mometasone furoate nasal spray formulations (batches
A and B) measured using an actuation force of 7.5 kg, (n = 3)
Device

#

Nasonex® 2015

20.5 (0.2)

Nasonex® 2007

†

Ovality

⃰Area (mm2)

22.9 (0.3)

1.1 (0.0)

363.4 (7.6)

23.8 (0.5)a ,b, c

28.7 (0.3)a, b

1.2 (0.1)

531.3 (11.2)a

Custom-made mometasone
furoate, batch B

21.3 (0.2)b

26.4 (1.3)a, b

1.2 (0.1)

462.4 (25.3)a,b

Custom-made mometasone
furoate, batch A

28.3 (0.6)a

34.6 (2.2)a

1.2 (0.0)

755.9 (35.2)a,c

Dmin (mm)

Dmax (mm)

Statistical analysis of variance (ANOVA), followed by Tukey’s HSD
#
P<0.05, significant difference in Dmin; †P<0.05, significant difference in Dmax *P<0.05, significant
difference in Area
a
compared to Nasonex 2015
b
compared to custom-made mometasone furoate batch A
c
compared to custom-made mometasone furoate batch B

(a)

(b)

(c)

(d)

Figure 4.15. Spray pattern images of (a) Nasonex 2015, (b) Nasonex 2007, and custom-made
mometasone nasal spray formulation batches (c) B and (d) A obtained using SprayVIEWTM NSP
system using an actuation force of 7.5 kg (Proveris Scientific, Corporation, Sudbury, MA)
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Results for plume angle measurements and width measured using an actuation force of 7.5
kg are shown in Table 4.18 and Figure 4.16. Compared to Nasonex ® 2015, the expired Nasonex®
2007 product and the two custom-made mometasone furoate formulations had significantly larger
plume angles and widths. The custom-made mometasone furoate batch A had the largest plume
angle 60.5º compared to the in-date Nasonex® 2015 product with the smallest plume angle of 47.7º.
The respective plume width was 33.1 mm for batch A and 27.2 mm for the in-date Nasonex® 2015
nasal spray product. Again, the expired Nasonex® 2007 nasal spray product showed a larger plume
geometry compared to the in-date formulation.
Table 4.18. Mean (SD) plume geometry data for a single actuation of the Oct 2015 and Feb
2007 expiry Nasonex® nasal spray products and custom made mometasone nasal spray
measured using an actuation force of 7.5 kg (n=3)
+

Device

Angle

*Width (mm)

Nasonex® 2015

47.7 (1.1)

27.7 (2.1)

Nasonex® 2007

55.4 (1.2)a, b

31.5 (0.8)

Custom-made mometasone furoate, batch B

54.4 (1.8)a, b

30.8 (1.2)

Custom-made mometasone furoate, batch A

60.5 (1.3)a

33.1 (2.6)a

Statistical analysis of variance (ANOVA), followed by Tukey’s HSD
+
P<0.05, significant difference in plume angle; * P<0.05, significant difference in plume width,
a
compared to Nasonex®2015
b
compared to custom-made mometasone furoate batch A
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(a)

(b)

(c)

(d)

Figure 4.16. Spray pattern images of (a) Nasonex® 2015, (b) Nasonex® 2007 nasal spray
products and custom-made mometasone nasal spray formulation batches (c) B and (d) A
obtained by SprayVIEWTM NSP system using an actuation force of 7.5 kg (Proveris Scientific,
Corporation, Sudbury, MA)

The DSD for the studied nasal sprays were also measured at two actuation forces of 4.5
and 7.5 kg and are summarized in Tables 4.19 and 4.20. At actuation force of 4.5 kg, the DSD of
the expired Nasonex® 2007 nasal spray product was significantly smaller than the in-date
Nasonex® 2015 with a mean (SD) Dv50 of 48.8 (0.1) µm compared to 57.2 (1.5) µm, respectively
(p-value=0.0112). Using the same actuation force, the custom-made mometasone furoate batch A
had the smallest DSD with a mean (SD) Dv50 of 43.1 (3.6) µm, however, batch B was observed
to have a mean (SD) Dv50 of 50.9 (3.6) µm which was comparable to expired Nasonex ® 2007
product. Increasing the actuation force to 7.5 kg resulted in smaller droplet size distribution for all
nasal spray products. Compared to in-date Nasonex® 2015, each of the nasal spray products had a
significantly smaller droplet size distribution.
There was a negative linear relationship between the area obtained from the spray pattern
results and the Dv50 obtained from the DSD measurements at 4.5 kg as shown in Figure 4.17.
Previous studies also showed a negative linear relationship between spray pattern data and DSD
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as formulation viscosity was reduced which was correlated with a larger spray area [131]. These
studies also showed that for nasal formulations containing carboxymethyl cellulose as viscosity
enhancer, which is present in Nasonex® formulation, the formulation behaved as Newtonian fluid
and the DSD was reduced by increasing the actuation force.

Table 4.19. Mean (SD) droplet size distribution results for a single actuation of the study nasal
sprays using an actuation force of 4.5 kg (n=4)
Device

#Dv 10 (µm)

†Dv50 (µm)

*Dv90 (µm)

Span

Nasonex® 2015

19.4 (0.4)

57.2 (1.5)

126.7 (4.0)

1.9 (0.1)

Nasonex® 2007

17.8 (0.1)a

48.8 (0.1)b

106.9 (2.0)a

1.8 (0.0)

Custom-made mometasone 20.3 (1.1)
furoate, batch B

50.9 (3.6)b

118.6 (10.5)

1.9 (0.1)

Custom-made mometasone 16.9 (0.6)a, b
furoate, batch A

43.1 (0.2)aa, b

99.1 (3.7)a ,b

1.9 (0.0)

Statistical analysis of variance (ANOVA), followed by Tukey’s HSD
# P<0.05, significant difference in DV10
† P<0.05, significant difference in DV50
* P<0.05, significant difference in Dv90
a
compared to custom-made mometasone furoate, batch B
b
compared to Nasonex® 2015
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Table 4.20. Mean (SD) droplet size distribution results for a single actuation of the study nasal
sprays using an actuation force of 7.5 kg (n=4)
Device

#Dv 10 (µm)

†Dv50 (µm)

*Dv90 (µm)

Span

Nasonex® 2015

16.5 (0.2)

47.0 (1.0)

109.8 (1.7)

2.0 (0.1)

Nasonex® 2007

14.3 (0.1)a, b

36.3 (0.8)a

88.8 (0.8)a, b

2.1 (0.0)

Custom-made
mometasone furoate,
batch B

16.1 (0.9)

38.7 (3.0)a

100.9 (8.5)

2.2 (0.1)

Custom-made
mometasone furoate,
batch A

14.3 (0.2)a, b

35.6 (0.5)a

91.1 (1.0)a

2.2 (0.0)

Statistical analysis of variance (ANOVA), followed by Tukey’s HSD
# P<0.05, significant difference in DV10
† P<0.05, significant difference in DV50
* P<0.05, significant difference in Dv90
a
compared to Nasonex® 2015
b
compared to custom-made mometasone furoate, batch B
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y = -27.735x + 1915
R² = 0.9386
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Figure 4.17. Linear relationship between spray pattern area and Dv50 measured using 4.5 kg
actuation force for four study nasal sprays
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The results of in vitro regional drug deposition for nasal spray products with varying plume
characteristics, are summarized in Tables 4.21 and 4.22. The measurements were performed at two
actuation forces of 4.5 kg and 7.5 kg, with the nasal model angled 30˚ forward from horizontal and
the nasal spray positioned at 9 mm from front of the nasal spray tip with synchronized nasal spray
actuation and inhalation (D). The mean total recovery for these experiments ranged from 88.9 %
to 103.1 %. Comparing the regional drug deposition of Nasonex® 2007 with the in-date Nasonex®
2015, there was no statistical differences between the mean (SD) amount of drug delivered to the
anterior part of the nose + drip of 65.9 (13.6) % vs 67.3 (7.4) % of recovered dose, respectively,
and middle passages of 33.9 (13.8) % vs 32.1 (8.0) % of recovered dose, respectively, when nasal
sprays were actuated using a force of 4.5 kg. For the two custom-made nasal spray products, mean
(SD) anterior + drip deposition was 63.4 (6.3) % and 54.0 (2.8) % for nasal formulation batches B
and A, respectively. The corresponding mean (SD) middle passage depositions were 34.1 (6.7) %
and 43.2 (6.5) %. When comparing the regional nasal drug deposition across the 4 nasal spray
products at actuation force of 4.5 kg, there was no statistically significant differences in anterior +
drip or middle passage drug deposition for these nasal spray products evaluated by ANOVA.
When tested using a 7.5 kg actuation force, the results shown in Table 4.22 reveal that the
anterior nose + drip deposition of batch A was significantly greater than in-date Nasonex® 2015
(p-value = 0.0430) with mean (SD) values of 67.1 (8.3) % versus 55.4 (7.6) %. The anterior nose
+ drip deposition of the two custom-made mometasone furoate nasal spray products was also
significantly different (p-value = 0.0017). Batch B produced a significantly lower mean (SD)
anterior + drip drug deposition (48.4 (9.2) %) compared to batch A (67.1 (8.3) %).
Correspondingly, the mean (SD) middle passage drug delivery of batch A (31.0 (8.5) %) was
significantly lower than batch B (49.6 (8.8) %) and also lower than the in-date Nasonex® 2015
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nasal spray product (44.6 (7.6) %) (p-value = 0.0008 and 0.0126, respectively). Finally, the
Nasonex® 2007 had significantly lower mean (SD) middle passage deposition of 38.8 (3.8) %
when compared with custom batch B (p-value = 0.0374).
When considering all four nasal sprays, with the data available from actuation using a 7.5
kg force, the greatest differences in droplet size and spray plume characteristics were observed
between Nasonex 2015 (large droplet size and small plume angle and area) and the custom made
batch A formulation (small droplet size and large plume angle and area), with Nasonex 2007 and
custom made batch B formulations appearing to have similar spray properties which were between
the extremes of the other two formulations. This was translated into the highest anterior nose
deposition observed with batch A corresponding with the large plume angle and spray area. Cheng
et.al [31] also showed increased anterior nose deposition with increasing spray angle. However, it
should be noted that in their study increasing in the plume angle was accompanied with larger
spray plume droplet size, which is in contrast to the observations for batch A which had the
smallest droplet size of the study nasal sprays. Newman et al. [16] using gamma scintigraphy,
reported that deposition of a spray with a 35° plume angle gave improved posterior (turbinate)
deposition compared to a spray with a similar droplet size (70 µm) but with a 60° plume angle. In
contrast, Guo and colleagues [146] compared two cellulose-containing formulations; they
observed an improved turbinate-region deposition from the spray with the wider plume angle (67°
vs. 32°), and the CFD predictions of Kimbell et al.[15] failed to show any effect based on plume
angle.
The two custom made nasal spray products, tested at an actuation force of 7.5 kg using
identical spray pump containers were found to have significant differences in the spray plume
properties while they droplet size distributions were found to be similar (mean Dv50 = 35.6 µm
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and 38.7 µm for batch A and B, respectively). For these products, there were significant differences
in the regional drug deposition when tested at 7.5 kg. With batch A having high anterior nose
deposition (67.1%) and low middle passage drug delivery (31%), compared to almost 50%
deposition in the middle passage for batch B. Further evidence the limited effect of droplet size in
determining the nasal deposition profile can be found when comparing Nasonex 2015 actuated at
4.5 kg, which had a mean Dv50 of 57.2 µm and Batch A actuated at 7.5 kg, which had a mean
Dv50 of 35.6 µm. Despite, large differences in the measured particle size of these sprays, the
regional nasal deposition in the anterior nose was nearly identical with 67.3% vs 67.1 % deposition
for Nasonex 2015 and batch A, respectively. Similarly values for middle passage deposition were
32.1 % and 31.0 %, respectively. From these results, it appears that for nasal spray plumes with
high initial plume velocities, due to the presence of the nasal valve, droplet size in the range of 35
– 60 µm was less important with respect to penetration through the nasal valve and deposition
fraction to the middle passages compared to the spray plume properties.
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Table 4.21. Mean (SD) in vitro regional nasal drug deposition (expressed as a percentage of recovered dose) and total recovery
(expressed as percentage of the label claim) for the Nasonex® nasal spray product and custom-made mometasone furoate formulations
in VCU model 1, when the nasal spray is located at position of 9 mm from front of the nose, nasal model head angle of 30˚forward
from horizontal, nasal spray actuation during nasal inhalation (D) using actuation force of 4.5 kg (n=4)
Nasal spray product

NSP

AD

MP

F

Total recovery (%)

Nasonex 2015

0.6 (0.9)

67.3 (7.4)

32.1 (8.0)

0.0 (0.0)

91.5 (7.3)

Nasonex 2007

0.2 (0.3)

65.9 (13.6)

33.9 (13.8)

0.0 (0.0)

92.2 (4.3)

Custom-made mometasone furoate, batch B

2.0 (1.1)

63.4 (6.3)

34.1 (6.7)

0.0 (0.0)

90.4 (5.7)

Custom-made mometasone furoate, batch A

2.8 (3.7)

54.0 (2.8)

43.2 (6.5)

0.0 (0.0)

89.7 (6.2)

NSP: Nasal spray, AD: Anterior + drip, MP: Combined middle passage and nasopharynx region, F: Filter

Table 4.22. Mean (SD) in vitro regional nasal drug deposition (expressed as a percentage of recovered dose) and total recovery
(expressed as percentage of the label claim) for the Nasonex® nasal spray product and custom-made mometasone furoate formulations
in VCU model 1, when the nasal spray is located at position of 9 mm from front of the nose, nasal model head angle of 30˚forward
from horizontal nasal spray actuation during nasal inhalation (D) using actuation force of 7.5 kg (n=4)
Nasal spray product

NSP

*AD

Nasonex 2015

0.0 (0.0)

Nasonex 2007

#

MP

F

Total recovery (%)

55.4 (7.6)

44.6 (7.6)

0.0 (0.0)

88.9 (3.2)

3.6 (2.8)

56.8 (7.5)

38.8 (3.8)b

0.9 (1.8)

90.5 (8.0)

Custom-made mometasone furoate, batch B

2.0 (0.9)

48.4 (9.2)

49.6 (8.8)

0.0 (0.0)

103.1(19.9)

Custom-made mometasone furoate, batch A

1.9 (1.9)

67.1 (8.3)a, b

31.0 (8.5)a, b

0.0 (0.0)

97.7(10.8)

NSP: Nasal spray, AD: Anterior + drip, MP: Combined middle passage and nasopharynx region, F: Filter
*P<0.05, significant difference in AD,
#
P<0.05, significant difference in MP
a
compared to Nasonex® 2015
b
compared to batch B
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The aim of this work was to identify the effect of changes in spray plume characteristics
and droplet size distributions on in vitro regional drug deposition for these nasal spray products.
Despite statistically significant differences in the droplet size characteristics of the nasal sprays
tested at 4.5 kg actuation force, these did not translate into statistically significant changes in the
in vitro regional nasal deposition for these sprays. Combining the data from in vitro
characterization tests of droplet sizing, plume geometry and spray pattern tests with the regional
nasal drug deposition test performed at actuation force of 7.5 kg, it appears the custom mometasone
furoate batch A with larger spray plume area, Dmin, Dmax, plume angle and width and smaller
DSD produced a lower middle passage drug deposition. In order to see investigate the relationship
between the in vitro plume characterization results and in vitro regional nasal drug deposition, the
correlation of these factors was studied using JMP 12.0 software. The response, Y, was selected
as combined middle passage and nasopharynx drug deposition measured at actuation force of 7.5
kg, nasal head angle of 30º, nasal spray position of 9 mm and nasal spray actuation occurred during
nasal inhalation (D). The predictors, Xs, were considered as Dmin, Dmax, ovality, area, plume
angle, width, Dv10, Dv50 and Dv90.
Firstly, the correlation between each predictors and response was evaluated by assessing
the correlation coefficient. As demonstrated in Table 4.23, the strongest correlation was observed
between the middle passage drug deposition and Dmin measured in spray pattern test with a
negative correlation of -0.5982 and with R2 = 0.3579, the line intercept of 90.5 and the slope of 2.1 (SE = 0.87) which was significantly different from zero (t ratio = -2.36, p value = 0.0399)
signifying the importance of the Dmin in determining middle passage drug delivery. The negative
correlation between these variables implies that increasing Dmin will produce a decrease in drug
delivery to the middle passages. Among the tested nasal sprays, the custom mometasone furoate
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formulatinon batch A with the largest Dmin exhibited the lowest middle passage drug delivery.
Negative correlation between the predictors and response were also found for Dmax, area, plume
angle and width. The remaining predictors had a positive correlation with middle passage drug
deposition. However, with regards to DSD, it is important to recognized the relatively small range
of droplet sizes that were considered using the actuation force of 7.5 kg (Dv50 36 µm - 47 µm)
which perhaps limits extrapolation of the effects of Dv50 on middle passage drug deposition.
The next step in the analysis was to identify the predictors and the most informative subset
among all the combinations that can be used to estimate combined middle passage drug deposition
in VCU nasal model 1 using a multiple regression approach. The previous approach of adding one
variable at a time and judging the models based on goodness of fit was employed. The co-linearity
between predictors was assessed and reported in Table 4.24. The lowest correlation was observed
between the two variables of Dmin and ovality as shown in Table 4.24.
In JMP using multiple regression platform, all possible models were constructed by adding
predictors one at a time and the models with best results for R2 and lower AIC, BIC and RMSE
for each subset are summarized in Table 4.25. The best model using only including one predictor
was the model using Dmin, which had the highest correlation with middle passage drug deposition
resulted in a R2 of 0.3579, AIC value of 94.1, BIC of 92.5 and RMSE of 9.2. The model which
included two predictors, Dmin and Ovality, was able to generate an R2 = 0.77, which indicates that
77 % of the variability of the response data around mean can be explained by the built model
(Figure 4.18). The analysis of variance for this model reports a p-value = 0.0014. The derived
model expression for predicting middle passage drug deposition (Y) was:
Y= -18.4 – (2.8*Dmin) + (105.4*ovality)

Equation 4.5
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The parameter estimates and the p-values of the predictors for this model are listed in Table
4.26. The ANOVA assumptions of normality of the data (Figure 4.19) and equal variance (p-value
of 0.9583 for Brown-Forsythe test) were also assessed. Considering the middle passage residual
versus predicted middle passage plot (Figure 4.20) for the model, no heteroscedasticity was
observed, meaning that there was no change in variance with change in the fitted value of the
response, for the model including the two predictors of Dmin and Ovality.
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Table 4.23. Correlation between in vitro middle passage drug deposition and spray plume properties and their reported levels of
statistical significance
Dmin

Dmax

Ovality

Area

Plume angle

Width

Dv10

Dv50

Dv90

-0.5982

-0.3428

0.4191

-0.4379

-0.3498

-0.1529

0.4934

0.2814

0.4793

Line intercept

90.5

65.2

-36.1

58.9

86.1

62.3

-26.7

17.2

-12.0

Estimate (SE)

-2.1 (0.9)

-0.8 (0.7)

65.5 (44.8)

0.0(0.0)

-0.8(0.7)

-0.6(1.3)

4.5(2.5)

0.6(0.7)

0.6(0.3)

-2.4

-1.2

1.5

-1.5

-1.2

-0.5

1.8

0.9

1.7

0.0399

0.2754

0.1750

0.1545

0.2506

0.6352

0.1031

0.3762

0.1149

Correlation

t ratio
p-value
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Table 4.24. Correlation matrix for in vitro spray plume properties measured for mometasone
furoate nasal formulations with varying spray plume characteristics
D min D max

Ovality

Angle Width

Area

Dv 10

Dv 90

Dv 50

Dmin

1.00

0.94

0.31

0.87

0.67

0.98

-0.80

-0.77

-0.75

Dmax

0.94

1.00

0.61

0.89

0.80

0.99

-0.82

-0.80

-0.83

Ovality

0.31

0.61

1.00

0.52

0.67

0.50

-0.43

-0.48

-0.65

Angle

0.87

0.89

0.52

1.00

0.78

0.91

-0.69

-0.76

-0.89

Width

0.67

0.80

0.67

0.78

1.00

0.74

-0.62

-0.70

-0.75

Area

0.98

0.99

0.50

0.91

0.74

1.00

-0.79

-0.77

-0.81

Dv10

-0.80

-0.82

-0.43

-0.69

-0.62

-0.79

1.00

0.96

0.83

Dv90

-0.77

-0.80

-0.48

-0.76

-0.70

-0.77

0.96

1.00

0.91

Dv50

-0.75

-0.83

-0.65

-0.89

-0.75

-0.81

0.83

0.91

1.00

Table 4.25. Possible linear models built to predict in vitro middle passage drug deposition of
mometasone furoate nasal spray products with spray plume characteristic data as predictors
Model

Number

R2

RMSE

AIC

BIC

Dmin

1

0.3579

9.2

94.1

92.5

Dmin, Ovality

2

0.7677

5.8

86.5

82.8

Ovality, Area, Dv90

3

0.8617

4.8

86.6

79.1

Dmax, Area, Dv90, Dv50

4

0.9050

4.2

90.9

77.0

Dmax, Area, Dv10, Dv90, Dv50

5

0.9283

4.0

100.8

76.2

Dmin, Ovality, Angle, Area,
Dv10, Dv90

6

0.9814

2.2

106.5

62.4

Dmin, Ovality, Angle, Area,
Dv10, Dv90, Dv50

7

0.9914

1.7

141.2

55.6

Dmin, Dmax, Ovality, Angle,
Area, Dv10, Dv90, Dv50

8

0.9939

1.6

269.1

53.9
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Table 4.26. Parameter estimates and significance of the model that includes Dmin and ovality
as predictors of middle passage drug deposition of mometasone furoate nasal spray
formulations with varying spray characteristics
Term

Estimate

Std Error

t Ratio

Prob>|t|

Intercept

-18.4

30.3

7.13

<.0001*

Dmin

-2.7

2.3

-5.27

0.0005*

Ovality

105.4

0.05

4.50

0.0015*

Figure 4.18. Plot of middle passage deposition for mometasone furoate predicted versus
observed data using a model including Dmin and ovality as two predictors

Figure 4.19. Normal quantile plot for middle passage drug deposition of mometasone furoate
nasal spray formulations with varying spray properties
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Figure 4.20. Residual plot for residual versus predicted middle passage deposition for
mometasone furoate nasal spray formulations with varying spray properties using a model that
includes two predictors of Dmin and ovality

4.4 Conclusion
In this chapter, the importance of nasal geometry on regional nasal drug deposition of nasal
spray products was demonstrated. In addition, it was observed that the effects of patient use
variables can vary with respect to the nasal cavity geometry employed for in vitro testing (Specific
Aim 2-1). The regional nasal drug deposition in VCU nasal model 2 appeared to be less sensitive
with respect to changes in patient use parameters. However, the previously identified critical
patient use variables that affect deposition in VCU nasal model 1 were observed to be similarly
important for determining deposition in VCU nasal model 2. Deposition testing using VCU nasal
model 2 confirmed that nasal inhalation during nasal spray actuation and head angle were
important patient use factors. The developed in vitro test methods were able to reliably produce
similar regional nasal deposition profiles for the nasal spray products with similar spray plume
characteristics (Specific Aim 2-2). These methods were also capable of detecting differences in
the regional nasal drug deposition of the nasal spray products with different plume geometries
which appeared to be more critical than droplet size in determining the deposition fate of the nasal
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spray (Specific Aim 2-2). Future studies should consider performing measurements of regional
nasal drug deposition for a series of nasal spray products with differing spray plume properties in
a series of nasal models with different nasal valve region geometries to further investigate the
importance of spray plume properties on regional nasal drug deposition in combination with intersubject variability.
It is important to recognize that the results and observations described in this chapter will
require further in vivo validation. The in vitro deposition data obtained in this study for the
Nasonex® and Flonase® nasal spray products was observed to agree with previous literature in vivo
deposition studies. However, due to the variability observed in the in vivo literature data, it would
be desirable to investigate in vivo deposition performed under controlled conditions alongside
simultaneous in vitro deposition studies with the same nasal spray used in the same manner and
possibly using models of the airway geometries of the in vivo test subjects. Only then can
meaningful in vitro - in vivo correlations be made to assess these nasal spray products and validate
the proposed approach. However, to date, it was only possible to examine retrospectively the
literature to identify an in vivo deposition study using the nasal sprays employed in this project
and observe that the in vivo regional drug deposition was comparable with the results obtained in
vitro using VCU nasal models 1 and 2.

145

Chapter 5
DEVELOPMENT AND EVALUATION OF A NOVEL
CIPROFLOXACIN NANOCRYSTAL FORMULATION FOR NASAL
DRUG DELIVERY

5.1 Introduction
Chronic rhinosinusitis (CRS) is a common chronic disease of the nasal airways and paranasal
sinuses affecting approximately 10 -15% of the US population [62, 63]. The etiology of CRS is
not completely clear, but it is believed that one or more factors, such as anatomical obstruction
due to high mucus secretion, accumulation of bacterial or fungal infection in the sinuses, or
allergies results in a chronic inflammation of the nasal airways. The main organisms in CRS
include Staphylococcus aureus, Enterobacteriaceae spp., and Pseudomonas spp., and less
commonly Streptococcus pneumoniae, Haemophilus influenza, and beta hemolytic streptococci
[64, 65]. The high rate of endoscopic sinus surgery demonstrates that current therapeutics are not
sufficiently effective [62]. One potential therapeutic option is the short-term administration of oral
or topical antibiotics.
Ciprofloxacin, a fluoroquinolone, is a broad-spectrum antibiotic which has been used widely
used to treat Pseudomonas aeruginosa infection [147, 148]. Pseudomonas aeruginosa is cultured
in patients with chronic rhinosinusitis, especially in patients with previous sinus surgery [149].
Systemic or nebulized delivery of ciprofloxacin has been administered in patients with chronic
rhinosinusitis [70, 71]. Local administration of antibiotics is the preferred mode of delivery, as it
ensures direct deposition of the medication to the site of infection, resulting in high local
concentrations and lower systemic levels and associated systemic toxicity. To date, topical

146

antibiotics, administered in patients who have not undergone surgical intervention, in the form of
nebulizers or sprays have failed to demonstrate any clinical benefit due to limited mucosal
distribution from nasal sprays as well as off-target delivery to the lungs in case of using nebulizers.
Therefore, there is a need to develop a formulation with high-efficiency drug delivery to the
posterior part of the nasal cavity [59] if antibiotic therapy is to become a viable therapeutic option.
Among the challenges of local nasal delivery, hyper-viscoelastic mucus in CRS patients
(because of high mucin, DNA and actin content from degenerated neutrophils) serves as a barrier
for drug penetration reaching the nasal epithelial. Lai et al. [76] estimated the average pore size of
mucus obtained from CRS patients was about 150 ± 50 nm measured based on the mobility of
PEGylated nanoparticles. The first aim of this chapter was to evaluate the feasibility of using a
sonocrystallization technique to produce ciprofloxacin nanoparticles which may better penetrate
the mucus barrier. The process variables related to the crystallization technique were assessed to
investigate the effects on particle size and to produce nanocrystals in the size range of 100 – 200
nm.
The second aim was to develop an aerosolizable nasal formulation incorporating the
ciprofloxacin nanoparticles into nanocomposite particles suitable for delivery to the middle
passages and paranasal sinuses. A spray drying technique was employed for this task to formulate
a water-soluble excipient powder composite containing ciprofloxacin nanoparticles in the target
particle size range of 5 – 10 µm. The nanocomposites should have the ability to release the
ciprofloxacin nanoparticles after dissolution of excipients in the nasal fluid lining. The particle
size distribution and dissolution profile of the optimized ciprofloxacin nanoparticles were
evaluated following their release from the nanocomposite formulation to determine their release
properties.
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The third aim was to characterize the delivery of the nanocomposite formulation using a
novel powder delivery system developed to enhance the nasal delivery to the middle passages
using the development realistic nasal airway geometry (VCU nasal model 1). The novel powder
delivery system utilizes the VCU low volume DPI (2.3-343) modified to deliver aerosol to the
nasal cavity and used in combination with a novel breathing maneuver. The method allowed
aerosol to be delivered to the nasal cavity at a low flow rate (10 – 15 Lmin-1) during a simultaneous
nasal exhalation [150].
The fourth aim was to develop a technique to assess post nasal deposition events such as
transepithelial transport of drugs after realistic deposition on human epithelial cell monolayers in
a realistic airway geometry. Previous attempts have been made to study the transport of fractionate
inhalation aerosols that have deposited drug on Transwell® based cell monolayers which have been
inserted into cascade impactors [151]. Deposition using these methods often produced focused
areas of drug deposition corresponding to the position of the Transwell ® under an individual
impactor jet and would not be considered realistic mimics of airway deposition. In this study, we
have inserted three Transwell® inserts into the nasal cavity walls such that a cell monolayer is
exposed to the airflow through the middle passages of a realistic nasal airway model. Drug
depositing on the monolayer may enable a more clinically relevant sampling of the aerosol and be
used to study the transepithelial transport of the drug.

5.2 Materials
Ciprofloxacin (base, anhydrous) and Polysorbate 80 (Tween™ 80) were purchased from
Sigma - Aldrich, St. Louis, MO. Pearlitol® PF-Mannitol was donated from Roquette Pharma,
Lestrem, France. Polyvinylpyrrolidone (PVP K30) was purchased from TCI Chemicals, Japan.
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Hydroxypropylmethyl cellulose (HPMC) capsules (size 3) were donated by Capsugel, NJ. HPLC
grade isopropyl alcohol, methanol, acetonitrile, phosphoric acid, and trimethylamine were
purchased from Fischer Scientific, Pittsburgh, PA.

5.3

Methods
Nanoparticle preparation

5.3.1.1 Preparation of ciprofloxacin solution
Aqueous solutions of ciprofloxacin base (CPF) were prepared by dissolving 37.5 mg of
drug in 1 mL of 0.1N hydrochloric acid with the aid of water bath sonication (Branson® 5510
Sonicator, Fischer Scientific, Pittsburgh, PA) for 30 min at room temperature (25 ºC). 37.5 mg of
drug was the highest mass that could be dissolved in 1 mL of 0.1N hydrochloric acid with the aid
of sonication. The ciprofloxacin solution was then filtered using an Anotop® syringe filter (0.2
µm, 25mm, Whatman, Sigma-Aldrich, St. Louis, MO) to remove any particulate matter.
5.3.1.2 Sonocrystallization of ciprofloxacin nanoparticles using liquid anti-solvent
precipitation with sonication
Ciprofloxacin crystallization was achieved by introducing 3 mL of ciprofloxacin in 0.1N
hydrochloric acid solution (37.5 mg / mL) at 25 ºC into 50 - 300 mL of phosphate buffer pH 7
(U.S. Pharmacopeial Convention, 29) as the anti-solvent solution. Ciprofloxacin has a solubility
of 70 µg/mL at pH 7 [152]. The drug solution was delivered through a PTFE tube with an internal
diameter of 0.12 inch which was maintained 2 cm above the anti-solvent. The aqueous solution of
CPF was pumped into the anti-solvent via a syringe pump (PHD 2000 Infusion, Harvard
Apparatus, Holliston, MA) at a constant infusion rate of 1.25 mL/sec using a 3-mL syringe (BD
Medical, VWR, Bridgeport, NJ). The experimental setup is shown in Figure 5.1. A solid ultrasound
probe (tip diameter = 0.5 inches; Qsonica, Newtown, CT) which is suitable for processing 20-250
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mL volumes of organic solvents or low surface tension liquids was used. The anti-solvent was
cooled to 6 °C prior to each experiment in the refrigerator. The probe was immersed in the antisolvent solution at a depth of 2 cm below the anti-solvent surface. The sonication was started
immediately prior the addition of the drug solution to the anti-solvent and was continued for 10
min at 100% amplitude (20 kHz, Q700, Qsonica, Newtown, CT). The volume of the jacketed
vessel containing the anti-solvent was either 100 mL (for 50 mL anti-solvent volume) or 600 mL
(for > 50 mL anti-solvent volumes). The temperature of the anti-solvent solution was monitored
during the process and cooled water was circulated through the jacketed vessel to control the
temperature when required. The final suspension containing the crystallized nanoparticles was
centrifuged (5.3 rotor, Sorvall ST 16R, Thermo Scientific, Waltham, MA) at 3000 rpm for 3 min
to separate large titanium residue contamination released from the probe. Particle size analysis and
zeta potential characterization were performed on the suspended nanoparticles. CPF nanoparticles
in solid form were collected immediately after centrifugation by vacuum filtration using PVDF
membrane filters (0.1µm, Durapore™ Membrane filters, Merck Millipore Ltd, Billerica, MA) and
allowed to dry overnight at room temperature (25 ºC).
Using the general method described above, the particle size distribution of the CPF
nanoparticles was optimized to produce particles in the size range of below 150 nm by assessing
the effect of the following experimental variables known to influence crystallization:
•

Anti-solvent temperature

•

Mixing during crystallization

•

Addition of excipient stabilizer to the anti-solvent solution

•

Solvent:anti-solvent volume ratio
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•

Anti-solvent composition

Probe sonicator

PTFE tubing to deliver drug
solution to anti-solvent vessel
Drug solution in 3 mL BD syringe
(Ciprofloxacin in 0.1N HCl)

Syringe pump
(Addition rate of 1.25 mL/sec)
Anti-solvent
(Phosphate buffer, pH 7)

Figure 5.1. Schematic representation of the experimental setup for the liquid anti-solvent
crystallization with sonication for ciprofloxacin (sonocrystallization technique)
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5.3.1.3 Particle size optimization of ciprofloxacin nanoparticles
The experimental conditions are summarized in Table 5.1. After each experiment, the
crystallized particles were characterized to determine their particle size distribution and zeta
potential. In addition, the particles were characterized by differential scanning calorimetry (DSC)
and thermogravimetric analysis (TGA) as described in Section 5.3.3.3. The goal of this study was
to identify conditions that produced a stable nanoparticle suspension with particles in the size range
of 100-200 nm.
5.3.1.3.1 Effect of anti-solvent temperature
The effect of anti-solvent temperature was assessed in the presence of probe sonication
(Qsonica, Newtown, CT). Prior to each experiment, the anti-solvent was cooled to 6°C. The
sonication process generates significant thermal energy that heats the anti-solvent during the
crystallization. Without additional cooling, the temperature of the anti-solvent during sonication
for 10 min increases to about 55 °C (Exp. 1). In order to assess the effect of anti-solvent
temperature, a cooling water recirculating bath (Fisher Scientific, Asheville, NC) was used to
maintain the anti-solvent temperature at 12°C throughout the crystallization process (Exp. 2). The
temperature of the anti-solvent was monitored at defined intervals using thermocouples inserted
into the reaction vessel (Easy View 10, Extech Instruments, Nashua, NH). In both studies, 3 mL
of CPF solution (37.5 mg/mL) was introduced into 100 mL phosphate buffer pH 7 (Exp. 1 and
Exp. 2). The solvent:anti-solvent ratio was 0.03. Characterization of CPF nanoparticles was
assessed using the methods described in Section 5.3.3.
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5.3.1.3.2 Effect of mixing during crystallization
Mixing during crystallization is important to ensure homogenous particle formation. In
this study, mixing using the ultrasonic probe or a single blade paddle stirrer was compared. Mixing
of drug solution with an anti-solvent solution was achieved by means of a paddle stirrer (Caframo
stirrer type RZR 50, Wiarton, ON, Canda) (Exp. 3) and compared with probe sonication (Exp. 2).
In the case of stirrer, a single blade paddle with the dimension of 5.1 x 2.5 x 1.5 cm was used with
the stirring rate of 1000 rpm. Similar to the sonication approach, the stirring was initiated just
before the addition of the drug solution and was carried out for 10 min. The anti-solvent
temperature was maintained at 12°C and all other conditions were held constant.
5.3.1.3.3 Effect of the addition of excipient stabilizer to the anti-solvent solution
The effect of the addition of an excipient surfactant stabilizer was assessed by adding
0.01%w/v Tween™80 to the anti-solvent solution (Exp. 4). The crystallization conditions were as
described in Table 5.1 with probe sonication and the anti-solvent temperature of 12°C.
5.3.1.3.4 Effect of solvent:anti-solvent volume ratio
The effect of solvent:anti-solvent ratio was assessed by increasing the volume of the antisolvent. For this study, 3mL of solvent drug solution (37.5 mg/mL) was added to 250 mL of antisolvent containing 0.01%w/v Tween 80 (Exp. 5), to produce a ratio of 0.012 and was compared to
results obtained using a ratio of 0.03 (Exp. 4). The crystallization conditions were as described in
Table 5.1 with probe sonication and the anti-solvent temperature of 12°C.
5.3.1.3.5 Effect of anti-solvent composition
Changing the anti-solvent composition was investigated by adding 20%v/v isopropanol to
the phosphate buffer pH 7 anti-solvent. For these studies, as shown in Table 5.1, 3 mL of the CPF
solution (37 mg/mL) was introduced to 3 volumes of the phosphate buffer pH 7 – isopropanol
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(80:20 % v/v) anti-solvent mixture, 50, 100, and 250 mL (Exp. 6, 7 and 8), producing solvent –
anti-solvent ratios of 0.06, 0.03 and 0.012, respectively. Crystallization was performed using probe
sonication with an anti-solvent temperature and 12°C as shown in Table 5.1.
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Table 5.1. Experimental conditions for the particle size optimization of ciprofloxacin nanoparticles.
Exp.

Anti-solvent
temp.
(°C)
55

Stabilizer

1

Solvent /Antisolvent ratio
(mL)
3/100

Mixing tool

-

Probe sonicator

Phosphate buffer pH7

2

3/100

12

-

Probe sonicator

Phosphate buffer pH7

3

3/100

12

-

Paddle stirrer

Phosphate buffer pH7

4

3/100

12

Tween™ 80 (0.01%w/v)

Probe sonicator

Phosphate buffer pH7

5

3/250

12

Tween™ 80 (0.01%w/v)

Probe sonicator

Phosphate buffer pH7

6

3/100

12

Tween™ 80 (0.01%w/v)

Probe sonicator

7

3/250

12

Tween™ 80 (0.01%w/v)

Probe sonicator

8

3/50

12

Tween™ 80 (0.01%w/v)

Probe sonicator

Phosphate buffer pH7: isopropanol
(80:20%v/v)
Phosphate buffer pH7: isopropanol
(80:20%v/v)
Phosphate buffer pH7: isopropanol
(80:20%v/v)

In all experiments the drug concentration was 112.5 mg/ 3mL in 0.1N of HCl solution
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Anti-solvent

Preparation of ciprofloxacin nanocomposites using spray drying
To prepare a powder for nasal administration containing ciprofloxacin nanoparticles, the
Büchi Nano Spray Dryer B-90 (Büchi Laboratory Techniques, Flawil, Switzerland) was used to
incorporate the nanoparticles into a 5-10 µm–sized nanocomposite powders with water soluble
excipients. Studies were performed to develop a powder formulation suitable for nasal inhalation.
The formulation variables that were investigated included the % solids concentration of the spray
drying stock mixture, the drug:excipient ratios and the composition of excipients employed. The
goal of this optimization was to produce a nanocomposite dry powder formulation which is easily
dispersed and contains primary particles in the size range of 5 – 10 µm. The general procedure
included initially suspending known masses of the optimized CPF nanoparticles (Section 5.3.1.3.5,
Exp. 6) in water with the aid of stirring for 3 minutes using a magnetic stirrer. A solution containing
the study excipients was then prepared in a water – ethanol solution. The nanosuspension and
solution were then combined to produce a spray drying feed stock mixture in water and ethanol
(80:20 %v/v). The final total solid concentration in this mixture was varied in the range of 0.4 – 4
%w/v, depending upon the individual experiment (Table 5.2). The following water soluble
excipients were employed PVP K30, or mannitol, together with leucine as a dispersion enhancer
and Tween™80 as the surfactant as components of the nanocomposite powder. The formulations
tested are tabulated in Table 5.2 showing the spray drying stock mixture solids concentration and
the nominal % composition of drug and excipient in the final powder formulation. The spray drying
stock mixture was placed on a magnetic stirrer at 6 rpm (Corning®, Steuben County, NY) and the
mixture was spray dried while continuously stirring. The following spray drying process
conditions were used: drying airflow = 120 Lmin-1, liquid feed rate = 50%, spray nozzle diameter
(vibrating mesh) = 7µm, dryer length = 90 cm and inlet temperature = 80C. The outlet temperature
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was recorded as 45C. The spray dried powders were collected from the spray drier electrostatic
precipitator and placed in sealed capped vials and stored in a desiccator (approximately RH <10%)
at room temperature.
Drug yield (%) was calculated using gravimetric analysis using the following equation of
5.1.

% Yield =

𝑀𝑎𝑠𝑠 𝑜𝑓 𝑑𝑟𝑖𝑒𝑑 𝑐𝑖𝑝𝑟𝑜𝑓𝑙𝑜𝑥𝑎𝑐𝑖𝑛 𝑠𝑝𝑟𝑎𝑦 𝑑𝑟𝑖𝑒𝑑 𝑓𝑜𝑟𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑐𝑜𝑙𝑙𝑒𝑐𝑡𝑒𝑑
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑡𝑜𝑐𝑘 𝑚𝑖𝑥𝑡𝑢𝑟𝑒

×100

Equation 5.1

The drug content of the spray dried powder was assessed by dissolving approximately 1.5
mg of powder (mass corrected for moisture content) in 50 mL of phosphate buffer pH 3. HPLC
quantification was performed to determine the concentration of CPF in the solution and was used
to calculate the mass of CPF per mg of spray dried powder (Section 5.3.3.4). The geometric particle
size distribution of the spray dried powder was characterized using the HELOS/RODOS
(Sympatec, GmbH, Clausthal-Zellerfeld, Germany) using the method described in Section 5.3.3.5.

Table 5.2. Spray drying feed composition and drug:excipient ratios in powder formulations
Exp.

Solid Conc.
(%w/v)

Formulation composition (% w/w)
Drug

1SD
2SD
3SD
4SD
5SD
6SD
7SD

0.4
0.7
1.0
4.0
2.0
3.0
4.0

22
22
22
20
20
21
22

Leucine

Mannitol

22
22
22
20
20
21
22

54
54
54
58
-
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PVP K30
58
56
54

Tween™80
2
2
2
2
2
2
2

Characterization of ciprofloxacin nanoparticle suspensions and spray dried
formulations
5.3.3.1 Suspension nanoparticle sizing
The size distribution of the CPF suspensions following crystallization were assessed
directly (without dilution) using the Malvern Mastersizer 2000 with the size measurement range
of 0.02 µm to 2000 µm (Malvern Instruments, Ltd., Worcestershire, UK). The Hydro 2000G was
used as liquid dispersion unit allowing characterization of wet samples. The corresponding antisolvent was used as a dispersant for background measurements in each experiment. The suspension
was added dropwise to the sample cell until an obscuration of ∼10 – 30% was obtained. The
optimized particle size measurement conditions to ensure particle deagglomeration without
attrition employed sonication at 20% and a pump speed of 1000 rpm prior the measurement. Three
measurements were performed for each formulation. Volume frequency versus particle size
distribution plots, D10, 50 and 90 as well as Span were reported. Span is calculated as follow:

Span =
5.3.3.2

𝐷90−𝐷10

Equation 5.2

𝐷50

Suspension nanoparticle zeta potential measurement
The Nanosizer NanoS (Malvern Instruments, UK) was used to characterize the zeta

potential of the suspensions produced following crystallization. Suspensions were diluted to the
final concentration of 0.01 %w/v using deionized water. A disposable folded capillary cell was
used for the measurement.
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5.3.3.3 Differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) of
solid nanoparticles
Differential scanning calorimetry (DSC) thermograms were measured using a DSC Model
7 (Perkin-Elmer Inc., Waltham, MA) equipped with a data station Thermal Analysis Controller
7/DX and Pyris Software for Windows (version 3.81). Dry nitrogen gas was used as the purge gas
through the DSC cell at a flow rate of 20 mL/min. Approximately 2 mg of nanoparticle powder
samples were weighed into aluminum pans which were hermetically sealed. Each sample was
allowed to equilibrate for 1 min at 30°C and then heated at a rate of 10°C /min to 350°C. Figure
5.2 shows a representative temperature program. Thermogravimetric analysis (TGA) was
conducted using a Pyris 1 system (Perkin-Elmer Inc., Waltham, MA) to assess the residual
moisture content in the CPF nanoparticles and in the spray dried formulations. Weight loss from
2 mg samples (dried ciprofloxacin precipitates or spray dried formulations) during heating at a rate
of 10C /min from 30C to 350C under nitrogen purge 40 mL/min was recorded.

Figure 5.2. Temperature program used for DSC characterization of ciprofloxacin nanoparticles
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5.3.3.4 Drug content measurement using high-performance liquid chromatography
(HPLC) of spray dried nanocomposite formulations
Ciprofloxacin drug content was quantified using the USP 29 HPLC assay method for
ciprofloxacin. The mobile phase contained a mixture of 0.025 M phosphoric acid previously
adjusted with trimethylamine to pH 3.0 ± 0.1 and acetonitrile (87:13 %v/v). The HPLC method
employed a Waters 2690 separation module, a 2996 PDA detector using the wavelength of 274
nm and the column used was a Hypersil Gold (4.6-mmx 15-cm, 5 µm pore size) maintained at a
temperature of 27C  2. The flow rate was 1.8 mL/min. Standard solutions in the range of 0.026
– 10.400 µg/mL were prepared in phosphate buffer pH 3 and used to test the linearity of the HPLC
assay method (Table 5.3 and Figure 5.3). The precision of the method was assessed by calculation
of % relative standard deviation (RSD) of the ciprofloxacin peak area following 6 replicate
injections of 0.104 µg/mL ciprofloxacin standard solution. The same solution was used to assess
the accuracy using 6 replicate injections and calculation of the concentration of ciprofloxacin
relative to the nominal concentration. The limit of detection (LOD) and quantitation (LOQ) were
calculated based on the equations of 3.1 and 3.2. The method validation results are summarized in
Table 5.3. A representative HPLC chromatogram for 1.04 µg/mL ciprofloxacin standard solution
is presented in Figure 5.4.

Table 5.3. System suitability parameters for the ciprofloxacin HPLC method
System suitability parameter

Value

Linearity range tested

0.026 – 10.400 (µg/mL), (r2>0.9999)

Precision

0.9 %

Accuracy

99.7 %

LOD

0.02 (µg/mL)

LOQ

0.06 (µg/mL)
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5.E+06
4.E+06

Area

3.E+06

Y = 3.83 e5 X + 1.15 e2
R² = 0.99997

2.E+06
1.E+06
0.E+00
0

1

2

3

4

5

6

7

8

9

10
11
Untitled

Concentration (µg/mL)
SAMPLE
INF O R MAT IO N
Sample
Cipro base1.04ug/ml
Acquiredfor
By:ciprofloxacin
System in the range of 0.026 Figure
5.3.Name:
Plot of response
(area) versus concentration
Sample Type:
Standard
Sample Set Name: Cipro base std 9 23 16
2
10.400
(µg/mL) measured
at 274 nm. The R fitted
by linear least square
calculated as 0.99997.
Vial:
102
Acq. Method Set:
Ciprofloxacin
Injection #:
1
Injection Volume: 100.00 ul
Run Time:
5.0 Minutes
Date Acquired:
Date Processed:

Processing Method: Cipro
Channel Name:
2998 Ch1 274nm@1.2nm
Proc. Chnl. Descr.: 2998 Ch1 274nm@1.2nm

9/23/2016 11:27:05 AM EDT
5/2/2017 9:35:10 AM EDT

Auto-Scaled Chromatogram
Ciprofloxacin - 3.964

0.050

AU

0.040
0.030
0.020

λ=274 nm

0.010
0.000
0.00

0.50

1.00

Name

RT

1.50

2.00

2.50
Minutes

3.00

3.50

4.00

4.50

5.00

Peak Results
Area

Height Amount Units

Figure 5.4. HPLC
chromatogram
1.04 1.040
µg/mL
1 Ciprofloxacin
3.964 399551 of
52753
ug/mlciprofloxacin standard solution in phosphate
buffer pH 3
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5.3.3.5 Particle size analysis measurement using Sympatec HELOS/RODOS
The primary particle size of spray dried powder (ciprofloxacin nanocomposite
formulations and unprocessed ciprofloxacin powder) was characterized using the HELOS laser
diffraction technique (Sympatec GmbH, Clausthal-Zellerfeld, Germany) equipped with the
RODOS/ASPIRO/L dispersion system. A small amount of test powder (about 3 mg) was filled in
sample vials, sealed and placed in ASPIROS/L dosing device. A feed velocity of 60 mm/s and
pressure of between 2 - 4.5 bar was used to disperse the powder sample into the measuring zone.
The measurement was set to trigger when the optical concentration (Copt) exceeded 2.1%. The
laser beam with measuring zone of 0.1- 35 µm were selected for these powder samples.
Development and evaluation of a nasal aerosol delivery method
5.3.4.1 Aerodynamic particle size characterization and emitted dose optimization for the
nanocomposite formulation
The optimized spray dried nanocomposite powder was evaluated for their aerosolization
characteristics in a series of dry powder inhalers (DPIs). A Next Generation Impactor (NGI; MSP
Co., Shoreview, MN) was used to determine aerodynamic particle size characteristics of the CPF
spray dried nanocomposite formulation. For each of the experiments, the impactor collection
stages and pre-separator were coated with Molykore®316 silicone spray to minimize particle reentrainment. About 3 mg of the spray dried nanocomposite formulation was filled into HPMC
capsules (size 3). The dry powder inhalers evaluated were the Aerolizer® (Novartis AG),
Handihaler® (Boehringer Ingelheim) and a VCU DPI designed to operate at low flow rates. The
VCU DPI was previously described by Longest et al., 2015 and has a 2.3 mm flow orifice and a
3D rod array for powder dispersion in an orientation of 3 rods – 4 rods – 3 rods. The inhaler is
denoted as the VCU DPI 2.3 – 343 and is shown in Figure 5.5 [126]. The DPI incorporates a flow
control orifice, capsule chamber and flow passage containing the 3D rod array that for these studies
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are attached to a streamlined nasal cannula with a single nasal exit prong. The nasal prong angle
for the initial design of the device was 60º to the vertical plane of the nasal airway. Additional
studies were also performed using a device in which the nasal prong angle was 90º to the vertical
plane of the nasal airway. For the VCU DPI, the capsule was pierced twice using a 0.5 mm needle,
as shown by the aperture location in Figure 5.5. The location was optimized previously by Behara
et al [153]. For the other inhalers, the capsule was pierced using the in-built device mechanisms.
To perform the aerodynamic particle size analysis, the inhalers were actuated into the NGI
through a pre-separator. For the Aerolizer®, it was operated at 80 Lmin-1 for 3 sec (producing an
approximate pressure drop of 2 kPa, [154]). For the Handhaler®, it was operated at 45 Lmin-1 for
5.3 sec (producing a pressure drop of 4 kPa, [155]). For the VCU 2.3-343 DPI, an air flow rate
through the device of 15 Lmin- 1 for 10 sec was supplied to the device. In each case, the inhaler
was positioned such that the emitted aerosol was delivered to the NGI pre-separator. Following
aerosolization, the CPF mass remaining in the device (including the capsule), deposited on the preseparator, and on each of the impactor collection stages was collected by washing each item with
10 mL of phosphate buffer pH 3. Wash solutions were analyzed using a validated HPLC method
to quantify the concentration of ciprofloxacin and calculate the deposited drug mass (Section
5.3.3.4). The emitted dose exiting the DPI was determined by subtracting the amount of CPF
remaining in the DPI (including capsule) from the nominal loaded drug dose. The emitted dose
was expressed as a % of the nominal dose. The initial dose of the drug loaded in the DPI was
calculated from the weight of spray dried nanocomposite formulation (based on the dried mass
after correcting for TGA determined water content) and the measured % CPF content in the
nanocomposite formulation. The aerosol fine particle fraction (FPF<5μmED) and submicrometer
particle fraction (FPF<1μmED), defined as the fraction of the emitted CPF dose with aerodynamic
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diameters smaller than 5 μm and 1 μm, respectively. These were calculated using a linear
interpolation method using a plot of the cumulative % drug mass less than the stated size versus
aerodynamic diameter. Each measurement was repeated three times.

(a)

(b)

Figure 5.5. (a) Illustration of the VCU DPI 2.3 – 343 connected to a streamlined nasal cannula
and (b) the site capsule piercing with a 0.5 mm needle

Similarly, the mass median aerodynamic diameter (MMAD) was determined at the 50th
percentile on the cumulative % drug mass less than the stated size (probability scale) versus
logarithmic aerodynamic diameter plot.
Cut off diameter for stages at each flow rate were calculated from the following equation
based on USP (U.S. Pharmacopeial Convention, 2013):
𝑄𝑛 𝑥

𝐷50,𝑄 = 𝐷50,𝑄𝑛 ( )
𝑄

Equation 5.3
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Based on USP equation, 𝐷50,𝑄 is the cut-off diameter at the flow rate, Q that is employed. 𝐷50,𝑄𝑛
is the nominal value of cut-off diameter at a flow rate of 60Lmin-1and the value of the exponent x
is an emprical constant calculated for the archival NGI [156]. Table 5.4 shows the calculated cutoff diameters employed at the three study flow rates and we used to calculate the aerodynamic
particle size distribution of the aerosols.
Table 5.4. Calculated NGI cut-off diameters for flow rates of 80 Lmin-1, 45 Lmin-1, and 15
Lmin-1 and used for the Aerolizer®, Handihaler® and VCU 2.3-343 DPIs respectively
80 Lmin-1

45 Lmin-1

15 Lmin-1*

Pre-separator

11.4

13.85

Stage 1

6.9

9.41

14.1

Stage 2

3.84

5.18

8.61

Stage 3

2.44

3.26

5.39

Stage 4

1.45

1.90

3.30

Stage 5

0.81

1.09

2.08

Stage 6

0.46

0.65

1.36

Stage 7

0.28

0.41

0.98

*

Calibration performed without including pre-separator [156]

In order to improve the emitted dose from the VCU 2.3-343 DPI, a series of modifications
were investigated including, varying the needle size for capsule piercing, coating the DPI using a
polytetrafluoroethylene (PTFE) suspension spray (LU™708, Sprayon™ Products, Cleveland, OH)
[153] and removing the 3D-rod array from within the flow passage. For needle size, the larger
needles from the Handihaler® were employed to increase the capsule hole size. The piercing
orientation was kept constant as described above (Figure 5.5). In an attempt to reduce powder
adhesion to the DPI, the inner surfaces of the DPI were coated using a PTFE suspension spray.
The capsule chamber, flow passage and nasal cannula were coated. Following coating, compressed
air was blown through the device until the surface appeared dry and then left at room temperature
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for 30 min before use. The device was coated prior to each experiment to ensure reproducible
surface coverage with PTFE. Finally, the 3D-rod array was removed from the flow passage to
further reduce device retention (Figure 5.6). This device was originally developed by Dr. Longest’s
group for the dispersion of submicrometer powder aerosols with the 3D-rod array providing
additional deagglomeration of submicrometer particles following initial dispersion in the capsule
[126].
Emitted drug dose determination from the nasal prong of the VCU DPI 2.3 was performed
by placing the prong in the center of the USP DUSA (dosage unit sampling apparatus). There was
no seal between the DUSA and the nasal prong. The emitted aerosol was entrained in air flowing
at 20 Lmin-1 for 10 sec drawn through the sampling apparatus. The DUSA and filter were washed
with an appropriate volume of phosphate buffer pH 3 and the drug was quantified using the HPLC
method for ciprofloxacin (Section 5.3.3.4).

Figure 5.6. Illustration of the VCU DPI 2.3 connected to a streamlined nasal cannula. The 343
3D-rod array in the flow passage part is removed
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5.3.4.2 Particle size characterization of the nanocomposite formulation emitted from the
optimized VCU DPI 2.3 using the Malvern Spraytec®
The geometric particle size distribution (PSD) of ciprofloxacin nanocomposite aersols
exiting from the VCU DPI 2.3-343 and VCU DPI 2.3 were also determined using a laser diffraction
technique (Spraytec, Malvern Instruments Ltd, Worcestershire, UK). To assess the geometric
diameter in an open environment, the device was mounted on a holder such that the nasal cannula
prong was orientated perpendicular to the laser beam. A distance of 2.5 cm was maintained
between the prong and the laser sensing zone. A respiratory filter (PulmoGuard II, Quest
Diagnostics, Brockton, MA) was attached to a vacuum line operating at 30 Lmin-1 and placed
under the nasal prong (at the distance of 10 cm) to capture the emitted dose after passage through
the laser sensing zone. The loaded dose of ciprofloxacin nanocomposites was approximately 5 mg.
As described previously, aerosols were generated using a flow rate of 15 Lmin-1 for 15 secs through
the DPI. Particle size measurement begins when laser transmission is below 99%. Drug deposition
on the filter was quantified by washing with an appropriate volume of phosphate buffer pH 3.
HPLC analysis was performed to quantify the ciprofloxacin concentration and used to calculate
the emitted dose from the device (Section 5.3.3.4).
5.3.4.3 Characterization of the dissolution and diffusion properties of the ciprofloxacin
nanoparticles and nanocomposite formulations
A commercial Transwell® system was used to assess and compare the dissolution and
diffusion properties of the ciprofloxacin nanoparticles and nanocomposite powder formulations.
The Transwell® insert used was a polyester membrane (6.5 mm diameter and 0.4µm pore size;
Corning®, Steuben County, NY). For this study, known amounts of CPF, as unprocessed
ciprofloxacin (mean (SD) = 12.7 (0.5) µg), ciprofloxacin nanoparticles (mean (SD) = 14.0 (1.3)
µg) and optimized nanocomposite (spray dried formulation) (mean (SD) = 9.0 (4.0) µg) were
placed on the outer surface of the membrane (apical side, A-side) (Figure 5.7). 200 µL of phosphate
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buffer pH7 (US Pharmacopeia 29) was added to the receiver compartment (B-side) and 800 µL of
the same media was added to the 24 well plate (donor compartment), (Corning®, Steuben County,
NY) containing a magnetic stirring bar (0.02 inches x 0.3 inches). These volumes of media were
selected to have equal levels of buffer inside and outside of the Transwell® inserts to avoid any
hydrostatic pressure and liquid transfer between chambers. The transport of ciprofloxacin solution
through the Transwell® membrane was also assessed using a 0.625 µg/mL ciprofloxacin solution
in phosphate buffer pH 3. For this study, 250 µL of this solution was diluted using 10 mL
phosphate buffer pH 7 to have the final concentration of 15.6 µg/mL of ciprofloxacin. 800 µL of
this solution was added to the donor compartment to produce 12.5 µg of ciprofloxacin in donor
compartment. The rpm of the magnetic stir plate was set to 6 (Corning ®, Steuben County, NY).
An addition experiment was performed to investigate the transport of unprocessed ciprofloxacin
with the addition of 0.01% w/v Tween™ 80 in phosphate buffer pH7. The dissolution test was
started by placing the insert inside the well plates. Samples of 200 µL were taken at 5, 10, 20, 30,
45, 60, 90,120, 180, 240, 270 and 300 min from the B-side and replenished with fresh dissolution
media. After the final sample was taken, the membrane was washed with phosphate buffer pH 3
to analyze the amount of undissolved drug. Three replicates were performed for each experiment.
The amount of dissolved drug dissolved at each time point (V x Ct) was determined by
quantification of the drug concentration at each sample time point (Ct) using validated HPLC
method for ciprofloxacin (Section 5.3.3.4) in the known volume (V) of 200 µL. This amount was
added to the previous amounts dissolved (𝑄𝑡−1 ) to calculate cumulative amount of dissolved and
transported drug over the 5-hour experimental period (Equation 5.4). This amount (Qt) was divided
by initial drug mass to calculate the cumulative percentage of drug dissolved and transported.

𝑄𝑡 = 𝑄𝑡−1 + (V x Ct)

Equation 5.4
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Ciprofloxacin powder
formulation

Semi-permeable membrane

Transwell® insert
(6.5 mm and 0.4µm pore size)

Receptor compartment, B-side

Ciprofloxacin powder formulation
Stirrer

Donor compartment, A-side

Well plate

Figure 5.7. Schematic view of dissolution and transport setup for ciprofloxacin
nanoparticle and nanocomposite formulations using a Transwell® system

5.3.4.4 Evaluation of the regional nasal deposition of ciprofloxacin nanocomposite
formulations administered using the VCU DPI and a novel delivery method
In order to maximize nasal deposition of the CPF nanocomposite formulation, a novel
delivery method was employed. The technique was developed by Dr. Longest (VCU School of
Engineering) and optimized using computational fluid dynamic simulations. The method employs
bolus aerosol delivery (via a soft mist spray, nebulizer or dry powder) in a fixed volume of air (vol
= 0.1 - 1.25 L) at a low flow rate (1-15 Lmin-1). The aerosol is delivered via a streamlined cannula
with the nasal prong sealed in a single nostril of the nasal model. Using a low, but fixed volume
of air allows the aerosol to penetrate into the nasal cavity and down to the pharynx and trachea.
Simultaneously, the patient employs a rapid nasal exhalation that will facilitate the nasal deposition
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in the nasal cavity as the aerosol is redirected through the other side of the nasal cavity and exiting
via the open nostril.
The optimized ciprofloxacin nanocomposite formulation with a mean particle size of about
5 – 10 µm was evaluated for nasal drug delivery. The regional nasal drug deposition of formulation
delivered using the VCU DPI in combination with the novel delivery method was evaluated a
realistic airway geometry (VCU nasal model 1; Chapter 3). The experimental setup is shown in
Figure 5.8. To enable the required simulated patient nasal exhalation and fixed volume aerosol
delivery, a compressed air source was connected to a mass flow meter and a timer controlled threeway solenoid valve. The compressed air source was split to provide air to the VCU DPI and for
the simulated patient exhalation. Flow control valves were used to control the flow rates and
simultaneous delivery and exhalation were achieved by opening the timer controlled 3-way
solenoid valve for the required duration. Two low pressure-drop flow meters (Sensirion SFM3000,
Sensirion AG, Stafa, Switzerland) positioned before the DPI device and a respiratory filter was
used to monitor flow rates. A respiratory filter was placed in the trachea region to collect drug that
would have been delivered to the lungs. Finally, to collect the drug that was exhaled and not
deposited in the realistic airway geometry, a respiratory filter was placed adjacent to the open
nostril (right nostril) and was attached to a vacuum pump drawing air at the flow rate of 60 – 90
Lmin- 1.
The regional nasal drug deposition was evaluated using combinations of DPI actuation
flow rates of 15 and 10 Lmin- 1 provided to the VCU DPI with simulated patient exhalation flow
rates of 60 and 90 Lmin- 1. The DPI actuation flow and expiratory flow were administered
simultaneously for 15 sec. For some experiments, the nasal model was coated with Brij mixture in
ethanol and glycerol (1mL of Brij 35 dissolved in 10 mL ethanol and diluted with 50 g glycerol)
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to simulate nasal fluid lining and investigate potential powder bounce on the nasal model surface
[157]. For this purpose, the nasal model was filled with the Brij 35 ethanol – glycerol mixture,
then drained and left at room temperature to dry for 30 min.
In all experiments, approximately 5.0 mg of nanocomposite powder formulation was filled
in a size 3 HPMC capsule and manually pierced as described in section 5.3.4.1. The experimental
conditions for each study are summarized in Table 5.5. The nasal cannula prong was sealed in the
left nostril of VCU nasal model 1. Following aerosol delivery, the DPI, capsule, nasal model parts
and respiratory filters were washed using the appropriate volume of phosphate buffer pH 3 to
extract the drug which was then quantified using the HPLC method to determine the regional
distribution of the drug powder mass.
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Table 5.5. Experimental conditions used for optimization of regional drug deposition of the
ciprofloxacin nanocomposite powder formulation tested in VCU nasal model 1
Exp.

DPI
actuation
airflow
(Lmin-1)

Exhalation
airflow

Nasal
cannula

VCU DPI

(º)

Nasal
model
coated

(Lmin-1)

1NASAL

15

60

60

N

2.3-343

2NASAL

15

60

60

Y

2.3-343

3NASAL

15

90

60

Y

2.3-343

4NASAL

15

90

90

Y

2.3-343

5NASAL

10

90

90

Y

2.3-343

6NASAL

10

90

90

Y

2.3-coated

7NASAL

10

90

90

Y

2.3-FormLabs
clear resin-coated
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Figure 5.8. Experimental setup for nasal administration of ciprofloxacin nanocomposite
formulation using the VCU DPI in VCU nasal model 1
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Development of a realistic nasal airway model incorporating cell monolayers into the
airway passage walls to investigate transepithelial transport after realistic nasal
deposition
5.3.5.1 Modification of VCU nasal model 1 to incorporate cell monolayer Transwell® inserts
into the nasal airway passage walls
The physically realistic nasal model used in previous studies was modified to allow
assessment of post nasal deposition events (e.g. transepithelial transport) on cell monolayers
positioned in the nasal airway passage walls. The ability to deposit drug particles on cell
monolayers realistically following nasal inhalation would be desirable compared to current
approaches. The physically realistic VCU nasal model 1 was modified to accommodate two
Transwell® inserts (TW) in its middle (TW1 and TW2) meatus region) and one insert in the
superior (TW3) meatus region as shown in Figure 5.9. The TWs were inserted in sampling ports
such that the outer membrane surface was aligned with the nasal airway surface wall allowing for
realistic deposition of nasally administered drugs.

TW3
TW1

TW2

(a)

(b)

Figure 5.9. (a) VCU nasal model 1 modified to accommodate three Transwell® inserts in middle
passages. Two Transwell® inserts in its middle (TW1 and TW2) meatus and one insert in the
superior (TW3) meatus region (b). Transwell® insert membrane is polyester (PET) with
diameter of 6.5 mm and surface area of 0.33 cm2
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Initial studies were performed by placing the Transwell® inserts in the modified VCU nasal
model 1 in the absence of cells to determine the mass deposition following administration of the
ciprofloxacin nanocomposite formulation delivered using the VCU DPI. An additional
unprocessed ciprofloxacin powder was also aerosolized using the same method. The internal
surfaces of the realistic airway model (modified VCU nasal model 1) were pre-coated with Brij
35. Known masses (approximately 6 mg) of the ciprofloxacin nanocomposite spray dried
formulation (drug content = 20. 8%w/w) or ciprofloxacin un-processed powder (CPF) were filled
into size 3 HPMC capsules and placed in the VCU DPI 2.3. The DPI was coated with PTFE and
the nasal cannula prong angle was 90º. The nasal prong was sealed in the left nostril of VCU nasal
model 1 and aerosol was delivered using a flow of 10 Lmin-1 through the DPI with a simultaneous
nasal exhalation at 90 Lmin-1 for 5 sec. After nasal administration of the powders, the Transwell®
inserts were removed and the amount of drug deposited on each Transwell® inserts, together with
the remaining drug deposited on the DPI, on nasal model walls, and the lung and exhalation filters
were determined by collecting the drug from each deposition site using appropriate volumes of
phosphate buffer pH 3 wash solution. The concentration of drug in each solution was determined
using the previously described HPLC method (Section 5.3.3.4) and then used to determine the
regional mass distribution of the delivered dose (for comparison with previous studies). In
addition, replicate experiments were performed to investigate the reproducibility of drug
deposition on the three TW surfaces.
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5.3.5.2 Preparation of Calu-3 cell monolayers on apical surface of Transwell® inserts
Human bronchial epithelial cells, Calu-3 cell line, was received from ATCC® HTB-55 at
passage numbers between 18 and 25. The cells were thawed based on the manufacturer protocol.
Next, the cells were seeded at the density of 0.1x106 cells/cm2 in a 25 cm3 culture flask (Corning®
polystyrene, VWR, Radnor, PA), and grown using Eagle’s minimum essential medium (EMEM,
Lonza, Walkersville, MD) (pH = 7 - 7.4) which was supplemented with 10% fetal bovine serum
albumin (FBS; VWR, Radnor, PA) and 1% penicillin-streptomycin (PS; potassium penicillin
(10,000 U/mL) and streptomycin sulfate (10,000 µg/mL) in 0.85% saline, Lonza, Walkersville,
MD) in the incubator (Symphony 5.3 A, VWR, Radnor, PA) providing 5 % CO2, 95 % CO2 at
37°C. The culture media was changed every other day until the monolayer reached to 70 – 80 %
confluency at days 5 – 7. At this point, cells were sub-cultured to a 75 cm3 culture flask based on
ATCC protocol using EDTA-Trypsin (Trypsin 0.25% and EDTA 0.02%, Quality Biological, Inc.,
Gaithersburg, MD) or seeded on the inverted surface of the Transwell® insert membrane
(Polyester, 6.5 mm, 0.4µm) (Corning®, Steuben County, NY). Communication with the
Transwell® inserts manufacturer indicated that the surface characteristics of the inverted surface
(coating, pore size) should be identical to the conventional surface that is normally employed to
grow the cell monolayer.
For seeding the cells on the Transwell® insert membrane, inverted inserts were placed in a
150mm culture dish (Corning®, Steuben County NY) and appropriate volume of cell suspension
in the growth media, (EMEM, 10% FBS and 1% PS) was added to the outer surface of the inverted
Transwell® inserts to have a cell density of 0.1 X 106 cells/cm2. The lid was placed on the culture
dish containing the inverted transwell® inserts and they were kept in the incubator overnight.
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The next day, the Transwell® inserts were inserted into a 24-well plate and 600 µL and 100
µL of the growth media was introduced to the apical (A-side, cells are present) and basolateral (Bside) sides, respectively, to grow the cells under liquid-covered culture (LCC) conditions. The
media on both sides was replaced every day.
5.3.5.3 Calu-3 epithelial cell integrity
The integrity of Calu-3 cell monolayer was assessed visually on days 12- 16 using an
inverted microscope and by measuring the transepithelial electrical resistance (TEER) using an
epithelial voltammeter equipped with chopstick electrodes, EVOM2 (World Precision Instrument
(WPI), Sarasota, FL). Before the measurements, the cells were equilibrated with fresh culture
media in both A and B sides for 15 minutes in the incubator (5 % CO2, 95 % CO2 at 37°C). The
measured TEER was corrected first by measuring the TEER for a blank insert (no cells) and then
the surface area considered. The TEER was reported as Ω cm2. Cell monolayers with a TEER
value in the range of 750-900 Ω cm2 were considered confluent and suitable for use in the
transepithelial transport study. The TEER measurement was repeated 1hr at the end of transport
study and 12 hours later.
5.3.5.4 Transepithelial transport across the Calu-3 cell line after realistic nasal deposition
Prior to the deposition experiment, 300 µL fresh growth media (or HBSS; Hank’s Balanced
Salt Solution) was added to the B-side, then three Transwell® inserts with cell monolayers were
inserted in the three sampling ports in the modified VCU nasal model 1. In order to maintain the
integrity of the cell monolayer, nasal powder delivery was performed within 10 minutes using the
method described previously (Section 5.3.4.4). The inserts were immediately removed from
airway model and placed cell monolayer faced down in a 24-well plate. Fresh growth media or
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HBSS (40 µL) was placed in the 24-well plate covering the cell monolayer surface with a thin
layer of media to prevent cell shrinkage during the transport studies (Figure 5.10).
The transport studies carried out over 5 hours and the media on the B-side was removed
every hour and replenished with the fresh media. After 5 hours, the A-side was washed three times
with the 600 µL of fresh media, acidified with 200 µL of phosphoric acid (85%) (Fisher Chemicals,
Asheville, NC) and sonicated for 30 minutes. Collected samples were analyzed by the HPLC
method described in section 5.3.3.4 to determine the concentration of ciprofloxacin in each sample
and the mass of drug transported. The percent cumulative mass transported across the Calu-3 cell
monolayers was calculated based on the mass transported (measured concentration x B-side
volume) at each time point and expressed as a percentage of the initial deposited dose. The initial
deposited dose was estimated as the sum of the cumulative mass transported over the 5 hours plus
the mass recovered from the A-side after 5 hours.
The cumulative ciprofloxacin mass transport – time profile was determined for each
Transwell® insert and plotted to calculate the Flux value:

J=(

𝑑𝑀
𝑑𝑡

)⁄𝐴

Equation 5. 5

In which J is the flux (the cumulative mass flow rate through the unit area of the surface)
and dM/dt is the linear slope for steady-state transport of ciprofloxacin in the plot (calculated
between 1 to 5 hours) and A is the surface area of the Transwell® used (0.33 cm2).
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Figure 5.10. Schematic representation of the transepithelial transport study following realistic
deposition of the ciprofloxacin nasal powder formulation

5.4 Results and Discussion
Nanoparticle preparation
5.4.1.1 Particle size optimization of ciprofloxacin nanoparticles
The primary parameter used to evaluate the nanoparticles was geometric particle
distribution in the suspension mixture following crystallization. The particle size distribution
results for each of the process optimization studies are summarized in Table 5.6 and discussed
below. For each of the experiments, the time for visual appearance of the particulate precipitate
was also recorded and summarized in Table 5.6 as the induction time.
5.4.1.2 Effect of anti-solvent temperature
As demonstrated in Figure 5.11, using the 100mL precooled anti-solvent at 6°C in
combination with sonication at 100 % amplitude, the anti-solvent temperature was observed to rise
to 55°C during the process. To control the temperature during the crystallization process, a
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recirculating cooler system was employed to minimize the change in anti-solvent temperature.
Using the cooler system at a temperature of 6 °C during 10 min sonication at amplitude of 100%
produced an anti-solvent temperature of about 12°C. The particle size distribution of the
precipitates formed under these two anti-solvent temperature conditions are shown in Figure 5.12
and Table 5.6 (Exp. 1 and 2). As demonstrated, crystallization at a controlled temperature of 12
°C using the controlled temperature system produced particles with a small size with the mean
(SD) Dv50 of 0.28 (0.12) µm. Crystallization using the un-controlled system, in which the antisolvent temperature rose to 55°C, resulted in ciprofloxacin precipitates with a larger particle size,
the mean (SD) Dv50 was 2.19 (1.24) µm, although there was a narrow distribution around the
median diameter with a Span of 1.3.
The pH of the anti-solvent following the addition of 3 mL ciprofloxacin solution to the 100
mL anti-solvent phosphate buffer changed from pH 7 to 6.8. It is expected that at this pH,
ciprofloxacin as a zwitterion, will exhibit low solubility. It has been reported that the solubility of
ciprofloxacin in water can be increased from 67 µg/mL to 158 µg/mL by increasing the
temperature from 20°C to 50°C. Yu et. al [79] reported at pH 6.8 that increasing the temperature
from 6°C to 40 °C resulted in a CPF solubility increase from about 60 µg/mL to 240 µg/mL.
Therefore, the formation of larger precipitates under the higher temperature conditions can perhaps
be explained by increased solubility of ciprofloxacin in the solvent-anti-solvent mixture at that
temperature. Controlling the anti-solvent temperature at 12°C reduces the solubility of
ciprofloxacin at pH 6.8, producing higher supersaturation leading to an increased nucleation rate.
In this case, more nuclei will form and the particle size of the crystallized particles will be smaller.
It was also observed that under these conditions, there was a relatively large polydispersity of the
nanoparticles, with a Span of 13.9. As demonstrated in Table 5.6 the appearance of the precipitates
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is faster when the smaller particles are formed using the controlled lower temperature conditions
with the higher nucleation rate (Exp.2).
In addition, increasing the temperature of the anti-solvent can change the interfacial tension
and perhaps reduce the viscosity of anti-solvent. This can alter the mixing in the reaction mixture
producing an increased molecular transport rate from the solution to the crystal surface by
diffusion, convention or a combination of the two processes and increased particle collision
frequency. Also, the increased temperature of the anti-solvent can enhance the reaction rate for the
incorporation of additional crystals to particle surfaces and result in more particle growth [158,
159]. It has also been reported that Ostwald ripening is reduced at lower temperatures [106].
Ostwald ripening is one of the major mechanisms causing widening of particle size distribution of
drug nanoparticles suspensions. Lifshitz et al. [160] reported that smaller particles (with diameters
smaller than the critical diameter) dissolve due to their high surface energy and will be transported
onto the surface of the larger particles causing particle growth. The main factors which cause
growth of particles by Ostwald ripening are reported as the polydispersity of nanoparticles formed,
drug solubility in the solvent / anti-solvent systems, and the amount of organic solvent in final
suspension [161].
From this study, it was concluded that for future studies using probe sonication the
temperature of the anti-solvent should be controlled using recirculating cooler.
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Figure 5.11. Anti-solvent temperature monitored during sonocrystallization of ciprofloxacin.
The volume of anti-solvent (phosphate buffer pH=7) was 100 mL. The probe sonication was
100% amplitude for 10 min. Results are presented as mean (error bars are SD), n = 3
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Figure 5.12. Representative volume frequency distribution of ciprofloxacin particles
precipitated in phosphate buffer pH 7 under continuous sonication. 3 mL of ciprofloxacin
(37.5 mg/mL) solution was added to 100 mL anti-solvent
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Table 5.6. Effect of formulation and process variables on the particle size distribution of ciprofloxacin precipitates measured by
Malvern Mastersizer. Results are presented as mean (SD) (n =3).
Exp.
Dv10

Size distribution (µm)
Dv50

Span

Zeta
potential
(mv)

Induction time
(sec)

Dv90

1

1.41 (0.35)

2.19 (1.24)

4.17 (0.68)

1.3

-7.4 (0.3)

180

2

0.08 (0.01)

0.28 (0.12)

3.96 (0.57)

13.9

-9.2 (2.1)

100

3

2.46 (0.44)

7.84 (2.45)

43.34 (4.35)

5.2

0.1 (0.1)

420

4

0.09 (0.01)

0.19 (0.9)

1.1 (0.24)

5.3

-11.8 (1.1)

100

5

0.09 (0.01)

0.64 (0.21)

1.1 (0.92)

1.6

- 9.3 (0.7)

140

6

0.07 (0.01)

0.12 (0.01)

0.24 (0.01)

1.4

- 12.8 (0.3)

20

7

0.06 (0.01)

0.13 (0.01)

0.95 (0.03)

6.8

-10.6 (1.0)

100

8

0.08 (0.01)

0.23 (0.01)

4.74 (0.85)

20.3

- 8.2 (1.0)

100

Exp. 1 and 2 compares the effect of antisolvent temperature (55°C and 12°C, respectively) at solvent:anti-solvent ratio of 0.03.
Exp. 2 and 3 compares the effect of mixing type (paddle mixing and probe sonication, respectively) at solvent:anti-solvent ratio of 0.03 at 12°C.
Exp. 3 and 4 compares the effect of addition of surfactant stabilizer (Tween™ 80 (0.01%w/v)) at solvent:anti-solvent ratio of 0.03 at 12°C.
Exp. 4 and 5 compares the effect of solvent:anti-solvent ratio in the presence of Tween™ 80 (0.01%w/v) at 12°C.
Exp. 6, 7 and 8 compares the effect of anti-solvent composition and solvent:anti-solvent ratio in the presence of Tween™ 80 (0.01%w/v) at
12°C.
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5.4.1.3 Effect of mixing during crystallization
The results presented in Table 5.6 (Exp. 2 and 3) reveal that the use of ultrasonic mixing
compared to paddle mixing significantly reduced the particle size distribution of the CPF
nanoparticles. There was a lower induction time (appearance of CPF precipitates in anti-solvent
vessel) of 100 sec with probe sonication assisted precipitation compared to 420 sec for the paddle
mixing conditions. Micrometer-sized CPF precipitates with a mean (SD) median volume diameter
of 7.84 (2.45) µm (Dv50 measured by Malvern Mastersizer) were produced by paddle mixing,
compared to nanoparticles with a mean (SD) median volume diameter of 280 (120) nm during
ultrasonic mixing. However, as shown in Figure 5.13, both mixing conditions produced bimodal
particle size distributions using the test experimental conditions. Similar results were reported with
respect to the use of ultrasound and paddle mixing for the preparation of griseofulvin particles
[106, 162].
It has been reported that the use of ultrasound results in more rapid and uniform mixing of
the two liquid streams (reflected in the shorter induction time) which results in the production of
cavitation energy together with the generation of supersaturation. This produces a rapid nucleation
rate and the precipitation of smaller particles. In addition, ultrasound energy can breakdown the
larger particles and agglomerates to a smaller particle size [163, 164]. In case of ciprofloxacin, the
use of ultrasound showed the positive effects on the particle size distribution.
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Figure 5.13. Representative volume frequency distribution of ciprofloxacin particles
precipitated in phosphate buffer pH 7 under continuous probe sonication using an anti-solvent
temperature of 12˚C. 3 mL of ciprofloxacin (37.5 mg/mL) solution was added to 100 mL antisolvent with or without Tween™ 80 (0.01%w/v)
12
Without Twewn 80 (0.01 %w/w)
With Tween 80 (0.01% w/w)

10

Volume (%)

8
6
4

2
0
0.01

0.1

1
10
100
Particle size (µm)
Figure 5.14. Representative volume frequency distribution of ciprofloxacin particles precipitated in
phosphate buffer pH 7 under continuous probe sonication using an anti-solvent temperature of 12˚C.
3 ml of ciprofloxacin (37.5 mg/ml) solution was added to 100 ml anti-solvent with or without
Tween™ 80 (0.01%w/v)
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5.4.1.4 Effect of the addition of excipient stabilizer to the anti-solvent solution
A decrease in particle size to nano-scale is accompanied by an increased surface area to
volume ratio. This large increase in surface area potentially creates excessive surface energy,
which may be thermodynamically unfavorable and produces un-stable formulations and particle
growth [164, 165]. Since crystal growth is a surface phenomenon, impurities (or stabilizers) that
adsorb at the crystal surface can potentially affect the crystal growth rate and alter the crystal shape
[166]. It is known that the adsorption of ionic and non-ionic surfactants and polymers onto the
surface of crystals at the solid – liquid interface is accompanied by a reduction in interfacial
tension, blocking the surface from further particle adsorption and an increase in the nucleation rate
[106, 164, 166-168]. Examples of surfactants include cetyltrimethylammonium bromide (CTAB)
Tween™ 80, Pluronic®127, sodium dodecyl sulfate (SDS). Examples of polymers include HPMC
and PVP.
Therefore, to produce a stabilized ciprofloxacin nanoparticle suspension, the effects of the
addition of a stabilizer to the anti-solvent was investigated. For this purpose, a nonionic surfactant,
Tween™ 80 (Polysorbate 80) at a concentration of 0.01% w/v was added to the 100 mL phosphate
buffer pH 7. (Tables 5.1 and 5.6, Exp. 4 and 2). It is hypothesized that Tween™ 80 will compete
with ciprofloxacin particles to adsorb to the formed surface and inhibits surface growth. The
combined effect of ultrasound and 0.01% w/v Tween™ 80 produced a larger fraction of
submicrometer CPF precipitates and reduced the micron sized portion of the distribution, the mean
(SD) Dv50 was reported as 0.19 (0.9) µm and the Dv90 was 1.1 (0.24) µm (Table 5.6 and Figure
5.14). It is believed that the amount of surfactant or polymer added to the system should enable
complete coverage of the large surface area of the nuclei.
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5.4.1.5 Effect of solvent:anti-solvent volume ratio
The solvent:anti-solvent ratio was varied by increasing the anti-solvent volume, from 100
mL to 250 mL in the presence of 0.01%w/v Tween™ 80 (Tables 5.1 and 5.6, Exp. 4 and 5). By
increasing the anti-solvent ratio volume and reducing the solvent:anti-solvent ratio, the solvent
content in the mixture of solvent – antisolvent reduces, therefore it is expected to reduce the degree
of particle growth due to Ostwald ripening and observe smaller and narrower particle size
distribution. As the results show in Table 5.6 and Figure 5.15 (Exp. 4 and 5), increasing the antisolvent volume, and decreasing the solvent:anti-solvent ratio did not result in smaller particle size
distribution. This might be due to reducing the effectiveness of the ultrasonic mixing for the larger
volume of the antisolvent used. It is hypothesized that mixing was not as effective and slower in
the larger volume compared to a smaller volume and there was potentially slower generation of
supersaturation, followed by a slower nucleation rate. Dalvi et al., [106] observed a similar effect
on the particle size of griseofulvin precipitates when increasing the anti-solvent volume under
sonication due lower quality of mixing.
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Figure 5.15. Representative volume frequency distribution of ciprofloxacin particles
precipitated in phosphate buffer pH 7 under continuous probe sonication using an anti-solvent
temperature of 12˚C. 3 mL of ciprofloxacin (37.5 mg/mL solution) was added to 100 or 250
mL anti-solvent in the presence of Tween™ 80
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5.4.1.6 Effect of anti-solvent composition
Isopropanol as an organic non-solvent for ciprofloxacin was selected to be added to the
anti-solvent phosphate buffer pH 7. The solubility of ciprofloxacin in isopropanol at 20°C is
reported as 55 µg/mL compared to its solubility of 67 µg/mL in water [169]. Also, mixing of
isopropanol with phosphate buffer pH 7 increased the pH to 7.2. Therefore, considering the
reduced solubility of ciprofloxacin in phosphate buffer pH7 – isopropanol (80:20 %v/v), it is
expected to increase the supersaturation ratio, nucleation rate and produce a smaller particle size
distribution. Based on the results in Table 5.6 comparing Exp. 4 and 6, the addition of isopropanol
as expected reduced the particle size with the mean (SD) Dv50 of 0.12 (0.01) µm and a narrower
distribution compared to 0.19 (0.9) µm in the absence of isopropanol (Figure 5.16). The induction
time or the time between generation of supersaturation and appearance of detectable precipitates
is also much lower with isopropanol in the anti-solvent compared to the other studies.
Given that the conditions described above appeared to produce CPF nanoparticles in the
target range (100-200 nm), the final optimization step re-assessed the effects of solvent:antisolvent ratio for the buffer / isopropanol anti-solvent. In this case, ratios of 0.06 (3 m:50 mL; Exp.
8), 0.03 (3mL:100 mL; Exp. 6) and 0.012 (3mL:250 mL; Exp. 7) were compared. Similar to the
previous results increasing the anti-solvent volume resulted in a larger and more polydisperse
particle size distribution due to inefficient mixing of the two streams of solvent and anti-solvent in
the large vessel. However, comparing the Exp. 7 and 5, in which the solvent:anti-solvent is
constant (0.012), results indicate the effect of the addition of isopropanol to the anti-solvent. The
CPF precipitates in the isopropanol containing anti-solvent had a smaller size distribution with a
mean (SD) volume median diameter of 0.13 (0.01) µm compared to 0.64 (0.21) µm without
isopropanol. Both methods produced a bimodal distribution at this solvent:anti-solvent ratio as
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shown in Figure 5.17 probably due to reduced mixing efficiency of the ultrasound in larger volume.
Reducing the anti-solvent volume from 100 to 50 mL (Exp. 6 and 8) resulted in an increased
median diameter together with an increased polydispersity. This might be explained by increasing
the solubility of ciprofloxacin due to the larger solvent content in smaller volume of anti-solvent,
reducing the supersaturation ratio and increasing the possibility of the Ostwald ripening.
Based on the particle size distribution data ciprofloxacin nanoparticles with median volume
diameter of 120 nm and narrow distribution can be prepared with the liquid anti-solvent
precipitation technique under sonication. Particle size distribution optimization using
sonocrystallization technique was performed with the aid of Tween™ 80 as a stabilizer in the antisolvent mixture of phosphate buffer pH7:isopropanol (80:20 %v/v) with the optimized volume of
100 mL. This condition was identified as the optimal condition (Exp. 6) for successful production
of a monodisperse and stable ciprofloxacin nanoparticle suspension.
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Figure 5.16. Representative volume frequency distribution of ciprofloxacin particles
precipitated in phosphate buffer pH 7 and isopropanol containing 0.01%w/v Tween™ 80 under
continuous probe sonication using an anti-solvent temperature of 12˚C. 3 mL of ciprofloxacin
(37.5 mg/mL solution) was added to 100 mL anti-solvent.

12

Phosphate buffer pH 7 : Isopropanol - 3/100 ml
Phosphate buffer pH 7 : Isopropanol - 3/250 ml
Phosphate buffer pH7 : Isopropanol 3/50 ml

10

Volume (%)

8
6
4
2
0
0.01

0.1

1
Particle size (µm)

10

Figure 5.17. Representative volume frequency distribution of ciprofloxacin particles
precipitated in phosphate buffer pH 7 and isopropanol containing 0.01%w/v Tween™ 80
under continuous probe sonication using an anti-solvent temperature of 12˚C. 3 mL of
ciprofloxacin (37.5 mg/mL solution) was added to 100 mL, 250 mL and 50 mL of antisolvent.
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5.4.1.7 Zeta potential measurement
The zeta potential is related to the surface charge and is an indicative of the stability of
suspension. The zeta potential exists as the potential difference between bulk of solution and the
outer layer of the electric double layer. Generally, a zeta potential higher than ±30 mV is a sign of
good stability of the suspension for long- term storage [164, 168]. The zeta potential values
measured for the ciprofloxacin nanosuspensions are summarized in Table 5.6. For all experiments
performed with probe sonication, the zeta potential had a negative value ranging from a mean (SD)
of -7.4 (0.3) to – 12.8 (0.3) mV. Figure 5.18 shows a representative zeta potential graph for Exp.
6. Mixing using the paddle stirrer resulted in an unstable suspension with a zeta potential of
approximately zero. This was visually observed at the end of mixing where all ciprofloxacin
particles were settled to the bottom of the vessel. However, after sonocrystallization, the
suspensions were stable for at least 3 days stored at 4°C with no particle settling observed. The
stability of the nanosuspension is important during the filtration, drying and particle collections
process. Unstable suspensions may result in particle growth and Ostwald ripening is possible.
The zeta potential was also measure for ciprofloxacin nanoparticles following recovery as
a dried powder. The nanoparticles had a median volume diameter of 120 nm (Table 5.6, Exp. 6)
and were re-dispersed in water at a concentration of 0.1%w/v (similar to the concentration in the
solvent:anti-solvent mixtures). The mean (SD) zeta potential values for the nanoparticles in the
original solvent:anti-solvent mixture and after powder collection with re-dispersion in water were
-12.8 (0.3) mV and -11.8 (0.2) mV, respectively. Development of a stable powder which is capable
of being re-dispersed to the primary particles is important following removal of the phosphate
buffer and isopropanol vehicle. From the zeta potential measurement, it appears that the re-
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dispersed suspension in water retained its original characteristics and is suitable for use during the
spray drying process.

Figure 5.18. Representative zeta potential graph showing negative value of -12.5 mV for
ciprofloxacin nano-suspension made by sonocrystallization (Exp. 6)

Preparation of ciprofloxacin nanocomposites using spray drying
The spray drying technique used a water-soluble excipient matrix to prepare ciprofloxacin
nanocomposites in the particle size range of 5 -10 m suitable for targeted nasal delivery.
The spray drying feed stock mixture contained a combination of suspended CPF
nanoparticles with a median volume dimeter of 120 nm (Exp. 6) and a water-soluble bulking
excipient, a dispersibility enhancer and surfactant dissolved in a water:ethanol mixture. This
mixture was spray dried to produce nanocomposite powders using a Büchi Nano spray dryer. As
shown, in Table 5.7, a total of 7 spray dried powder formulations were investigated. The geometric
diameter of the spray dried powder depends upon the formulation composition and the spray
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drying conditions such as inlet temperature, feed rate and spray airflow. The geometric diameter
for dry powders can be estimated based on the following equation:

𝑑𝑔 =

3

𝐶

𝐹
√ 𝜌 𝑑𝐷

Equation 5.6

𝑝

Where 𝑑𝑔 is the geometric diameter for a particle with the density of the 𝜌𝑝 . From above equation,
it can be inferred that the geometric diameter depends on feed stock solution solids concentration
(𝐶𝐹 ) for the spray drying and primary droplet size after atomization in spray drying system (𝑑𝐷 ).
The mass median aerodynamic diameter (MMAD or da) is defined as:

𝜌𝑝

𝑑𝑎 = √ ∗ 𝑑𝐷
𝜌

Equation 5.7

Combining equations 5.6 and 5.7, the aerodynamic particle size of a spray dried powder can be
estimated by knowing the values of particle density and the solids concentration of feed stock
solution as below:

𝑑𝑎 =

6

𝜌𝑝

3

𝐶

𝐹
√ 𝜌 ∗ √ 𝜌 ∗ 𝑑𝐷

Equation 5.8

Previously, extensive investigations performed in our labs have produced spray dried
monodisperse particles with an MMAD of 1.0 - 1.4 m using a stock solution with a solids
concentration of 0.5% w/v and vibrating mesh spray nozzles with diameter of 4 m [154]. This
nozzle size is reported (Büchi Laboratory-Techniques, Flawil, Switzerland) to generate water
droplets with the size of 8 m. A larger vibrating mesh spray nozzle option of 7m is also available
and is reported to generate a mean water droplet size of 21m.
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To achieve particles in the size range of 5 -10 m, the total solid concentration in feed
stock mixture for spray drying and selection of water soluble bulking excipient (mannitol and PVP
K30) were varied. All studies were performed with the nozzle size of 7m. Drying of nanoparticles
can creates thermal stress on the particles causing particle aggregation which is undesirable. Sugars
such as mannitol have previously been used to protect nanosuspensions from aggregation during
spray drying and help re-dispersibility of the nanoparticles in an aqueous media [170].
Table 5.7 shows the measured mean (SD) drug content which ranged from 19.7 (0.5) % to
21.7 (0.4) % and was very close to the nominal values of 20-22 %w/w (Table 5.2). Two-way
ANOVA for the two variables of water soluble excipient type and % solids concentration was
performed to assess the effects on the particle size of the spray dried powder. There were
significant effects of both variables (excipient and % solids) on Dv50 (p-value<0.0001 and pvalue<0.0001). Within the mannitol group, it was observed that by changing the % solids
concentration of 0.4 to 1 % w/v, the mean (SD) median volume particle size measured by Sympatec
only increased from 2.7 (0.3) m to 3.1 (0.1) m. The changes in Dv10, 50 and 90 for the mannitol
formulations were statistically significant but perhaps the small magnitude of change in particle
size would not change nasal airway deposition. In addition, the mannitol formulations were below
our target size for the nasal drug delivery application. For the mannitol formulations, increasing
the % solids resulted in greater powder yield. Further increasing the % solids to 4.0 % for the
mannitol formulation significantly increased the particle size distribution with mean (SD) Dv10,
50 and 90 of 0.9 (0.1) m, 4.5 (0.2) m and 9.7 (0.2) m (Table 5.7 and Figure 5.19).
The effect on the spray dried powder particle size distribution of PVP K30 with % solids
of 2-4 % w/v was also assessed. It appears that particle sizes were larger when PVP K30 was used
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compared to mannitol (Figures 5.19 and 5.20). At the highest % solids concentration of 4.0%, the
mean (SD) Dv50 of the spray dried powder was 6.5 (0.2) m with mean (SD) Dv10 and Dv90 of
1.7 (0.0) m and 12.3 (0.1) m, respectively.
The stability of nanoparticles following spray drying and their ability to produce primary
nanoparticles following the dissolution of the excipient matrix was assessed using the powder
generated from Exp 6SD. The nanocomposite powder was added to water and the particle size of
suspended nanoparticles were characterized (Figure 5.21). The results indicate a similar size
distribution of the nanoparticles following spray drying (Exp 6SD) compared to the freshly
prepared nanosuspension (Exp. 6, Table 5.6). The mean (SD) Dv10 and 50 were 0.07 (0.01) m
and 0.14 (0.01) m for the spray dried nanoparticles and not significantly different from the
original values of 0.07 (0.01) m and 0.12 (0.01) m for freshly made ciprofloxacin
nanosuspension (Student t-test, p-value<0.05). Corresponding values for Dv90 were observed to
have a small but significant increase (p- value< 0.05; Student t-test, mean (SD) = 0.31 (0.02) m
and 0.24 (0.01) m), respectively).
The spray dried nanocomposite formulation generated using the conditions described in
Exp. 6SD produced a powder within the target size range. In addition, it appeared that it was
possible to successfully obtain primary nanoparticles following dissolution of the matrix
excipients. Therefore, future nasal aerosol development would use this spray drying protocol to
produce nanocomposite powders with a 3% solids concentration in the feed stock mixture. The
ratio of solids would be 21 %w/w CPF, 21 %w/w leucine, 56 % w/w PVP K30 and 2 %w/w
Tween™ 80.
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Table 5.7. Feed stock composition used for spray drying of ciprofloxacin nanocomposite formulations and their measured particle
size distributions. Formulations differ in % solids concentration and the type of water soluble excipient. Results are presented as mean
(SD) (n = 3).
Exp.

Solid Conc.
(%w/v)

Yield
(%w/w)

CPF content
(%w/w)
Dv101,2

Particle size distribution
(measured by Sympatec) (m)
Dv50 3,4

Dv905,6

1SD

0.4

45

21.7 (0.4)

0.7 (0.4)*

2.7 (0.3)+, ++

6.1(0.2)≠≠

2SD

0.7

53

21.6 (0.4)

0.7 (0.1)*#

2.4 (0.1)+, ++

5.6 (0.1)≠≠

3SD

1.0

69

21.0 (1.5)

0.8 (0.0)*

3.1(0.1)+

6.6 (0.1)≠≠

4SD

4.0

66

19.7 (0.5)

0.9 (0.1)

4.5 (0.2)≠

9.7 (0.2)≠≠

5SD

2.0

57

20.6 (0.2)

1.3 (0.1)

5.2 (0.1)≠

12.5 (0.3)"

6SD

3.0

60

20.8 (0.5)

1.8 (0.1)**

5.6 (0.1)≠

10.6 (0.1)

7SD

4.0

63

21.8 (0.7)

1.7 (0.0)**

6.5 (0.1)≠

12.3 (0.1)"

All formulations had similar concentrations of leucine and drug (20-22 %w/w) and 2 %w/w Tween™ 80.
Exp. 1 - 4SD contain mannitol (54-58 %w/w) and 5 - 7SD contain PVP K30(54-58 %w/w).
1.

Significant difference in Dv10 for mannitol containing formulation (Exp.1 - 4SD). * P<0.05, significant difference compared to Exp.4SD.#
P<0.05, significant difference compared to Exp.3SD.
2
Significant difference in Dv10 for PVPk30 containing formulation (Exp.5 - 7SD). ** P<0.05, significant difference compared to Exp.5SD.
3
Significant difference in Dv50 for mannitol containing formulation (Exp.1-4SD). + P<0.05, significant difference compared to Exp.4SD.++
P<0.05, significant difference compared to Exp.3SD.
4
Significant difference in Dv50 for PVPk30 containing formulation (Exp.5-7SD). ≠P<0.05, significant differences for values compared.
5
Significant difference in Dv90 for mannitol containing formulation (Exp.1-4SD). ≠≠P<0.05, significant differences for values compared.
6
Significant difference in Dv90 for PVPk30 containing formulation (Exp.5-7SD). " P<0.05, significant differences compared to Exp.6SD.
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Figure 5.19. Representative cumulative volume distribution plot for ciprofloxacin spray dried
nanocomposite formulations measured by Sympatec. For experiments 1 – 4 SD, the % solids
concentration of feed stock suspension varied from 0.4 to 4 %w/v (Table 5.7). These
formulations contained similar concentration of drug and leucine (20-22 % w/w) and 54-58%
mannitol and 2 % Tween™ 80. The legend also show the percentage particles in the size fraction
below 5µm.
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Figure 5.20. Representative cumulative volume distribution plot for ciprofloxacin spray
dried nanocomposite formulations measured by Sympatec. For experiments 5 – 7 SD, the %
solids concentration of feed stock suspension varied from 2 to 4 %w/v (Table 5.7). These
formulations contain similar concentration of drug and leucine (20-22 % w/w) and 54-58%
PVPK30 and 2 % Tween™ 80. The legend also show the percentage particles in the size
fraction below 5µm.
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Figure 5.21. Representative volume frequency distribution of ciprofloxacin nanocomposite
powder re-dispersed in water following spray drying (Exp. 6SD) and the corresponding freshly
made ciprofloxacin nanosuspension (Exp. 6)

Differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA)
characterization of CPF nanoparticles and nanocomposite formulations
Figure 5.22 shows the representative thermogram for ciprofloxacin (base, anhydrous) as
the source material used for sonocrystallization technique and production of CPF nanoparticles
(Section 5.3.1). Figure 5.22 also shows the thermogram for ciprofloxacin hydrochloride. Figure
5.22 demonstrates that the endothermic peaks for the melting of the ciprofloxacin base and
hydrochloride forms are at 273.2 °C and 334.4°C respectively. Similar values of 277°C and 326
°C were reported for the melting points of ciprofloxacin base and hydrochloride, respectively [171,
172] other endothermic peak observed at 155°C in the ciprofloxacin hydrochloride sample was
related to dehydration of ciprofloxacin hydrochloride and its associated monohydrate form. This
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loss of 1 water molecule is further confirmed by TGA thermogram [172]. As demonstrated by the
thermograms, DSC could distinguish between the two forms of ciprofloxacin. Figure 5.23 is a
representative thermogram for ciprofloxacin nanoparticles produced using the optimized process
described previously (Exp. 6). The thermogram reveals a sharp endothermic melting peak
corresponding to a mean (SD) temperature of 275 (1.4) °C. This supports the hypothesis that the
CPF nanoparticles remain as the base form following crystallization. The endothermic peak with
a mean (SD) temperature of 125 (1.1) °C in nanoparticle thermogram represents the loss of 3.5
molecules of water. This was confirmed by TGA analysis (performed using an identical heating
rate profile) where a weight loss corresponding to 16.2% was observed for the nanoparticle
formulation (Figure 5.24). This weight loss corresponds to 3.5 molecules of water. Weers et al
[173] also reported a 3.5 hydrate for ciprofloxacin base (ciprofloxacin betaine) formulated for
pulmonary delivery. For the spray dried formulations containing PVP K30, leucine and Tween 80
(Exp 6SD), two endothermic events with mean (SD) temperatures of 132 (1.3) °C and 255 (0.3)
°C were observed (Figure 5.23). For the spray dried formulations containing mannitol, leucine and
Tween™ 80 (Exp 4SD), two endothermic events of 146 (1.3) °C and 255 (0.3) °C were observed.
For both spray dried formulations the first endothermic peak is associated with a mean (SD) weight
loss of 9.3 (0.4) % and 12.5 (1.0) %, respectively, measured by TGA (Figure 5.24). It appears that
there is a higher content of water for mannitol containing nanocomposite formulation possibly due
to the more hygroscopic nature of mannitol.
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Figure 5.22. Representative DSC thermograms for ciprofloxacin base (top) and ciprofloxacin
hydrochloride (bottom) heated at 10°C /min
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Figure 5.23. Representative DSC thermograms for ciprofloxacin nanoparticles (Exp. 6) (top) and
the optimized spray dried nanocomposite formulation containing PVP K30 (Exp. 6SD) (bottom)
heated at 10°C /min
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Figure 5.24. Representative TGA thermogram for ciprofloxacin nanoparticles (Exp. 6) (top)
and the optimized spray dried formulation containing PVP K30 (Exp. 6SD) (bottom) heated at
10°C /min
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Characterization of the dissolution and diffusion properties of the ciprofloxacin
nanoparticles and nanocomposite formulations
The result for the dissolution of a series of ciprofloxacin samples in phosphate buffer pH 7
are presented in Figure 5.25. As demonstrated in the Figure, the dissolution method could
distinguish between different formulations of ciprofloxacin. For powders to be transported across
the semi-permeable membrane, the powder first needs to dissolve in the dissolution media and
then diffuse through the membrane. However, for the ciprofloxacin solution the only barrier is the
diffusion process across the membrane as the drug is already in solution. For all samples, a zeroorder appearance of drug into the receptor compartment was observed. For ciprofloxacin powder
(unprocessed raw material), the mean (SD) cumulative percent mass of drug transported into the
receptor compartment over the period of 5 hours was 20.1 (2.6) % of the nominal dose. For
ciprofloxacin solution, prepared in phosphate buffer pH 3, the mean (SD) cumulative percent mass
of drug transported into the receptor compartment was 33.2 (1.5) % and significantly higher than
was observed for the unprocessed powder (p-value = 0.0028, Student t-test). From the time profile,
it was observed the amount of drug transported was higher at each individual sampling time point
for the solution versus the unprocessed powder. However, it was observed that even for the
solution transport did not reach 100 % after 5 hours due to slow diffusion through the semipermeable membrane. The effects of producing nanoparticles and a nanocomposite formulation
on the dissolution and diffusion of CPF are also shown in Figure 5.25. The nanoparticle suspension
formulation (Exp. 6) and the spray dried nanocomposite powder CPF formulation (Exp. 6SD)
exhibited a similar transport rate. The mean (SD) cumulative % mass drug transport for
nanoparticle suspension and the spray dried nanocomposite CPF formulation were 31.7 (2.3) and
34.5 (2.4), respectively, and not significantly different from each other. However, they were
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significantly higher than the unprocessed ciprofloxacin powder (p-value = 0.0029 and 0.0004,
respectively, Tukey HSD). This indicated that the rate and extent of dissolution for the nanoparticle
formulations was significantly higher compared to the ciprofloxacin unprocessed powder with its
median volume diameter of 2 µm. In addition, the spray drying to produce nanocomposite
formulations did not appear to result in any changes to the dissolution of the primary nanoparticles.
Further studies were performed to investigate the apparent increased dissolution rate of the
nanoparticles compared to the unprocessed powder and to exclude the effects of surfactant
excipients (Tween™ 80) used in both the crystallization and spray drying process. Figure 5.25
also shows the dissolution rate of unprocessed ciprofloxacin powder in the presence of Tween™
80 at same molar concentration used in the ciprofloxacin crystallization process. The addition of
Tween™ 80 did not result in any increase in the dissolution rate of the unprocessed ciprofloxacin
powder. It was concluded that the increased dissolution rate for the CPF nanoparticle suspension
and the spray dried CPF nanocomposite formulation was due to reduced particle size of the CPF
nanoparticles resulting in an increased surface area of the drug according to the Noyes-Whitney
equation:
𝑑𝑄
𝑑𝑡

=

𝐷
ℎ

𝑆(𝐶𝑠 – 𝐶)

where the dissolution rate

Equation 5.9

𝑑𝑄
𝑑𝑡

is directly proportional to the diffusion coefficient of the drug (𝐷 ),

the available surface area (𝑆), and the difference between saturation solubility of the drug in the
boundary layer (𝐶𝑠 ) and concentration of drug in the bulk fluid (𝐶 ). Therefore, as particle size
decreases, surface area increases which leads to an increased dissolution rate. Any change in the
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nanoparticle size following spray drying as nanocomposite would also be reflected by changes in
the dissolution rate. If the nanoparticles form fused aggregates, then the overall surface area would
decrease and the dissolution rate would be negatively impacted. Such phenomena were not
observed for the nanocomposites obtained in this study, indicating that the nanoparticles retained
their improved dissolution characteristics after spray drying as nanocomposites and that the
dissolution and transport process was not rate limited by the dissolution of other excipients
contained in the spray dried nanocomposite formulation or its 5 m particle size prior to dissolution
and release of the CPF nanoparticles.
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Figure 5.25. Cumulative percent mass of ciprofloxacin transported into the receptor
compartment as a function of time in phosphate buffer pH 7. The following mean (SD) masses
of CPF were used: solution = 12.5 µg, nanocomposite formulation 9.0 (4.0) µg, nanoparticle
suspension = 14.0 (1.3) µg, unprocessed ciprofloxacin base powder =12.7 (0.5) µg. Results are
presented as mean (error bars are SD) (n=4)
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The dissolution and transport rate of the spray dried formulation and unprocessed powder
was also assessed in water (pH = 5). As the results in Figure 5.26 show the mean (SD) cumulative
percent mass of drug transported for unprocessed ciprofloxacin powder was slightly increased in
water at pH 5 (26.9 (4.1) %), compared to phosphate buffer at pH7 (p-value= 0.0291) (Figure
5.25). It is expected that the zwitterion CPF will have increase ionization at the lower pH resulting
in increased solubility. However, for the spray dried nanocomposite formulation, in water at pH 5,
the mean (SD) cumulative percent mass of drug transported after 5 hours remained same as 34.5
(2.4) %. It appears that phosphate buffer at pH 7 as the dissolution media is better able to
distinguish between different ciprofloxacin formulations. The primary purpose of these
experiments was to assess if there were any measurable difference in the dissolution rate of
ciprofloxacin nanoparticles due to their particle size and using this Transwell system it was
possible to detect chances in the dissolution rate comparing unprocessed CPF and nanoparticles.
Finally, these studies provide sham dissolution and transport studies for the transepithelial
transports studies of the nanocomposite formulation across the Calu-3 cell monolayer grown on
these Transwell membranes. Initial baseline values were obtained for dissolution and diffusion of
the nanocomposite CPF formulation through membranes in the absence of cells.
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Figure 5.26. Cumulative percent mass of ciprofloxacin transported into the receptor
compartment as a function of time in water (pH 5). The following mean (SD) masses of CPF
were used: nanocomposite formulation = 11.3 (6) µg, unprocessed ciprofloxacin base powder
= 22 (6) µg. Results are presented as mean (error bars are SD) (n=4)
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Development and evaluation of a nasal aerosol delivery method
5.4.5.1 Aerodynamic particle size characterization and emitted dose optimization for the
nanocomposite formulation
The previously described optimized spray dried ciprofloxacin nanocomposite powder with
a median volume diameter of about 6 µm (Exp. 6SD) was further characterized to evaluate its
aerosolization properties and suitability for nasal drug delivery. The mean (SD) drug content of
this powder was 20.8 (0.5) %w/w (Table 5.7). To investigate the powder aerosolization properties,
two commercial dry powder inhalers, the Aerolizer® and Handihaler®, and the VCU low volume
DPI were used and the results are shown in Table 5.8. Drug recovery from the impactor and inhaler
devices was acceptable in the range of 89.4 % to 100.4 %. Using the Aerolizer® and Handihaler®,
the CPF nanocomposite formulation had a good emitted dose of over 82 % (mean (SD) = 82.9
(3.7) % and 82.6 (4.5) %, respectively) of the nominal dose. A significant fraction of the emitted
dose was deposited in the pre-separator for both these devices. The mean (SD) dose deposited in
the impactor from the Aerolizer® and Handihaler® was 44.8 (6.0) % and 57.8 (6.0) % of the
nominal dose, respectively. The MMAD of the aerosol was calculated based on the impactor dose.
The calculated mean (SD) MMAD from Aerolizer® and Handihaler® was 8.9 (2.0) µm and 11.5
(3.4), respectively. These results suggest that the aerosolized nanocomposite formulation was not
fully dispersed by these commercial devices to the primary particles given that its initial size was
about 6 µm. For the VCU 2.3-343 DPI operated at a flow rate of 15 Lmin- 1, a mean (SD) dose of
50.7 (2.4) % was emitted from the device which was significantly lower than both the Aerolizer®
and Handihaler® (p-value <0.0001). Also, there was lower a mean (SD) FPF<5µmED of 18.2 (1.6)
% with the VCU DPI compared to 31.2 (6.3) % and 35.0 (5.0) % for the Aerolizer® and
Handihaler®, respectively (p-value = 0.112, p-value = 0.0349). For nasal drug delivery, it is
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important to minimize the fraction of the aerosol that is less than 5 µm to prevent potential
inhalation of the nasal powder. For the VCU DPI, the mean (SD) MMAD was 8.7 (1.4) µm which
was not significantly different from the other devices. Previous studies using submicrometer spray
dried formulations and the VCU DPI reported emitted doses of 66.5 to 71.3 % using a ciprofloxacin
EEG (excipient enhanced growth) formulation that had an MMAD of 1.4 – 2.7 µm [126]. Further
studies were designed to increase the emitted dose from the VCU DPI with the nanocomposite
powder formulations. This was investigated by changing parameters such as the needle size for
capsule piercing, coating the device using PTFE spray and removing the 343-rod array within the
flow passage.

Table 5.8. Mean (SD) aerosolization properties of the optimized ciprofloxacin nanocomposite
formulation measured using the Next Generation Impactor and delivered from three dry powder
inhalers (Aerolizer®, Handihaler® and VCU 2.3-343 DPI) (n=3)
Aerolizer®

Handihaler®

VCU 2.3-343

Emitted dose (% nominal) 1

82.9 (3.7) *

82.6 (4.5) *

50.7 (2.4)

FPF <5 µm (% ED) 2

31.2 (6.3) **

35.0 (5.0) **

18.2 (1.6)

MMAD (µm)

11.5 (3.4)

8.9 (2.0)

8.7 (1.4)

Mass in impactor (% ED)

44.8 (6.0)

57.8 (6.0)

69.0 (4.8)

Recovery (%)

89.4 (3.7)

90.7 (8.1)

100.4 (4.0)

Aerolizer® flow rate = 80 Lmin-1 for 3 sec, Handihaler® flow rate = 45 Lmin-1 for 5.3sec, VCU 2.3-343
flow rate = 15 Lmin-1for 10 sec. n=3.
1P<0.05, significant difference in emitted dose; *P<0.05, significant difference in emitted dose compared
to VCU 2.3-343.
2P<0.05, significant difference in FPF< 5 µm; **P<0.05, significant difference in FPF< 5 µm to VCU
2.3-343.
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Enhancement of the emitted dose from the VCU DPI device was investigated by changing
the needle size for capsule piercing using Handihaler® device needle, coating the device using a
commercial PTFE spray and removing the 343-rod array within the flow passage and the results
are summarized in Table 5.9. Using the Handihaler® needle to produce a hole size of 2mm diameter
did not significantly increase the nanocomposite power aerosol emitted dose compared to the
piercing with the 0.5 mm needle (Exp. 1VCU and 2 VCU). There did appear to be improved
emptying from the capsule with the larger holes, however this did not result in a significant change
in the emitted dose and the drug retention in the device remained unchanged (Student t-test).
Coating the device using PTFE spray significantly increased the emitted dose up to 63.5
(1.1) % compared to 50.7 (2.4) % in the absence of coating as PTFE coating. PTFE coating on the
device surface provides smoother surface and reduces the particle adhesion. Finally, removing the
343-3D rod array from the flow passage significantly reduced the device retention. The 3D rod
array was designed to increase deagglomeration of submicrometer spray dried particles. However,
for the current application using a 6 µm formulation the presence of the rods appeared to prevent
compete emptying of the device and the additional deaggregation may not be required for these
larger primary nanocomposite particles. We also tested the emitted dose from VCI-DPI 2.3 a
device prototyped in Dr. Golshahi’s lab in VCU School of Mechanical Engineering. This device
was made from a FormLabs clear resin and coated with PTFE. This device had a significantly
higher mean (SD) emitted dose of 85.0 (1.9) % compared to the Stratasys VeroWhitePlus resin
manufactured devices. This implies that the selection of the plastic resin used to manufacture the
3D printed DPI may play a significant role in determining the adhesion of these ciprofloxacin
nanocomposite formulations to the surface of the device either due to the device surface roughness
or electrostatic interactions. From these optimization studies a low flow VCU DPI design was
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identified that produced an acceptable emitted dose (85.0 %). Additional studies were then
required to measure the aerosol performance of the nanocomposite CPF formulation in this
modified inhaler.
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Table 5.9. Optimization of the mean (SD) device retention and emitted dose from the VCU
DPI powder inhaler operated at 15 Lmin-1 for 15 sec (n=3-4)
Exp.

Conditions

Capsule
(% nominal)

Device
(% nominal)

Emitted dose
(% nominal)

1VCU

VCU DPI 2.3-343
0.5mm capsule hole size
no coating

21.0 (3.2)

28.3 (2.4)

50.7 (2.4)

2VCU

VCU DPI 2.3-343
2mm capsule hole size
no coating

12.1 (5.4)

32.6 (3.9)

55.3 (3.6)

3VCU

VCU DPI 2.3-343
0.5mm capsule hole size
PTFE coated

10.8 (0.9)

25.7 (1.1)

63.5 (1.1) *

4VCU

VCU DPI 2.3
0.5mm capsule hole size
PTFE coated

9.6 (0.5)

18.3 (1.9) **

72.1 (1.9) ***

5VCU

VCU DPI 2.3 FormLabs clear
resin
0.5mm capsule hole size
PTFE coated

4.9 (2.3)

10.1 (1.9) #

85.0 (1.9) ##

Emitted dose was calculated by subtracting the measured ciprofloxacin mass retained in the capsule, DPI
and nasal cannula from the nominal dose, and expressed as a % of the nominal dose.
*P<0.05, significant difference in emitted dose, compared to Exp. 1VCU (Student t-test, p-value = 0.0076).
** P<0.05, significant difference in device deposition, compared to Exp. 3VCU (Student t-test, p-value =
0.0176).
*** P<0.05, significant difference in emitted dose, compared to Exp. 3VCU (Student t-test, p-value=
0.0188).
#
P<0.05, significant difference in device deposition, compared to Exp. 4VCU (Student t-test, p-value=
0.0102).
##
P<0.05, significant difference in emitted dose, compared to Exp. 4VCU (Student t-test, p-value=
0.0016).
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5.4.5.2 Particle size characterization of the nanocomposite formulation emitted from the
optimized VCU DPI using the Malvern Spraytec®
The geometric particle size distrbution for ciprofloxacin nanocomposite aerosols exiting
the VCU DPIs were evaluated using the Malvern Spraytec instrument (Malvern Instruments Ltd,
Worcestershire, UK). The aerosol spray emitted from the nasal prong was directed through the
laser beam to measure the laser diffraction. The device was mounted on a holder such that the
nasal cannula prong was facing prependicular to the laser beam and the emitted dose was collected
using a respiratory filter after passage through the laser. The results are presented in Table 5.10.
The device containing 343 3D rod array operating at the flow rate of 15 Lmin-1 resulted in an
aerosol with a mean (SD) median volume dimeter of 9.1 (0.3) µm (Exp. 6VCU). This measured
size was slightly larger than that observed for analysis of the bulk formulation sized using the
Sympatec HELOS/RODOS indicating that the VCU DPI did not fully disperse the powder to its
primary particles. Removing the rod array slightly increased the mean (SD) Dv50 to 10.1 (0.5) µm
(Exp. 7VCU). The % cumulative volume versus particle size graph for the VCU DPIs with and
without the 3D-rod array and their respective time history plot are presented in Figures 5.27 and
5.28. As the graphs demonstrate in the presence of the 3D-rod array produces an aerosol with a
bimodal distribution indicative of primary particles and particle aggregates in the emitted aerosol.
When the 3D-rod array was removed, they were less deaggregation to primary particles and a
monomodal distribution of aggregates was observed with a median diameter around 10 µm. Time
history plots are also presented in Figures 5.27 and 5.28 showing the variation in the Dv10 (green),
Dv50 (blue) and Dv90 (red) measured during the emission of the aerosol cloud from the DPI. The
transmission (black) relates to the concentration of particles in the measurement zone. The time
history plots indicate that for both devices, the particle size distribution of the emitted aerosol were
relatively constant throughout the spray duration. The spray duration for capsules loaded with
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about 5 mg of formulation was less than 1 sec indicating rapid emptying of powder formulation
from the DPI. Finally, the effects of lowering the aerosolization flow rate to 10 Lmin- 1 on the
aerosol particle size distribution was assessed (Exp. 8VCU). As the results in Table 5.10 show
reducing the flow rate from 15 to 10 Lmin- 1 did not result in significant changes in the emitted
dose from the device or the aerosol particle size distribution.

Table 5.10. Mean (SD) emitted dose and aerosol size distribution data for ciprofloxacin
nanocomposites measured by Malvern Spraytec (n=3)
Exp.

Conditions

Emitted
dose
(% nominal)
63.0 (2.4)

Dv10
(µm)

Dv50
(µm)

Dv90 (µm)

Span

2.3 (0.4)

9.1 (0.3)

26.1(3.2)

2.1 (0.0)

6VCU

VCU DPI 2.3-343
0.5mm capsule hole
size
PTFE coated
15 Lmin-1

7VCU

VCU DPI 2.3
0.5mm capsule hole
size
PTFE coated
15 Lmin-1

75.1 (1.0)

3.2 (0.1)

10.1 (0.5)

24.4 (1.3)

2.6 (0.5)

8VCU

VCU DPI 2.3
0.5mm capsule hole
size
PTFE coated
10 Lmin-1

73.3 (4.8)

3.1 (0.1)

11.6 (0.3)

25.3 (3.4)

2.8 (0.3)
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(a)

(b)

Figure 5.27. (a) Aerosol size distribution of ciprofloxacin nanocomposites aerosol exiting
from VCU DPI 2.3-343 device operated at flow rate of 15 Lmin-1 (b) Time course showing
Dv10 (green), Dv50 (blue) and Dv90 (red) measured during spray emission. The
transmission (black) relates to the concentration of particles in the measurement zone
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(a)

(b)
Figure 5.28. (a) Aerosol size distribution of ciprofloxacin nanocomposites aerosol exiting
from VCU DPI 2.3 device operated at flow rate of 15 Lmin-1 (b) Time course showing Dv10
(green), Dv50 (blue) and Dv90 (red) measured during spray emission. The transmission
(black) relates to the concentration of particles in the measurement zone
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Evaluation of the regional nasal deposition of ciprofloxacin nanocomposite
formulation administered using the VCU DPI and a novel delivery method
The effectiveness of the developed device-formulation-breathing maneuver combination
as a method to improve drug delivery to the nasal middle passages was tested using a realistic nasal
airway geometry. Specifically, the deposition of an aerosol generated from the VCU DPIs loaded
with the optimized spray dried ciprofloxacin nanocomposite powder formulation with a median
particle size of 5.6 µm (Exp. 6SD) was evaluated in combination with the nasal exhalation
breathing maneuver. Aerosol is delivered to one nostril with the DPI sealed in place. Deposition
is achieved by simultaneously exhaling and directing the aerosol away from the lungs and out of
the open nostril. Table 5.11 demonstrates experimental conditions and corresponding emitted dose
for VCU DPI device. Figures 5.29 and 5.30 show the regional nasal deposition of CPF when these
methods were evaluated using VCU nasal model 1. In preliminary studies to evaluate the novel
breathing maneuver, VCU DPI 2.3-343 was used in combination with an aerosolization flow rate
of 15 Lmin-1and nasal exhalation flow rate of 60 Lmin-1 (Exp. 1NASAL). In this study, emitted
dose was 52.2 % of the nominal dose and the mean (SD) total nasal drug deposition was 62.6 (3.8)
% of the emitted dose. Despite the low emitted dose, these initial studies with the VCU DPI 2.3343 device provided useful information to optimize the breathing maneuver and other delivery
parameters as described below. The mean (SD) exhaled dose was 37.4 (3.4) % of the emitted dose.
The regional nasal distribution indicated that the mean (SD) deposition in the anterior nose was
24.6 (3.5) % and 23.4 (6.1) % in combined middle passage and nasopharynx regions. There was
14.4 (4.9) % of the emitted dose recovered in throat and filter. In order to exclude the possibility
of drug bounce and re-entrainment, the nasal model surface was coated with a mucus mimic to
simulate the presence of a mucus blanket in the nose and its ability to trap inhaled particles. This
approach was resulted in a significant reduction in the mean (SD) % exhaled dose (21.2 (2.3) %,
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Exp. 2NASAL) compared to the dose exhaled without mucus coating (p-value = 0.0038). The
mean (SD) amount of drug deposited on the anterior nose was 31.0 (3.0) % and 27.0 (1.9) % of
the emitted dose was deposited in combined middle passage and nasopharynx regions. It appeared
that there was increased deposition in the throat and respiratory filter region (mean (SD) = 20.8
(1.1) %), however, this was not statistically different compared to the model without coating. To
reduce the throat and filter drug deposition, the higher exhalation flow rate was increased to 90
Lmin- 1 (Exp. 3NASAL). This resulted in a reduction in drug deposition in the mean (SD) throat
and filter deposition with only 2.4 (0.4) % of the emitted dose being recovered in that region which
was statistically significant compared to the 60 Lmin- 1 study (p-value=0.0004). Using a flow of
90 Lmin- 1 produced significant increases in the regional nasal drug deposition in the anterior nose,
combined middle passage and nasopharynx regions together with the exhaled dose with mean (SD)
values of 38.1 (1.4) %, 32.2 (2.6) % and 27.2 (2.2) %, respectively (p-values in comparison to 60
Lmin- 1 were 0.0372, 0.0266 and 0.0272, respectively).
In order to reduce anterior nose deposition and improve delivery to the middle passage
region, the design of the nasal cannula prong was altered. The streamlined nasal cannula prong
angle was changed from 60º to 90º to better align the exit part of the nasal cannula prong with the
entrance to the middle passages in VCU nasal model 1. This change in angle was also designed to
prevent particle impaction on the anterior nasal walls (Exp. 4NASAL). Changing the nasal cannula
prong angle resulted in a significant reduction in anterior nose deposition compared to the 60º
angle (p-value< 0.0001) and increased drug delivery to the middle passages (p-value= 0.0275).
However, the exhaled dose fraction was also increased. Future studies would all employ the 90º
angle in the DPI design as it provided the optimal regional drug distribution within the nasal model,
with low anterior nose deposition and enhanced delivery to the middle passages.
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The nasal drug delivery of ciprofloxacin nanocomposites from VCU DPI 2.3-343 was also
tested using an aerosolization flow rate of 10 Lmin-1 (Exp. 5NASAL). Deposition efficiency in the
nasal airway is the function of impaction parameters of aerodynamic particle size (𝑑𝑎2 ) and flow
rate (Q) [174]. However, this magnitude of the reduction in aerosolization flow rate for the
ciprofloxacin nanocomposite aerosols using the VCU DPI did not result in any significant changes
in regional nasal drug deposition or the amount of exhaled dose compared to aerosolization at 15
Lmin-1 (Exp. 4NASAL)
As described previously, the development of the VCU DPI produced a modified version
with the 3D-rod array removed and device was PTFE coated to improve the emitted dose. The
modified DPI employed a nasal cannula prong angle of 90º. Using the VCU DPI 2.3, the regional
nasal deposition was evaluated and was observed to produce similar deposition fractions in the
nasal model but less drug loss by exhalation compared to the DPI with the 3D-rod array. Most
significantly for the development of a viable DPI, the emitted dose was increased from 46.4 (3.7)
% with 3D-rod array (Exp. 5 NASAL) to 79.2 (2.7) % without the 3D-rod array (p-value = 0.0180).
It appeared that as the emitted dose increases the relative amount of drug that is lost by exhalation
decreases (Exp. 5NASAL, 6NASAL and 7NASAL). The VCU DPI 2.3 manufactured using the
FormLabs clear resin (Exp. 7NASAL) produced a mean (SD) emitted dose of 85.0 (1.6) % and
had the lowest exhalation drug losses compared to the (p-value = 0.0035 and p-value=0.0134,
respectively compared to 32.2% and 18.4%). Using this DPI, the middle passage drug delivery of
the ciprofloxacin nanocomposite formulation was increased to 65 % of the emitted dose which
was equivalent to approximately 650 µg of drug from a 5 mg powder formulation contains 20.8
w/w% of drug content with an 85.0 % emitted dose. Figure 5.30 shows that these modifications of
altering the exhalation flow rate, removal of the 3D-rod array and coating the device, altering the
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nasal cannula prong angle to 90º and use of the FormLabs clear resin improved the emitted dose
of the formulation from the device and resulting reducing deposition in the anterior nose, throat
and filter and increasing the deposition in the target middle passage region.
CFD simulations performed by Dr. Longest and his group using a similar approach in
which aerosol was delivered at 15 Lmin-1 to one nostril while simultaneously exhaling at 60 Lmin-1
through the other nostril. Using a similar sized aerosol (5 – 10 µm), the CFD predicted drug
deposition in combined middle passage and nasopharynx area was 77.5 % which was similar to
our experimentally determined value of 65 % (Exp. 7NASAL). The CFD predicted a slightly lower
anterior nose deposition of 5.1% and an exhaled dose of 4.2 %. The results shown in Figure 5.31,
it should be noted that the CFD conditions were not identical to those used for the experiments and
simulated delivery via a tubing interface for administration of the aerosol to the nasal cavity.

223

Table 5.11. Experimental conditions used for optimization of regional drug deposition of the
ciprofloxacin nanocomposite powder formulation tested in VCU nasal model 1. The emitted
dose is calculated based on (%) nominal dose
Exp.

DPI
actuation
airflow
(Lmin-1)

Exhalation
airflow
(Lmin-1)

Nasal
cannula
(º)

Nasal
model
coated

VCU DPI

Emitted
dose
(%nominal)

1NASAL

15

60

60

N

2.3-343

52.2 (3.8)

2NASAL

15

60

60

Y

2.3-343

55.3 (4.1)

3NASAL

15

90

60

Y

2.3-343

53.1 (2.8)

4NASAL

15

90

90

Y

2.3-343

60.1 (9.2)

5NASAL

10

90

90

Y

2.3-343

46.4 (3.7)

6NASAL

10

90

90

Y

2.3-coated

79.2 (2.7)

Y

2.3 FormLabs
clear resincoated

85.0 (1.6)

7NASAL

10

90

90
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Figure 5.29. Optimization of the regional drug deposition of ciprofloxacin using the
nanocomposite formulation delivered from the VCU DPI 2.3-343. Mean (error bars are SD)
deposition in the anterior nose (AD), combined middle passage and nasopharynx region (MP),
throat and filter T+F and the exhaled dose (Exh) are reported (n = 3). * P < 0.05

Figure 5.30. Optimization of the regional drug deposition of ciprofloxacin using the
nanocomposite formulation delivered from the VCU DPI 2.3-343. Mean (error bars are SD)
deposition in the anterior nose (AD), combined middle passage and nasopharynx region (MP),
throat and filter T+F and the exhaled dose (Exh) are reported (n = 3-6). * P < 0.05
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Figure 5.31. CFD simulation of regional nasal deposition of an aerosol delivered using a flow
rate of 15 Lmin-1 to one nostril while simultaneously exhaling at 60 Lmin-1 through the other
nostril.

In an effort to increase the drug load in the spray dried formulation, leucine was removed
from the spray drying feed stock mixture, the concentration of PVP K30 reduced to 34.8 % w/w
with the concentration of Tween 80™ remaining at 2.0 %w/w. This allowed the concentration of
ciprofloxacin to be increased to 65 %w/w. This modified feed stock mixture had a solids
concentration of 3.0 % w/v in water - ethanol 80:20 %v/v and was spray dried using the conditions
described previously (section 5.3.2). The primary particle size distribution of the modified
nanocomposite powder was measured using the Sympatec HELOS/RODOS (Section 5.3.3.5). For
comparison, the unprocessed ciprofloxacin powder (starting material) was also sized. As shown in
Table 5. 12 and Figure 5.32, the particle size distribution of the modified nanocomposite powder
formulation was bigger to the previously optimized nanocomposite formulation was a mean (SD)
Dv50 of 7.7 (0.1) µm compared to 5.6 (0.1) µm (p-value = 0.0080). The un-processed raw material
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CPF powder exhibited a broad particle size distribution as shown in Figure 5.32, with mean (SD)
Dv10, 50 and 90 values of 0.7 (0.01), 2.1 (0.1) and 21.2 (0.7).
In order to assess the effects of increasing the drug load in the CPF nanocomposite
formulation on nasal drug distribution, a study was performed to compare the modified and
previously optimized formulation, together with the unprocessed CPF powder. These three
formulations were administered to the nasal cavity of VCU nasal model 1 using the experiment
conditions that produced highest middle passage drug delivery and lowest exhaled dose as
described above (Exp. 7NASAL). The results presented in Table 5.13 show that the modified
nanocomposite formulation produced a similar mean (SD) emitted dose of 85 (4.4) % compared
to the previously optimized nanocomposite formulation. The regional nasal deposition profile
between the two formulations was also similar, with mean (SD) deposition in the anterior nose of
11.3 (3.8) %, combined middle passage and nasopharynx deposition of 72.2 (4.2) % and exhalation
losses of 17.9 (6.0) % for the modified nanocomposite formulation. It appeared that the small but
significant increase in particle size for the modified formulation did not significantly affect the
emitted dose or regional nasal drug delivery compared to the previously optimized nanocomposite
formulation. However, using the modified formulation the dose of CPF delivered to the middle
passages was tripled using the same capsule formulation loaded mass compared to the optimized
formulation due to the increased drug loading. In this study, a single capsule administration of the
modified ciprofloxacin nanocomposite formulation containing a mean (SD) loaded nanocomposite
formulation mass of 9.3 (0.4) mg produced a mean (SD) middle passage deposited dose of 3.7
(0.3) mg of CPF. This was significantly higher than the delivery achieved using either the
previously optimized nanocomposite formulation with the lower loaded mass of CPF or the
unprocessed ciprofloxacin powder (100% drug). For the unprocessed CPF powder with a mean
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(SD) loaded powder mass of 8.2 (0.3) mg, the mean (SD) middle passage deposition was 2.2 (0.5)
mg with a significantly fraction of the dose being deposited in the DPI and anterior nose indicating
poor aerosolization of the unformulated raw material powder.
Regional nasal drug deposition within the middle passages for ciprofloxacin
nanocomposite formulation was tested using the segmented VCU nasal model 1. The VCU nasal
model 1 was segmented into anterior nose, middle and superior meatuses, olfactory region,
maxillary sinuses and the base of middle passages (Figure 5.33). Ciprofloxacin modified
nanocomposite powder was administered to the segmented model based on Exp. 7NASAL (Table
5.11). Regional nasal drug deposition data is presented in Table 5.14 (based on the total drug
deposited in the combined middle passage and nasopharynx region). Based on the data shown in
Table 5.14, it can be seen ciprofloxacin from modified nanocomposite formulation was distributed
over all the different segments. Overall, drug deposition was higher in the left side compared to
the right side of the nasal cavity which was the side of drug administration (nasal cannula was
placed in the left nostril). Mean (SD) for drug deposition in the left meatus was 6.7 (3.6) % and
8.4 (3.9) % in the left olfactory segment. Similar values for the left sinus was 1.0 (0.7) % and 0.1
(0.7) % in the right sinus.
Drug delivery to the non-ventilated sinuses with narrow opening is known to be
challenging. Maxillary sinus drug delivery of nasal sprays is reported as non-significant, however,
7.1 ± 1.7 (% of nasal deposited dose) sinus drug delivery was reported in healthy volunteers after
pulsating aerosol application using a Vibrant nebulizer prototype with the use of pressure wave of
25 Hz (PARI Pharma GmbH, Germany)[137].
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The observed regional nasal deposition results for the nanocomposite formulation and
novel breathing maneuver are promising in the treatment of paranasal sinuses infection as targeted
drug delivery can be observed to the potentially infected regions of meatuses (where the openings
of paranasal sinuses are located).

Table 5.12. Mean (SD) particle size distribution properties measured by Sympatec for the
modified ciprofloxacin nanocomposite formulation and unprocessed CPF powder (n=3)
Formulation

Drug content
(%w/w)

Particle size distribution
(measured by Sympatec) (m)

Optimized
nanocomposite

20.8 (0.7)

Dv10
1.7 (0.0)#

Modified
nanocomposite

64.5 (0.6)

1.8 (0.1)#

7.7 (0.1)*,+

13.5 (0.1)**,++

100

0.7 (0.0)

2.1 (0.1)

21.2(0.7)

Unprocessed CPF
powder
#

Dv50
5.6 (0.1)*

Dv90
10.6 (0.1)**

P<0.05, significant difference in Dv10 (one-way ANOVA), P <0.001 for optimized and modified
nanocomposite formulations compared to unprocessed powder
* P<0.05, significant difference in Dv50 (one-way ANOVA), P <0.001 for optimized and modified
nanocomposite formulations compared to unprocessed powder
+
P<0.05, significant difference in Dv50 (one-way ANOVA), P <0.001 between the optimized and
modified nanocomposite formulations
** P<0.05, significant difference in Dv90 (one-way ANOVA), P <0.001 for optimized and modified
nanocomposite formulations compared to unprocessed powder
++
P<0.05, significant difference in Dv90 (one-way ANOVA), P <0.001 between the optimized and
modified nanocomposite formulations
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Modified nanocomposite
Unprocessed CPF powder

Optimized nanocomposite

Figure 5.32. Representative cumulative volume fraction particle size distributions for the
optimized and modified ciprofloxacin nanocomposite formulations (containing 20.8 (0.5) %
and 64.5 (0.6) % drug content, respectively) and the unprocessed ciprofloxacin powder
measured by Sympatec.
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Table 5.13. Mean (SD) regional nasal drug deposition of the optimized and modified
ciprofloxacin nanocomposite formulations and the unprocessed ciprofloxacin powder using
the optimized VCU DPI and delivery technique. Ciprofloxacin powders were delivered using
the VCU DPI 2.3 at a flow rate of 10 Lmin-1 with simultaneous nasal exhalation at flow rate
of 90 Lmin-1 for 15 sec (n=4-6)
Optimized
nanocomposite
formulation

Modified
nanocomposite
formulation

Unprocessed CPF
powder

Capsule loaded mass (mg)

5.9 (0.9)

9.3 (0.4)

8.2 (0.3)

Drug content (%w/w)

20.8 (0.7)

64.5 (0.6)

100

Emitted dose (% nominal)

85.0 (1.6)

85.0 (4.4)

52.3 (4.9)*

15.6 (1.1)

11.3 (3.8)

30.6 (15.1)**

65.8 (7.6)

72.7 (4.2)

47.2 (10.9)***

Exhaled (% ED)

18.6 (2.2)

16.0 (6.0)

22.2 (5.2)

Mass of CPF in middle
passages and nasopharynx
(mg)

0.7 (0.1)

3.7 (0.2)

2.2 (0.5)

Recovery (%)

88.3 (4.9)

91.8 (5.2)

88.9 (3.4)

Anterior nose deposition
(% ED)
Middle passage and
nasopharynx deposition
(% ED)

*P<0.05, significant difference in emitted dose compared to the modified nanocomposite formulation
(p-value = 0.0123) (one-way ANOVA)
**P<0.05, significant difference in anterior nose deposition compared to the modified nanocomposite
formulation (p-value = 0.0368) (one-way ANOVA)
***P<0.05, significant difference in middle passage drug deposition compared to the modified
nanocomposite formulation (p-value = 0.0123) (one-way ANOVA)
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(a)

(b)

SM

LMM

(c)

LMS

(d)

Figure 5.33. Images of segmented VCU nasal model 1 depicting (a) anterior nose, (b) base
of middle passages, (c) left middle meatus (LMM) and superior meatus (SM), (d) left
maxillary sinus and left – right olfactory regions attached to the base of middle passages
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Table 5.14. Mean (SD) regional nasal drug deposition of the modified ciprofloxacin
nanocomposite formulations using the optimized VCU DPI and delivery technique
presented based on total middle passage and nasopharynx drug deposition. Ciprofloxacin
modified nanocomposite powder was delivered using the VCU DPI 2.3 at a flow rate of
10 Lmin-1 with simultaneous nasal exhalation at flow rate of 90 Lmin-1for 15 sec (n=3)
Middle passage and nasopharynx deposition (% ED)

71.3 (3.6)

Inferior meatus

76.1 (8.7)

Right Meatus

1.5 (0.8)

Left Meatus

6.7 (3.6)

Superior meatus

2.7 (0.8)

Right olfactory

3.0 (1.4)

Left Olfactory

8.4 (3.9)

Right Sinus

0.1 (0.0)

Left Sinus

1.0 (0.7)

Inferior meatus

76.1 (8.7)

Right Meatus

1.5 (0.8)
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These studies have shown that the combined nasal drug delivery strategy using the VCU
DPI and nanocomposite formulation did produce efficient drug delivery to the posterior part of the
nasal cavity. Studies were performed using a capsule loaded formulation powder mass of
approximately 10 mg of spray dried nanocomposite formulation which was efficiently aerosolized
producing emitted drug doses of 80 – 85 % of the nominal CPF and good delivery to the target
region in the middle passage and minimal off-target deposition. In this study, it was possible to
achieve milligram levels of drug delivery to the nasal cavity (3.7 mg) that would make it feasible
to deliver medications such as antibiotics including ciprofloxacin that require relatively high local
doses for therapeutic effect. It is unclear as to the dose of ciprofloxacin required for efficacy within
the nose to treat local infection due to a lack of literature data. A dry powder inhalation formulation
of ciprofloxacin for treatment of infection in Non-CF bronchiectasis patients that are chronically
infected with P. aeruginosa is currently being developed by Aradigm Corporation for lung
delivery and has completed phase three clinical trial. For those studies, the administered dose of
formulation is 50 mg, which is stated to correspond to 32.5 mg ciprofloxacin and is administered
twice a day [175]. The estimated deposition of CPF in the trachea and bronchi was 22.3 % of the
administered dose. Drug delivered to alveolar space was 17.2 % of the administered dose and was
calculated to correspond to a delivered mass of 12.8 mg ciprofloxacin [176]. Assuming a similar
dose for treatment of P. aeruginosa infection in the nasal cavity, this could be achieved by
administration of three capsules of the modified nanocomposite formulation or by increasing the
formulation capsule load. Despite powder delivery being popular in pulmonary delivery but so far
rare in nasal administration. Powder formulations enhance drug stability and shelf life and its
clearance by mucociliary clearance (MMC) is slower [177]. 50 to 60 % of initial nasal spray
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formulations are typically removed by MCC to the nasopharynx in less than 20-30 minutes [16,
17, 140].
The dose of drug delivered by nasal sprays is limited by the ability to form a stable solution
or suspension formulation and is usually delivered in a relatively low metered volume in the range
of 25 – 200 µL [2]. Therefore, for high dose antibiotics, drug has to exhibit fairly good solubility
to be formulated as a nasal spray product. Secondly, drug formulation from nasal sprays usually
impacts closer to the site of release due to their large particle size of bigger than 40 µm which
results in high drug losses in the anterior non-ciliated part of the nasal cavity near the nasal valve
and base of the inferior turbinate [145] with little distribution in the middle passages and most of
the deposited dose is quickly eliminated via the digestive tract. For nasal sprays, the effectiveness
of the administered drug depends on mucociliary clearance of the deposited dose, which has been
shown to be crucial for drug distribution and subsequent elimination [2]. In vivo studies show
highly variable drug delivery to the middle passages for nasal sprays. However, it should be noted
that mucociliary clearance may be impaired in cystic fibrosis (CF) patients with sinusitis and CRS
patients who would be a potential target population for nasal antibiotic delivery. There are three
targets for aerosol drug to treat sinusitis: i) the middle meatus which is a major site of drainage of
maxillary and ethmoid, ii) superior and posterior regions of the nasal cavity and iii) maxillary and
ethmoid sinuses [7]. In contrast to nasal sprays, nasal nebulization improves the drug deposition
beyond the nasal valve and allows a larger dose to be delivered by continuous nebulization [178].
Nasal sonic jet nebulizers applying a frequency of 100 Hz have been developed to improve aerosol
deposition in the sinuses compared to regular nasal jet nebulizers. The 100 Hz sonic waves
generated by the sonic jet nebulizer creates a positive pressure between the ostium and the sinus
allowing gas exchange within the sinus similar to a Helmholtz resonator and may increase aerosol
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deposition into the sinuses by a factor two [179, 180]. Previous in vitro and in vivo experiments
have demonstrated the benefit of applying an ultrasonic frequency during nebulization to improve
sinus ventilation and aerosol deposition [39, 180]. Nasal sonic jet nebulizers are therefore
considered the current best option for targeting aerosols to the sinus infection site. However, a
disadvantage of using nasal jet nebulizers compared to nasal sprays for targeting the sinuses is that
they also deliver a relatively large dose of aerosol to the lungs (33% to 58% of the dose) [17]. This
has been shown to increase the risk of side effects, influence the efficiency of treating sinus
infections and may result in a variable dose–response relationship. Similar levels of drug
deposition in the lungs were obtained utilizing a conventional jet nebulizer and a nasal sonic jet
nebulizer, indicating that the sonic effect did not have a significant influence on the level of aerosol
deposition in the lungs [17]. In contrast, a new type of mesh nebulizer intended for nasal
administration of drugs considerably reduced the inhaled fraction of the aerosol deposited in the
lungs [137]. A similar aerosol particle size is produced by the sonic jet and mesh nebulizer.
however, it appears that they do not have the same aerosol flow path through the sino-nasal cavity.
The nasal sonic jet nebulizer delivers drug by inhalation through the nostrils of the patient. For this
system, it is possible for the nebulized particles to reach the lungs via the nasal cavity during the
patient’s breathing due to their particle size and low velocity. In contrast, for the new mesh
nebulizer system, the aerosol is administered using a constant air flow via one nostril and exhaled
via the other nostril with the patient closing their soft palate to prevent inhalation. To achieve this,
during aerosol delivery with the mesh nebulizer, the patient is instructed to breathe through the
mouth. This approach bi-directional delivery is similar to the method proposed for the
nanocomposite powder delivery developed in this dissertation [178]. However, using developed
nasal administration technique for the dry powder nanocomposites formulation, deep penetration
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into the nasal cavity and improved distribution over the nasal mucosa can be expected. Moreover,
due to the smaller particle size distribution for the developed nasal powder formulation, variability
in the delivered dose to the middle passages for from the novel developed delivery system is
anticipated to be lower compared to the nasal spray products (with respect to nasal airway
geometry variabilities due to inter and intra-subject variability including race, sex and age, along
with the variability associated with the presence of the nasal disease, nasal septal deviation or the
presence of the nasal cycle which can result in increased variability in delivered dose).

Development of a realistic nasal airway model incorporating cell monolayers into the
airway passage walls to investigate transepithelial transport after realistic nasal
deposition
5.4.7.1 Regional nasal deposition of ciprofloxacin after nasal administration – nasal
exhalation technique with modified VCU nasal model 1
To investigate the transepithelial transport of the ciprofloxacin nanocomposite powder
formulation deposited in a realistic manner on a cell monolayer modifications to the VCU nasal
model 1 were made to incorporate Transwell inserts into the middle passage walls. The first task
was to assess the regional nasal drug deposition of the powders in the modified nasal model in the
presence of the Transwell® inserts. The results for regional drug deposition for the optimized
nanocomposite formulation in the modified VCU nasal model 1 and drug deposition on the three
Transwell® inserts are presented in Table 5.15. The regional nasal drug deposition did not change
in the presence of the Transwell® inserts for the optimized nanocomposite formulation as shown
in Tables 5.15 and 5.13. The mean (SD) mass of CPF on the three Transwell® inserts TW 1, 2 and
3 for the optimized nanocomposite formulation were 4.2 (1.4) µg, 11.3 (1.0) µg and 14.2 (2.1) µg,

237

respectively. Similar values were obtained when the unprocessed CPF powder was aerosolized
into the modified nasal airway model with Transwells. The mean (SD) mass of CPF on the three
Transwell® inserts, TW 1, 2 and 3 for the unprocessed CPF powder were 5.1 (3.0) µg, 11.2 (6.4)
µg and 16.5 (4.2) µg, respectively. As previously described, the first and second inserts are located
in the left middle meatus and the third insert is located in the superior meatus. Each Transwell
insert has a surface area of 0.33 cm2 and the total surface area of middle passage for VCU nasal
model 1 is 80.24 cm2. Therefore, each Transwell® insert represent 0.4% of the middle passage
surface area [44]. The surface area of the left middle meatus is 8.76 cm 2 and the left superior
meatus is 5.49 cm2, therefore in these regions the inserts cover about 7 % of the left middle meatus
region and 6% of the left superior meatus with respect to surface area. The mean (SD) percentage
of the middle passage dose deposited on Transwells 2 and 3 was 1.9 (0.1) and 2.4 (0.4) %,
respectively, with the optimized nanocomposite formulation. Similar values for the unprocessed
CPF powder were lower with only 0.9 (0.1) % and 1.2 (0.3) % of the middle passage deposition
on Transwells 2 and 3.
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Table 5.15. Mean (SD) regional drug deposition for ciprofloxacin from ciprofloxacin
formulations after nasal administration - nasal exhalation technique in VCU nasal model 1
with Transwell inserts (n=4)
Optimized
nanocomposite
formulation

Unprocessed CPF
powder

Capsule loaded mass (mg)

6.5 (0.5)

6.1 (0.3)

Emitted dose (% nominal)

77.0 (8.1)

52.1 (8.6)

Anterior nose deposition (% ED)

17.5 (6.4)

31.0 (11.0)

Middle passage and nasopharynx
deposition (% ED)

62.8 (12.1)

41.3 (12.9)

Exhaled (% ED)

19.7 (6.6)

27.7 (3.1)

Mass of CPF in middle passages
and nasopharynx (mg)

0.7 (0.1)

1.3 (0.4)

Drug mass on TW1 (µg)

4.2 (1.4)

5.1 (3.0)

Drug mass on TW2 (µg)

11.3 (1.0)

11.2 (6.4)

Drug mass on TW3 (µg)

14.1 (2.1)

16.5 (4.5)
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5.4.7.2 Transepithelial transport across the Calu-3 cell line after realistic nasal deposition
TEER measurements performed on the Calu-3 monolayers prior to deposition studies and
ranged from 780 – 950 Ω.cm2. The Calu-3 cell monolayers were grown on the outer surface of the
Transwell insert membrane using liquid covered culture (LCC) conditions, visual observation and
TEER measurements provided evidence of the integrity of the cell monolayer and their confluency.
Previous transport studies using this cell line reported the TEER measurements of 300 – 400 Ω.cm2
for LCC and 700 - 1473 Ω.cm2 and 350-600 Ω.cm2 for air interface culture [181-183]. Transport
media was maintained in the basolateral side during the deposition study to provide some structural
rigidity for the membrane and monolayer during the nasal powder administration. The media on
the basolateral side of the membrane prevented any movement of the insert membrane and cells
during the deposition study while the airflow was passing through the modified nasal airway
model. The initial deposition and transport studies were performed using HBSS as the transport
media. However, it was observed that 1hr post deposition, the TEER measurements began to
decrease by 50% (350 - 450 Ω.cm2) although they did recover to their original range of 780 – 950
Ω.cm2 after 18 hrs. Therefore, as an alternative, EMEM growth media was used as the transport
media. It appeared that the cells were very sensitive to any change in their environment and use of
EMEM growth media minimized the changes experienced by the cell monolayers. Using growth
media, the TEER mesurement 1 hr post deposition studies was in the range of 550 – 680 Ω.cm2
and a second measurement after 12 hr showed TEER values of approximately 900 Ω.cm2. In both
cases, there was no evident of cell leakages or changes to the monolayer cell integrity when
observed visually using inverted microscope. The results from sham and deposition experiments
indicate a small transient change in TEER following administration of the nasal powder. However,
the measured TEER values following the 5 hr transport studies for all experiments performed were

240

larger than the reported literature TEER values for transport studies using Calu-3 cell lines,
suggesting that the cell monolayer retained its integrity during nasal powder administration and
realisitic deposition in the modified nasal airway geometry.
For all studies drug depositon on TW 1 was low and prevented analysis of the
transepithelial transport due to limits of analytical detection. Therefore, the results presented below
reflect drug transport studies performed on TWs 2 and 3 only. Figure 5.34 shows the cumulative
mass drug transport from the optimized ciprofloxacin nanocomposite formulation across the
confluent Calu-3 cells (TEER ranged 780 – 950 Ω.cm2) over 5 hours using HBSS and EMEM
growth media (containing 1% PS) as the transport media at 37 °C. The data represents the
combined transport data for drug deposited on TWs 2 and 3. The mean (SD) total average mass of
drug deposited on the TWs 2 and 3 was 11.9 (1.4) µg and 12.6 (2.0) µg, (n=8) using HBSS and
EMEM growth media as the transport media, respectively. Sham experiments reported a higher
mass of drug deposited on the Transwells (Table 5.15) in the absence of the cell monolayer perhaps
suggesting that the presence of cells altered the insert membrane surface properties and affected
the total mass of formulation deposited. From Figure 5.34, it was observed that there was no
change in the drug transepithelial transport across the Calu-3 cells when using HBSS or EMEM
growth media as the transport media. The TEER measured 1 h after completion of the transport
study was statistically different for the two transport media conditions (p-value = 0.0012) but this
change in the TEER did not result in a change in the cumulative drug transport across the Calu-3
cell monolayer. The transport profile shows a linear increase in the drug transport across the Calu3 cells using the HBSS (R2 > 0.9982) and EMEM growth media (R2 > 0.9972). This suggests
uniform permeation across the cells as a function of time with the rate limiting step being the
dissolution of drug on the cell surface and then transport across the cells. The mean (SD)
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cumulative drug mass transported for the optimized ciprofloxacin nanocomposite formulation
after 5 hours was 1133.2 (163.2) ng and 1179.3 (90.5) ng in the HBSS and EMEM transport media,
respectively, which was 10.2 (2.3) and 9.5 (1.5) % of the amount of ciprofloxacin deposited on the
Transwell cell monolayer surface.
A comparison of the transport of the optimized nanocomposite formulation with the
unprocessed CPF powder delivered nasally to the modified realistic model is shown in Figure 5.35.
These results reveal the effects on ciprofloxacin transport when the drug is formulated as
nanoparticles compared to unprocessed micrometer sized particles. For this study, EMEM growth
media was used as the transport media and the results are shown in Figure 5.35. The mean (SD)
total average mass of drug deposited on the TWs 2 and 3 was 12.6 (2.0) µg and 10.6 (3.2) µg for
the optimized nanocomposite and unprocessed CPF powder, respectively.
As shown in Figure 5.35, ciprofloxacin transepithelial transport from the unprocessed
ciprofloxacin powder also exhibited a linear increase as a function of time (R2 > 0.9931) but it was
observed to be slower than compared to the optimized ciprofloxacin nanocomposite formulation.
The mean (SD) cumulative percent mass transported across the Calu-3 monolayer over 5 hours for
the unprocessed CPF powder was 5.4 (0.8) % which was significantly lower (p-value = 0.0198)
than observed for the nanocomposite formulation (9.5 (1.5) %). Flux was calculated based on the
linear slope from 1 to 5 hours and summarized in Table 5.16. There was a higher flux for the
nanocomposite formulation compared to the unprocessed CPF powder. For transepithelial
transport across the Calu-3 monolayer, powder drug formulations must be first dissolved. For the
nanocomposite ciprofloxacin formulation, this process includes dissolution of the excipient matrix
to release the ciprofloxacin nanoparticles which are then dissolved and transported across the cell
monolayer. Despite this multi-step process, it appears that formulation of ciprofloxacin as
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nanoparticles in the nanocomposite formulation increases the rate of drug transport compared to
the unprocessed CPF powder raw material. The higher rate and extent of transport for the
nanocomposite formulation compared to the unprocessed ciprofloxacin powder could be due to
the transport of nanoparticles across the Calu-3 cells after dissolution of the nanocomposite matrix.
However, results of dissolution test measured at pH 7 also showed the increased dissolution rate
of nanocomposite formulation (Section 5.4.4) compared to unprocessed ciprofloxacin. Therefore,
an alternative explanation could be that improved dissolution for nanocomposite formulation could
be translated in higher transport across the Calu -3 cells.
Comparing the results obtained in this study with literature data, Ong et al. reported 33 %
drug transport for ciprofloxacin (with median size of 3.6 µm) across the Calu-3 cell monolayer
after 4 hours when grown at AIC [151]. In that study, ciprofloxacin was nebulized into a twin stage
impinger (operating at the flow rate of 15 Lmin-1) while replacing the solution in second stage with
a Transwell insert which allowed deposition of 8.7 (2.0) µg ciprofloxacin on the cell monolayer
[151]. The greater transport observed transport (33 %) compared to values of 5.4-9.5 % in these
present studies. Differences may be attributed to the lower cell monolayer TEER reported by Ong
of 550 Ω cm2 compared to values of 780 – 950 Ω.cm2 in the present study. Darweesh et. al [181]
reported a TEER dependent transport for ciprofloxacin hydrochloride as steady state flux was
significantly reduced when the TEER was over 700 Ω.cm2.
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Figure 5.34. Mean (error bars are SD) cumulative ciprofloxacin transport for the optimized
nanocomposite formulation across the Calu-3 cell monolayer over 5 hours using HBSS and
EMEM as transport media. Linear regression was performed between for 1- 5 hr (n=3)
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Figure 5.35. Mean (error bars are SD) cumulative ciprofloxacin transport for the optimized
nanocomposite formulation and the unprocessed CPF powder across the Calu-3 cell monolayer
over 5 hours using EMEM as transport media. Linear regression was performed between for 1- 5
hr (n=4)
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Table 5.16. Mean (SD) steady state ciprofloxacin flux for the optimized ciprofloxacin
nanocomposite formulation and the unprocessed CPF powder. Mean (SD) total drug masses
of 12.6 (2.0) µg (n=8) and 10.6 (3.2) µg (n=6) were deposited on TWs 2 and 3 for the
optimized ciprofloxacin nanocomposite formulation and the unprocessed CPF powder,
respectively.
Flux (ng/h/cm2)
Optimized nanocomposite formulation

725 (92)

Unprocessed CPF powder

321 (94)

In this section, the successful deposition of ciprofloxacin powder formulations on the
surface of liquid cover culture Calu-3 cell monolayer using a modified VCU nasal model was
described. These studies have demonstrated the development of methodology that will allow
realistic nasal deposition of drug followed by investigation of its transepithelial transport (Specific
Aim 3-4). Using this newly developed technique, the transepithelial transport of a novel
nanocomposite ciprofloxacin formulation was investigated following realistic nasal deposition. Its
dissolution, cellular uptake and transport across the Calu-3 monolayer was compared to
unprocessed CPF powder. The developed methods were able to discriminate between the two
powders and identified differences in their dissolution and transport.
Future continued development of this method should focus on the incorporate of a more
relevant cell model including a cell monolayer based on an air-interface culture method (AIC). In
this technique, the monolayer is more morphologically similar to the airway epithelial by
differentiating and developing tight junction and producing ciliated cells and goblet cells which
produce mucus and has been used for both nasal and lower respiratory region cells [184-190].
Also, the use of a nasal epithelial cell model should be considered to improve the realism of the
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airway model system. In these initial studies developing the technique, a Calu-3 cell monolayer
was employed, however, future studies should investigate the feasibility of growing nasal
epithelial cells as the monolayer. It is possible to obtain nasal epithelial cells by nasal scrape
biopsies from healthy subjects or patients with allergic rhinitis (AR) or other disease states such
as nasal polyps, cystic fibrosis [185, 191]. A reduced number of ciliated cells, loose tight junctions
and hyperplasia of the secretory cells were observed in nasal epithelial cells from AR patients
developed based using the AIC method and these characteristics may affect the transepithelial
transport of nasally administered drugs [185].

5.5 Conclusions
In this chapter, the influence of crystallization variables was investigated to optimize the
methods to produce ciprofloxacin nanoparticles. Conditions were identified using ultrasound
energy in combination with an appropriate anti-solvent system to control nucleation and crystal
growth of ciprofloxacin nanoparticles. The ciprofloxacin nanoparticles were characterized with
respect to their stability, composition and particle size. Methods were also developed to produce
spray dried nanocomposite particles. Composition of the spray drying feed stock mixture was
optimized to produce stable and re-dispersible nanocomposites suitable for nasal administration
(Specific Aim 3-1). High efficiency targeted delivery of the developed nasal nanocomposite
powder was achieved using a modified VCU DPI in combination with a novel breathing maneuver
(Specific Aim 3-2). The delivery of the developed formulation was assessed using the previously
developed realistic airway model and showed good emitted dose characteristics together with low
anterior nose deposition losses and high drug deposition in the target middle passage nasal cavity.
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(Specific Aim 3-3) A modified version of the realistic airway model was developed and used to
investigate the transepithelial transport of the nanocomposite formulation across a Calu-3 cell
monolayer that was incorporated in the wall of the airway model to allow realistic deposition of
the nasal aerosol (Specific Aim 3-4). This system was used to demonstrate improved dissolution
and transport characteristics of the nanocomposite formulation in the cell system compared to
unprocessed CPF powder.
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Chapter 6
SUMMARY AND CONCLUSION

The nasal cavity has been widely used as a route of drug administration for topical and
systemic delivery of medications. Several factors play a critical role in determining the efficacy of
nasal drug delivery, including drug and formulation properties, delivery device characteristics and
inter-subject variability in the nasal cavity geometry. In recent years and in this dissertation,
physically realistic nasal airway models have been used to assess the delivery efficiency and drug
deposition pattern of nasal spray products using in vitro experiments. The in vitro tests utilizing
hollow physical models have been shown to offer realistic characterizations of regional drug
deposition of nasal spray products when compared with in vivo studies. In contrast, some of the
traditional in vitro tests focus on droplet size and plume geometry characteristics and the link to
clinical deposition is less well established. For these realistic in vitro methods to capture the range
of inter-subject variability found in the clinical population, it is unlikely to be achieved using a
single geometry and efforts should be directed to developing a range of models or an idealized
average nasal airway geometry model, similar to the approach taken for the mouth-throat models
used to evaluate inhalation drug products [192].
The first part of this project focused on developing a realistic in vitro test for nasal spray
products (Specific Aim 1-1) and investigating the influence of patient-use factors on regional drug
deposition in a physically realistic model of the nasal cavity for a commercially available nasal
spray product, Nasonex® nasal spray (Specific Aim 1-2). We tested the hypothesis that simulated
patient-use experimental conditions can influence the in vitro regional drug deposition of nasal
spray products in realistic nasal models. A full factorial design of experiments was conducted to
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assess the effect of variables including nasal spray positioning in the nostril, head angle, nasal
spray actuation force and coordination of actuation of the nasal spray with patient inhalation. Using
the realistic physical nasal model, regional deposition of the nasal spray was evaluated using the
simulated patient use conditions. The overall regional deposition pattern and lung delivery were
similar to previous in vivo studies performed for nasal spray products [16-18, 140, 193]. The in
vivo deposition results revealed regional nasal drug deposition was observed to varied widely for
nasal spray products with mean middle passage deposition for the Nasonex® product being
reported as 65 % [34] and about 35 % [18]. A similar range of in vitro middle passage deposition
was observed in this study, with differences in the deposition being dependent on the patient use
conditions employed. Mean in vitro drug delivery to middle passage ranged from 17 % to 57 % of
the delivered dose when tested using VCU model 1. The presence of nasal inhalation during nasal
spray delivery was observed to play a significant role in determining drug penetration through the
nasal valve and into the middle passage. With simultaneous inhalation and actuation, there was a
reduced fraction of drug loss due to deposition in the anterior region and improved drug deposition
in the posterior nasal cavity. The DOE study using VCU nasal model 1 revealed an interaction
between the nasal head angle and inhalation during actuation. Conditions were identified that
would appear to enhance delivery of drug to the site of action in the middle passages and may be
useful to advise patients seeking to increase the effectiveness of the Nasonex® nasal spray and
minimize drug deposition losses in the anterior nose. Therefore, we can conclude that simulated
patient-use experimental conditions can influence the in vitro regional drug deposition of nasal
spray products in realistic nasal models.
The next hypothesis stated that the in vitro regional drug deposition of nasal spray products
in realistic nasal models is determined the differences in the airway geometry of the nasal model
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and the formulation / spray device properties. The initial studies were performed in a single nasal
airway geometry. As described earlier, it is important to consider the effects of inter-subject
variability and its effects on the nasal spray deposition. Also, having identified a series of patient
use parameters which influenced deposition in VCU nasal model 1, it was important to characterize
their effects in a second nasal model, with differing nasal cavity geometric dimensions. Therefore,
the regional nasal deposition pattern of Nasonex® was investigated using a 2nd nasal model (VCU
nasal model 2) and the effects of the patient use conditions compared with VCU nasal model 1
(Specific Aim 2-1). In general, drug deposition in the middle passage of VCU nasal model 2 was
higher than observed under similar test conditions with VCU nasal model 1. The mean drug
deposition fraction in the middle passages ranged from 47 to 77 % in VCU nasal model 2 compared
to 17 to 57 % in VCU nasal model 1. Clearly demonstrating evidence of significant inter-subject
variability which was possibly related to differences in the geometry of the nasal vestibule and
valve regions. In addition, it was observed that VCU nasal model 2 was less discriminating or
sensitive with respect to the varying patient use parameters which across the range of conditions
tested produced only a 1.7-fold change in middle passage deposition compared to a 3.4-fold change
for VCU nasal model 1. Testing with a second airway model emphasized the significant effect
nasal geometry can have on the regional drug deposition of the tested nasal spray product and can
be indicative of the potential range of inter-subject variability that can be expected in vivo. With
respect to the patient use parameters, both models indicated the benefits of coordinating inhalation
with spray actuation and tilting the head forward during actuation to improve drug delivery to the
middle passage region and minimize anterior nose deposition. There are some limitations of the in
vitro nasal airway models, due to their rigid inflexible structure, they are unable to simulate the
Bernoulli forces present during inhalation which narrow the nasal valve with increasing inspiratory
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flow rate [61]. The current in vitro studies indicated that deposition was independent of inhalation
flow rate and that only a very small fraction of drug penetrated the nasal valve in the absence of
an inhalation. The in vitro studies have revealed positioning of the nasal spray within the nostril,
patient head angle and the coordination of inhalation and actuation all have significant influence
on the ultimate deposition of the Nasonex® nasal spray and that providing detailed information
regarding administration technique to the users could be used to ensure maximal drug delivery of
the nasal spray.
The ability of the realistic in vitro nasal deposition method to discriminate between nasal
sprays was also investigated using innovator and generic nasal sprays, together with sprays with
differing droplet size and spray plume characteristics (Specific Aims 2-2 and 2.3). The range of
drug delivery observed in vitro using VCU nasal models 1 and 2 for the Nasonex® and Flonase®
nasal sprays were similar to the published range of in vivo deposition for these devices with respect
to the fraction of drug penetrating the nasal valve region and depositing in posterior nose[18].
When comparing the differences in the spray characteristics of these innovator nasal sprays,
differences in their droplet size distributions did significantly change their in vitro regional nasal
drug deposition between the two nasal sprays products. The utility of the developed technique to
assess regional nasal deposition of products designed to be generic copies of the innovator
products, with therefore equivalent droplet size and spray plume characteristics, was also
investigated using “in house” copies or marketed generic nasal spray products. The developed in
vitro test methods were able to reliably produce similar regional nasal deposition profiles for the
nasal spray products with similar spray plume characteristics. Finally, the in vitro test method did
reveal that changes to spray plume properties could result in regional nasal deposition differences
in the realistic airway geometry. Using a nasal spray with an increased spray diameter (Dmin and
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Dmax), and plume angle produced higher drug deposition in the anterior nose region and lower
deposition in the middle passages of VCU nasal model 1. Previous, in vitro and in vivo studies
showed similar effects of increasing anterior nose deposition for nasal spray formulations with an
increasing spray plume angle [16, 31]. In general, it was found that deposition in VCU nasal model
1 was more sensitive to experimental conditions (patient use and nasal spray) than VCU nasal
model 2.
This comprehensive evaluation of the drug delivery to the nose for the Nasonex® spray
product performed using controlled multi-variant conditions can provide guidance for the rational
targeting of the nasal spray plume for delivery to the site of action within the middle passages with
respect to both the device – formulation characteristics (spray plume, droplet size) and
administration technique (head angle, inhalation / actuation coordination). Further studies are
required to investigate the methodology as a tool for the evaluation of innovator and generic nasal
spray products. It will be important to examine the nasal drug delivery efficiency of the products
in a series of nasal airway models representing the variability observed in the patient population
with respect to airway geometry. The selection of these representative nasal airway models and
the establishment of criteria to characterize critical geometric features was beyond the scope of
this study but will be essential for the future utility of this method. However, these studies have
shown that the in vitro methods have potential advantages for the study of nasal drug delivery
efficiency and for the assessing the equivalence of nasal spray products. These studies
demonstrated that the combined use of physically realistic nasal airway models with simulated
patient use experimental conditions could allow quantification of in vitro spray deposition patterns
within the nose.
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The developed in vitro nasal deposition model was also used as a tool to evaluate a novel
antibiotic formulation – device combination that was developed. We hypothesized that enhanced
middle passage drug delivery can be accomplished using a novel nanocomposite formulation and
nasal powder delivery system. Potential applications of a nasal antibiotic include the treatment of
infection in CRS. Drug nanoparticles were identified for the formulation, as it has been suggested
the micrometer-sized particle delivery systems were unlikely to enhance flux through the mucus
in CRS or CF patients [75, 76, 194]. Ciprofloxacin nanocrystals in the targeted particle size
between 100-200 nm, suitable for penetration through mucus and potentially through biofilm
layers produced by bacteria such as P. aeruginosa, were produced by an optimized
sonocrystallization process. Rapid mixing of drug solution and anti-solvent, under controlled
temperature conditions, was provided by application of ultrasound and crystallization variables
were optimized to increase local supersaturation and increase nucleation rate of ciprofloxacin.
Optimized conditions employing a mixture of aqueous and organic anti-solvent together with the
use of Tween® 80 a stabilizer yielded a stable nanoparticle formulation with a mean size of 120
nm and relatively monodisperse particle size distribution.
A spray drying technique was used to convert the antibiotic nanocrystals into a
nanocomposite powder in the size range of 5 - 10 µm suitable for nasal drug delivery. The goal
was to produce a powder formulation suitable for use in a nasal dry powder inhaler containing
dispersed nanoparticles in a matrix of water soluble excipients. On delivery to the nose, the
excipients would rapidly dissolve leaving the nanoparticles on the airway surface which would
then penetrate through the mucus layer and exert their antimicrobial effects. Previous studies have
demonstrated that nanoparticle aggregation during spray drying was often observed which would
be undesirable [102]. Water soluble excipients such as PVP K30 and mannitol were evaluated for
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their ability to prevent nanoparticle aggregation during spray drying. Optimized conditions
employing PVP K30 and increasing the solids concentration in the stock feed mixtures produced
particles with desired size distribution (5 - 10 µm) which were readily soluble in water and released
ciprofloxacin nanoparticles. The mean size of the nanoparticles before and after spray drying was
120 and 140 nm (Specific Aim 3-1). A Transwell® system, with limited fluid volume simulating
the local environment within the nose, was developed to compare the dissolution of unprocessed
ciprofloxacin powder (2 µm) with the nanoparticles, both as the initially produced nanosuspension
following crystallization and in the spray dried nasal formulation. An increased dissolution rate
was observed for the ciprofloxacin nanosuspension compared to the unprocessed ciprofloxacin
powder due to reduced particle size of the nanoparticles. Spray drying and the addition of Tween™
80 did not appear to affect the dissolution rate of the ciprofloxacin nanoparticles, with similar
dissolution profiles observed for the nanosuspension and the spray dried nanocomposite powder.
High efficiency targeted delivery of the nanocomposite nasal powder formulation was
achieved using a modified low flow VCU DPI used in combination with a novel breathing
maneuver (Specific Aim 3-2). This method offers the ability to target delivery to the nasal middle
passages and allows delivery of milligram doses that would be required for antibiotic therapy. The
delivery efficiency of the developed nanocomposite formulation was assessed using the previously
developed realistic in vitro airway model. The optimized emitted dose of the spray dried
nanocomposite nasal formulation was about 80 % using the modified VCU DPI with a low
actuation flow rate in a fixed air volume to prevent lung inhalation. This was significantly higher
than the emitted dose for the unprocessed ciprofloxacin powder using the same DPI. For the spray
dried nanocomposite nasal formulation, there was low anterior nose loss and drug deposition in
the target middle passage nasal region was 72 % of the nominal dose (Specific Aim 3-3). Future
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studies should evaluate the deposition in nasal airway models with varying airway geometries in
the anterior nose and middle passages to assess the effects of inter-subject variability for this novel
delivery technique. In this study, we demonstrated the delivery of approximately 3.7 mg of
ciprofloxacin as a novel nanoparticle formulation to the site of action within the middle passages.
Finally, the realistic nasal airway model was modified to allow an in vitro assessment of
dissolution and transepithelial transport following realistic deposition on a cell monolayer
positioned in the wall of the airway model (Specific Aim 3-4). In this study, VCU nasal model 1
was modified to accommodate three Transwell® inserts with Calu-3 monolayers on the surface
such that they are positioned on the walls of the middle passage. Studies were performed to
determine drug deposition in the presence and absence of the cell monolayer and to confirm the
integrity of the monolayer following nasal aerosol administration. Ciprofloxacin nasal aerosols
were delivered to the modified airway model and the transepithelial transport of drug deposited on
the Calu-3 cell monolayers was investigated. Studies revealed that the nanocomposite formulation
appeared to have an increased flux compared to unprocessed ciprofloxacin delivered using the
same technique. Future studies should employ a more relevant cell model; nasal epithelia cell lines
would provide a more clinically relevant assessment of the fate nasally administered drugs. In
addition, the effectiveness of the produced nanoparticles to penetrate through highly viscous
mucus was beyond the scope of these studies. Future work should examine the functional ability
of the formulated nanocomposites and nanoparticles to improve delivery of antibiotics.
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